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Abstract 
 
Metabolic syndrome (MetS) represents a cluster of metabolic abnormalities, characterised 
by the presence of 3 or more of 1) abdominal obesity, 2) insulin resistance, 3) 
hypertension, 4) dyslipidaemia, and 5) emerging risk factors, such as pro-thrombotic and 
pro-inflammatory states, which are each independent cardiovascular disease (CVD) risk 
factors. This clustering of risk factors is reported to increase the odds ratio for 
cardiovascular and all-cause mortality above the risk associated with the individual 
components (Wilson, 2004). The precise aetiology of MetS is currently unknown, however 
an energy-dense diet, particularly high in carbohydrate, and an inactive lifestyle or low 
fitness may interact with a genetic susceptibility to contribute to the pathophysiology of 
MetS (Bouchard, 2007). Therefore the purpose of the studies included in this thesis were to 
determine whether accumulative brisk walking may improve risk factors associated with 
MetS and whether one single session of brisk walking at a moderate intensity may improve 
risk factors associated with MetS in middle-aged men at risk of MetS. Study one recruited 
85 males aged 38-73 onto a 24-week randomised controlled trial with participants allocated 
to control (CON), single 30 minute daily brisk walking (SBW) or accumulative 30 minutes 
of daily brisk walking (ABW; 3×10 min or 2×15 min) groups. Measures included aerobic 
fitness (OO2max), body composition and selected blood variables. The main findings were 
that 24 weeks of accumulating 150 min·wk-1 of brisk walking at ~65% HRmax significantly 
improved insulin sensitivity, which was associated with decreased abdominal adiposity, 
assessed by waist circumference, and was at least as effective as a single daily session of 
equal volume in middle-aged men at risk of MetS. Study two investigated the 24-hour 
effect of walking for 30 minutes at 50% OO2max (30×50%), 30 minutes at 65% OO2max 
(30×65%) and 60 minutes at 50% OO2max (60×50%) compared to rest (CON) on 
cardiovascular control, resting metabolism and selected blood variables. The main findings 
were that a single 30 minute walking session at 50% OO2max favourably improved 
cardiovascular control, indicated by decreased heart rate and systolic blood pressure, thus 
decreasing the workload of the heart, whereas increasing the intensity of the walk to 65% 
OO2max attenuated this effect, while increasing the duration to 60 minutes had no additional 
effect compared to 30 minutes at 50% OO2max in men at risk of MetS. 
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Glossary of abbreviations 
 
ABW – Accumulative brisk walking group refers to the group of participants who 
performed brisk walking in multiple sessions during the day 
 
ACSM – American College of Sports Medicine is an international organisation for 
health-fitness professionals 
 
AHA – American Heart Association is a charity that supports research related to heart 
disease 
 
Apos A-I, A-II & B – Apolipoproteins A-I, A-II and B are the protein moieties of 
lipoproteins  
 
ARIC – Atherosclerosis Risk in Communities is a large-scale, long-term prospective 
study that measures associations of established and suspected coronary heart disease risk 
factors 
 
ATPIII – National Cholesterol Education Panel Adult Treatment Panel III published 
guideline criteria for diagnosing metabolic syndrome 
 
Db – Body density is the ratio of mass to volume of the body and used in models to 
estimate body composition, which can be estimated by a number of methods  
 
BF% - Body fat percentage is the percentage of the body composed of fat 
 
BMI – Body mass index is an anthropometric estimation of body composition used in 
clinical practice by dividing body mass (kg) by height (cm)2 
 
CAD – Coronary artery disease is a form of cardiovascular disease that relates 
specifically to the vessels supplying the heart with blood 
 
CDC – Centers for Disease Control and Prevention is an organisation that provides 
health information in the United States 
 
CETP(a) – Cholesteryl Ester Transfer Protein (activity) relates to the activity of a 
lipoprotein-bound enzyme that transfers cholesteryl esters and triacylglycerol between 
lipoproteins, which has implications for reverse cholesterol transport 
 
CHD – Coronary heart disease is similar to coronary artery disease and relates to 
problems occurring from defects in the vessels supplying the heart with blood 
 
CMO – Chief Medical Officer produced a report in 2004 to promote participation in 
physical activity 
 
CON – Control refers to the sedentary control group within a trial 
 
CRP – C-reactive protein is a marker of systemic inflammation 
 
 xii 
CVD – Cardiovascular disease relates to damage and impairments of the heart and blood 
vessels 
 
DBP – Diastolic blood pressure is the residual pressure exerted by the vessels and blood 
in between contractions of the heart, measured in millimetres of mercury (mm Hg) 
 
EE – Energy expenditure is energy used per unit of time and is used as a measure of 
physical activity 
 
EGIR – European Group for the Study of Insulin Resistance is a European group of 
investigators studying insulin resistance and related disorders 
 
EPOC – Elevated post-exercise oxygen consumption refers to the residual increase in 
metabolism related to a previous exercise bout 
 
FXIIa – Factor XIIa is the active form of FXII which is involved in blood clotting  
 
FFM – Fat-free mass relates to the proportion of the body that contains no fat, measured 
in kilograms 
 
FM – Fat mass is the proportion of the body composed of fat, measured in kilograms 
 
FRS – Framingham Risk Score is a 10-year risk of heart disease based on age, gender, 
TC, HDL-C, smoking status, SBP and prescribed cardiovascular medication use 
 
GLUT-4 – Glucose transporter-4 is found in skeletal & cardiac muscle and liver tissue 
and translocates to the plasma membrane in response to increases in circulating insulin or 
glycogen depletion 
 
HDL-C – High-density lipoprotein cholesterol is a micellular molecule involved in 
reverse cholesterol transport 
 
HOMA – Homeostasis Model of Assessment is a model for expressing insulin resistance 
 
HPA axis – Hypothalamic-pituitary adrenal axis controls reactions in the body through 
secretion of endocrine hormones into the circulation from endocrine organs in the brain 
and kidneys 
 
HRmax – Maximum heart rate is the age predicted maximum heart rate based on 220 
beats·min-1 minus age 
 
HRpeak – Peak heart rate is peak heart rate attained during an exercise test 
 
hrs·wk-1 ≥4 METs - hours per week of PA at or above 4 METs and is a measure of the 
volume of PA at a sufficient intensity to enhance health 
 
IDF – International Diabetes Federation provides guidance on matters relating to 
diabetes 
 
 xiii
IFG – Impaired fasting glucose is an elevation in fasting glucose and a risk factor for 
type II diabetes mellitus 
 
IGT – Impaired glucose tolerance is a decreased ability to deal with an oral glucose load 
and a risk factor for type II diabetes mellitus 
 
IL-6 – Interleukin-6 is a cytokine that is secreted by adipose tissue and acts as an 
inflammatory mediator 
 
Kcal – kilocalories is measure of energy consumption and expenditure 
 
LB – Long bout is a long exercise session in studies investigating the efficacy of 
accumulative short bouts of activity vs. longer sessions  
 
LCAT(a) – Lecithin-cholesterol acyltransferase (activity) relates to the activity of a 
lipoprotein-bound enzyme that esterifies cholesteryl esters to be retained within 
lipoproteins as part of reverse cholesterol transport 
 
LDL-C – Low-density lipoprotein cholesterol is a micellular molecule implicated in the 
pathogenesis of atherosclerosis 
 
LPL(a) – Lipoprotein lipase (activity) relates to the activity of a capillary-bound enzyme 
that hydrolyses triacylglycerol-rich very-low-density lipoprotein 
 
MAP – Mean arterial pressure is the mean pressure derived from systolic and diastolic 
blood pressures 
 
MET – Metabolic equivalents are multiples of resting metabolic rate, specifically resting 
oxygen consumption, where 1 MET = 3.5 mL·kg-1·min-1  
 
MetS – Metabolic syndrome is a cluster of cardiovascular disease risk factors 
 
MI – Myocardial infarction is also known as a heart attack, where a section of heart 
tissue dies 
 
Min·wk-1 – Minutes per week of activity performed 
 
mL·kg-1·min-1  - millilitres of oxygen consumed per kilogram of body mass per minute 
is a measure of oxygen consumption relative to body mass 
 
MOO2 – Myocardial oxygen demand is the volume of oxygen required by the heart per 
minute, an index of which can be estimated from heart rate and systolic blood pressure 
 
NEFA – Non-esterified fatty acids are hydrocarbon chains mobilised from triacylglycerol 
stores in adipose tissue 
 
NHANES II – Second National Health and Nutrition Survey is a national heath survey 
from the United States conducted between 1976 and 1992 
 
 xiv
NHANES III – Third National Health and Nutrition Survey is a national heath survey 
from the United States conducted between 1988 and 1994 
 
NHANES 1999-2000 –National Health and Nutrition Survey is a national heath survey 
from the United States conducted between 1999 and 2000 
 
PA – Physical activity is any bodily movement produced by skeletal muscles that results 
in increased energy expenditure 
 
PAI-1 – Plasminogen activator inhibitor-1 is an inhibitor of fibrinolysis and increases 
the risk of blood clotting 
 
PLTP(a) – Phospholipid transfer protein (activity) relates to the activity of an enzyme 
that exchanges surface phospholipids from TAG-rich lipoproteins to HDL-C 
 
PP – Pulse pressure is the additional pressure on diastolic blood pressure exerted by 
contractions of the heart and is the difference between SBP and DBP 
 
Preβ1-HDL-C – Pre-beta-high-density lipoprotein cholesterol is the initial plasma 
acceptor of cell-derived cholesterol plasma 
 
RCT – Randomised Controlled Trials are investigations where participants are randomly 
allocated to either a control group or the experimental group 
 
RevCholT – Reverse cholesterol transport is the process where cholesterol is removed 
from peripheral tissues and returned to the liver to be re-processed 
 
RMR – Resting metabolic rate refers to resting energy expenditure, measured in kcal 
 
RPP – Rate-pressure product an index of myocardial workload, estimated from heart 
rate and systolic blood pressure 
 
SB – Short bout refers to studies investigating the efficacy of accumulative short exercise 
sessions vs. longer sessions of exercise 
 
SBP – Systolic blood pressure is the pressure exerted by the heart, blood and blood 
vessels when the heart contracts, measured in millimetres of mercury (mm Hg) 
 
SBW – Single brisk walking group refers to those participants who performed brisk 
walking in one single daily brisk walking session 
 
SeDS – Sedentary death syndrome describes a collection of physical inactivity-induced 
chronic diseases, such as type II diabetes mellitus 
 
SNS – Sympathetic nervous system is the component of the autonomic nervous system 
generally responsible for excitation 
 
TAG – Triacylglycerol is a fat source incorporating three fatty acids bound together by a 
glycerol molecule 
 
 xv
TC – Total cholesterol is the term used for all of the micellular cholesterol-carrying 
molecules in the circulation 
 
TC/HDL-C – Total cholesterol/High-density lipoprotein cholesterol ratio is a ratio of 
total cholesterol to ‘healthy’ cholesterol and provides an index of total cholesterol to 
‘healthy’ cholesterol 
 
tPA – Tissue plasminogen activator is involved in the the process of fibrinolysis which 
decreases the risk of blood clots 
 
USGR – US Surgeon General Report is a report published in 1996 to promote 
participation in physical activity for public health 
 
VLDL-C – Very-low density lipoprotein cholesterol carries triacylglycerol in the 
circulation 
 
OO2max – Maximal oxygen uptake is the maximal volume of oxygen that may be 
consumed during maximal intensity aerobic activity, measured in mL·kg-1·min-1 
 
OO2peak – Peak oxygen uptake is the peak volume of oxygen measured during an 
incremental test but without meeting the criteria for a maximal test, also measured in 
mL·kg-1·min-1 
 
WC – Waist circumference is the circumference around the waist at the level of the 
umbilicus and is used to estimate abdominal adiposity 
 
WHR - Waist:hip ratio is a measure of abdominal adiposity using hip circumference as a 
point of reference 
 
WHO – World Health Organisation promotes health worldwide 
 
30×50% - 30 minutes of walking performed at 50% OO2max 
 
30×65% - 30 minutes of walking performed at 65% OO2max 
 
60×50%- 60 minutes of walking performed at 50% OO2max 
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1.0 Introduction 
The term metabolic syndrome (MetS) is used to classify a cluster of co-related 
cardiovascular disease risk factors that predict coronary heart disease and diabetes 
(Wannamethee et al., 2005). Initially, Reaven (1988) used the term ‘syndrome X’ to 
describe a disorder characterised by insulin resistance, hypertension and dyslipidaemia, 
which are mediated through insulin resistance-induced compensatory hyperinsulinaemia, 
and abdominal obesity was later included to make the ‘deadly quartet’ of related CVD risk 
factors (Kaplan, 1989), where abdominal obesity appears to be more biochemically toxic to 
health than total adiposity (Moller & Kaufman, 2005). This clustering of risk factors is 
reported to increase the odds ratio for cardiovascular and all-cause mortality above the risk 
associated with the individual components (Wilson, 2004). Insulin resistance is a pre-
cursor for the more serious type II diabetes mellitus (T2D), where tissues of the body 
become resistant to the action of insulin, causing compensatory hyperinsulinaemia. 
Hypertension is a chronic elevation in systolic and diastolic blood pressure and 
hypertriglyceridaemia is a disorder of blood lipids marked by high levels of triacylglycerol 
(TAG). Due to the perturbations in TAG metabolism related to MetS, an atherogenic 
dyslipidaemic profile occurs, where low levels of the ‘healthy’ high-density lipoprotein 
cholesterol (HDL-C) and elevations in pathogenic total cholesterol (TC) and small dense 
low-density lipoprotein cholesterol (LDL-C) are common. Due to these related disorders of 
lipoprotein metabolism in MetS, agents involved in reverse cholesterol transport 
(RevCholT), which is the process by which cholesterol is transported from peripheral 
tissues to be processed by the liver, are disrupted (Moller & Kaufman, 2005). Pro-
inflammatory and prothrombotic states have been implicated with MetS, including markers 
such as C-reactive protein (CRP) and plasminogen activator inhibitor-1 (PAI-1) (Reaven, 
1994). 
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The precise aetiology of MetS is currently unknown, however an energy dense diet, 
particularly high in carbohydrate and fat, and an inactive lifestyle or low fitness may 
interact with a genetic susceptibility to contribute to the pathophysiology of MetS 
(Bouchard, 2007). Other purported precedents include gender (male), (Fox et al., 2007), 
age (Schubert et al., 2006), stress-neuroendocrine disorders (Kyrou et al., 2006) and post-
viral disorders (Vasilakopoulou & le Roux, 2007). Despite the aetiology of MetS still 
being debated, the future health outcomes are relatively clear: MetS may increase the risk 
of cardiovascular death 2-4 fold and reduce life expectancy by 5-10 years (Libby & 
Theroux, 2005), and using the National Cholesterol Education Panel Adult Treatment 
Panel III (ATPIII) definition of MetS the estimated worldwide prevalence of MetS may be 
~56.7% and ~43.6% in men and women, respectively (Resnick, 2002). Due to the 
prevalence and potential costs of MetS, both financially and in terms of morbidity and 
mortality, those individuals diagnosed with the condition are encouraged to undergo 
lifestyle modification, with habitual physical activity (PA) (Carroll & Dudfield, 2004), 
aspects of diet (Mendoza et al., 2007) and medication (Williams & Franklin, 2007) 
receiving most attention. Focusing on the impact of PA in particular, evidence 
demonstrates that long term participation in PA may improve aerobic fitness (OO2max) 
(Church et al., 2007), obesity level (Jakicic, 2003), abdominal obesity (Kay & Fiatarone 
Singh, 2006), insulin resistance & glucose tolerance (Henriksen, 2002; Yates et al., 2007), 
blood pressure (Pescatello, 2005), lipid and lipoprotein profile (Durstine et al., 2001), 
markers of pro-inflammatory & pro-thrombotic states (Kasapis & Thompson, 2005; El-
Sayed et al., 2005) and markers of RevCholT (Seip et al.,1993). 
 
Current public health guidelines recommend that individuals perform at least 30 minutes 
per day (min·d-1) of moderate intensity PA on at least five days of the week (d·wk-1) or 
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vigorous intensity PA at least three d·wk-1 (American College of Sports Medicine (ACSM) 
& American Heart Association (AHA), 2007). These recommendations also support the 
accumulation of PA throughout the day in activities of daily living, such as walking, using 
stairs and household activities. Much of the research into the efficacy of accumulative PA 
has used walking as the mode of exercise, however many of these studies use changes in 
aerobic fitness (OO2max) as a surrogate measure of health outcomes. Therefore, the aims of 
study one in section 3.0 was to determine a) whether brisk walking performed for 30 
min·d-1 at an intensity >65% of age-predicted maximum heart rate (HRmax) on five d·wk-1 
for 24 weeks could improve risk factors associated with MetS and markers of RevCholT 
compared to a control group, and b) whether accumulating the same volume of brisk 
walking through the day in sessions of at least 10 minutes and less than 20 minutes would 
have a similar effect.  
 
In addition to the long term adaptations associated with habitual PA, there are also 
immediate, although short-term, benefits that may be accrued from a single PA session. 
Evidence demonstrates that short-term improvements in independent MetS risk factors, 
such as blood glucose control (Englert et al., 2006), blood pressure (Jones et al., 2007), 
lipid and lipoprotein profile (Ferguson et al., 1998), markers of pro-inflammatory 
(Murtagh et al., 2005a) and pro-thrombotic states (Ivey et al., 2003) may be gained from a 
single session of PA. Therefore, the aims of the follow-up study, (study two in Section 
4.0), were to determine a) whether walking at 50% OO2max for 30 minutes may have an 
effect on risk factors associated with MetS during the 24 hour post-exercise period 
compared to a control trial, and b) whether increasing the intensity of the walk to 65% 
OO2max for 30 minutes or maintaining the intensity at 50% OO2max and increasing the 
duration to 60 minutes would alter the magnitude or duration of these responses. 
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2.0 Review of literature 
 
2.1 Metabolic syndrome: Definitions and mechanisms 
The concept of metabolic syndrome has been noted for 50 years, where obesity was 
recognised as a predisposition to diabetes and atherosclerosis (Vague, 1956). However, it 
was not until Reaven’s Banting Lecture in 1988 when insulin resistance was highlighted as 
a major public health problem associated with hypertension and hypertriglyceridaemia 
(Reaven, 1988). Subsequently, ‘upper-body obesity’, otherwise known as abdominal 
obesity, was added to the syndrome, which then became known as the ‘deadly quartet’ of 
insulin resistance, obesity, hypertension and hypertriglyceridaemia (Kaplan, 1989). Since 
then a number of related terms have been used to describe the syndrome, such as ‘athero-
thrombogenic syndrome’, ‘beer-belly syndrome’ and ‘chronic cardiovascular risk factor 
clustering syndrome’, but for ease of reference in this thesis it will be termed metabolic 
syndrome (MetS) (Ford, 2004a). Insulin resistance is characterised by decreased insulin-
mediated glucose clearance from the blood and abdominal obesity is an accumulation of 
adipose tissue particularly around the internal organs (viscera) and is a potent mediator of 
fatty acids (NEFA) and chemical messengers (adipokines) into the circulation (Moller & 
Kaufman, 2005). Hypertension is a chronic elevation in blood pressure that is mediated 
through increased sympathetic nervous system activity and impaired renal function and 
hypertriglyceridaemia relates to the elevations in blood triacylglycerol (TAG), which is 
associated with visceral obesity and is recognised today as dyslipidaemia, which also 
includes low levels of the ‘healthy’ high-density lipoprotein cholesterol (HDL-C) and 
elevations in pathogenic total cholesterol (TC) and low-density lipoprotein cholesterol 
(LDL-C). Pro-thrombotic and inflammatory markers have also since been implicated in the 
pathology of MetS (Reaven, 1994; Devaraj et al., 2004). 
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2.1.1 Obesity 
The purpose of adipose tissue is to store calories as TAG and release the energy in the 
form of NEFA when needed, but once the capacity of the adipocytes is exceeded, TAG 
accumulates in hepatocytes, myocytes and visceral adipocytes (Miranda et al., 2005). 
Excess TAG in myocytes and abdominal adipose tissue appears to cause insulin resistance 
within these cells. Total body fat can be assessed using a number of techniques, such as 
body mass index (BMI), body fat percentage, using skin fold callipers or more elaborate 
techniques, such as underwater weighing (Wajchenberg, 2000). Furthermore, since 
abdominal adiposity is an indicator of metabolic health, simple techniques such as waist 
circumference and waist:hip ratio (WC divided by hip circumference; WHR)  may be used 
to estimate abdominal adiposity in the absence of more elaborate techniques, such as 
computed tomography and magnetic resonance imaging. Waist circumference is 
significantly associated with MetS risk factors across white black and Hispanic Americans 
and can be used as a non-invasive clinical marker for the presence of MetS, and thus for 
assessing cardiovascular risk (Okosun et al., 2000), and is one of the best predictors of 
MetS (odds ratio 1.7 per 11 cm) (Palaniappan et al., 2004).  
 
Positive energy balance and increased adiposity are capable of provoking other aspects of 
MetS, where the pathogenesis of visceral fat (fat accumulation around the internal organs) 
on metabolic processes may be mediated through the release of damaging molecules or the 
juxtaposition of visceral fat allowing direct provision of NEFA to the liver (Moller & 
Kaufman, 2005). Larger adipocytes (fat cells), particularly visceral adipocytes, are more 
metabolically active, with higher rates of lipolysis and visceral adiposity may drive the 
impact of NEFA on insulin resistance through enhanced release of NEFA due to their large 
number of β-adrenergic receptors. The greater presence of these receptors increases the 
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release of NEFA into the blood, thus increasing the risk of NEFA-mediated muscular 
insulin resistance and hepatic triacylglycerol-rich very low-density lipoprotein-cholesterol 
(TAG-rich VLDL-C) output (Björntorp, 1990). Data indicate that activities of lipoprotein 
lipase (LPLa) and hormone-sensitive lipase increase more in visceral adipose tissue with 
fat feeding relative to subcutaneous adipose tissue leading to enhanced flux of NEFA into 
the portal circulation of the liver (Bergman et al., 2007). However, the high rates of 
lipolysis need to be matched with equally high rates of deposition through maintenance of 
positive energy balance, otherwise the visceral fat depot would disappear (Frayn, 2000).  
 
As well as aspects of MetS being mediated through elevations in circulating NEFA related 
to visceral obesity, adipose tissue-derived increases in adipokines (fat hormones), such as 
interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), resistin and 
reduced adiponectin secretion may also  mediate components of MetS (Bergman et al., 
2007). Increased adipocyte mass is also associated with increased expression of 
angiotensinogen, plasminogen activator inhibitor-1 (PAI-1) and leptin (Miranda et al., 
2005). Angiotensinogen is implicated with hypertension in the presence of obesity, PAI-1 
is related to anti-fibrinolysis, leptin is involved in suppressing appetite and TNF-α and 
resistin are involved in obesity-mediated insulin resistance. When adipose tissue becomes 
resistant to the action of insulin, the anti-lipolytic effect of insulin on adipose tissue TAG 
lipolysis is lost and NEFA release continues despite no metabolic need and either causing 
or amplifying muscular and hepatic insulin resistance (Björntorp, 1994). However, over the 
course of the day plasma NEFA concentrations are highly variable, which generally 
precludes their practical use in clinical medicine (Miranda et al., 2005). 
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2.1.2 Insulin resistance 
Metabolic syndrome may manifest itself through impaired glucose tolerance (IGT) or 
insulin resistance. This results in hyperinsulinaemia to compensate for the decreases in 
insulin-mediated glucose uptake (Reaven, 1988; 2001) and insulin resistance, characterised 
by IGT or type II diabetes, is the feature most often suggested as the underlying cause of 
the symptoms of MetS (Robinson & Graham, 2004). Insulin resistance may be a secondary 
phenomenon of excess fat, where even normal weight individuals may be metabolically 
obese and present increased abdominal obesity (Moller & Kaufman, 2005). Visceral 
obesity in particular may contribute significantly to insulin resistance, because abdominal 
adipose tissue is capable of secreting adipokines, such as adiponectin and resistin, which 
may contribute to insulin resistance. Larger adipocytes secrete lower levels of adiponectin, 
an adipokine that enhances insulin sensitivity by reducing lipid accumulation, and secrete a 
greater amount of resistin, which induces insulin resistance, increases plasma glucose and 
enhances hepatic glucose production. Insulin resistant adipocytes continue to secrete 
NEFA, despite the hyperinsulinaemic state, due to the inability of insulin to suppress 
lipolysis (Miranda et al., 2005). These NEFA are transported to the liver, which stimulates 
hepatic glucose output, and to muscle where they appear to inhibit insulin-mediated 
glucose disposal, thus impairing glucose clearance from the circulation.  
 
Acute increases in NEFA inhibit muscular glucose oxidation through the glucose-fatty acid 
cycle, where elevations in NEFA cause preferential NEFA oxidation rather than glucose 
oxidation and the accumulation of muscular glycogen, mediated through increases in 
muscular glucose, decreases insulin-mediated glucose uptake through decreased 
presentation of glucose transporter-4 (GLUT-4) on the plasma membrane (Moller & 
Kaufman, 2005). Disruptions to muscular NEFA disposal may contribute to insulin 
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resistance, however evidence for this appears to be confined to only those with a BMI ≥35 
kg·m-2 and it is difficult to differentiate cause and effect between insulin resistance and 
obesity, since both influence glucose and NEFA clearance from the circulation (Blaak, 
2005). Therefore, in lean individuals with impaired glucose tolerance, insulin resistance 
may be initiated through initial decreases in mitochondrial oxidative phosphorylation, 
where both fatty acids and glucose oxidation is insufficient, thus causing accumulation of 
these substrates within the muscle, which may be exhibited in lean and healthy individuals 
(Davidson & Yannicelli, 2006). Chronically, long-term obesity-induced elevations in 
circulating NEFA lead to increased intramuscular TAG, which also impairs insulin 
signalling and intracellular TAG may also accumulate in pancreatic islet β-cells and 
possibly impair insulin secretion (Moller & Kaufman, 2005). The maintenance of normal 
postprandial glucose homeostasis relies on pancreatic β-cells to secrete sufficient insulin to 
stimulate muscular glucose uptake, which is responsible for the disposal of 80-90% of the 
ingested glucose and suppress endogenous glucose production, of which over 80% derives 
from the liver (Miranda et al., 2005). For a given level of obesity an individual may have 
normal glucose tolerance, impaired glucose tolerance or type II diabetes mellitus, where 
the degree of the impairment is related to insulin sensitivity and β-cell reserve capacity, 
and long term over-stimulation of pancreatic β-cells to maintain euglycaemia can lead to β-
cell exhaustion and blood glucose levels begin to rise, eventually manifest as type II 
diabetes mellitus. 
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2.1.3 Dyslipidaemia  
A triad of lipid abnormalities are associated with MetS, forming an atherogenic blood lipid 
profile, including hypertriglyceridaemia, low HDL-C and greater concentrations of small 
dense LDL particles, where hypertriglyceridaemia is the central metabolic defect leading to 
risk of atherosclerosis rather than the usual culprit, elevated LDL-C (Moller & Kaufman, 
2005). Data indicate that both insulin resistance and obesity determine the lipoprotein 
profile, where those with insulin resistance have greater intra-abdominal fat, which are 
related to a higher cholesterol content in the VLDL, intermediate-density lipoproteins 
(IDL), small dense LDL particles and a lower cholesterol content in HDL particles (Nieves 
et al., 2003). Plasma HDL-C concentrations are one of the best predictors of the incidence 
of MetS (odds ratio 0.6 per 0.38 mmol·L-1) (Palaniappan et al., 2004). 
Hypertriglyceridaemia was recognised as being related to insulin resistance and the 
accompanying hyperinsulinaemia 40 years ago (Reaven et al., 1967) through increases in 
hepatic TAG-rich VLDL-C output, secondary to hepatic insulin resistance (Adiels et al., 
2006), and elevations in insulin and NEFA due to skeletal muscle and adipose tissue 
insulin resistance (Boden, 2006).  
 
Circulating plasma insulin concentrations determine the hepatic TAG-rich VLDL-C output 
response to the hepatic NEFA input dose, where the higher the insulin concentration the 
greater the degree of NEFA that enter the liver and are synthesised into, and secreted as, 
TAG (Reaven, 2005). This is due to the maintenance of insulin sensitivity by the liver in 
the face of adipose tissue and muscular insulin resistance-mediated compensatory 
hyperglycaemia, and small dense LDL particles are associated with this condition. Hepatic 
lipase hydrolyses TAG-rich lipoproteins, including TAG-rich HDL, which serves as a 
potential mechanism by which insulin resistance-induced increases in plasma NEFA 
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increase hepatic TAG production, which is transferred from TAG-rich VLDL to HDL 
particles to form TAG-rich HDL by the action of cholesteryl ester transfer protein (CETP) 
(See section 2.3)  (Moller & Kaufman, 2005). Furthermore, this same mechanism may be 
how LDL-C are transformed into small dense LDL particles in MetS, due to LDL-C being 
enriched with TAG by CETP and being cleared from the circulation by hepatic lipase, 
leaving only small dense LDL particles (Kathiresan et al., 2006). Compared with 
individuals with no MetS risk factors, those individuals characterised with MetS have 
smaller mean LDL particle size, which are associated with intima media (artery wall) 
thickness and inversely related to plaque occurrence and size (Hulthe et al., 2000). 
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2.1.4 Hypertension 
More than 85% of individuals with MetS have elevated blood pressure or hypertension 
(Franklin, 2006) and data indicates that individuals with MetS and elevated blood pressure 
demonstrate greater carotid atherosclerosis compared with those who present aspects of 
MetS but not elevated blood pressure (Irace et al., 2005). This illustrates the relative 
importance of the presence of hypertension in MetS as a predictor of CVD risk. Isolated 
systolic hypertension, without diastolic hypertension, is the most common hypertensive 
subtype in MetS, however isolated diastolic hypertension generally occurs at a younger age 
and exposes those to greater cardiovascular risk in the long term (Franks, 2006). 
Prospectively, baseline body mass predicts future increases in blood pressure, as does 
baseline blood pressure for future increases in body mass, i.e. elevated blood pressure at 
baseline indicates greater future risk of overweight/obesity (Julius et al., 2000). It has been 
postulated that there is a two-way relationship between obesity and blood pressure through 
a primary increase in sympathetic tone, whereby increased energy consumption, leading to 
positive energy balance, may enhance sympathetic tone and conversely β-adrenergic 
responsiveness in adipocytes may become diminished due to the sympathetic overactivity 
in hypertension.  
 
Mechanisms for the presence of elevated blood pressure in MetS include enhanced 
sympathetic nervous system (SNS) activity, insulin resistant blood vessels, insulin-
mediated enhanced tubular sodium reabsorption, increased release of regulatory agents 
from enlarged adipocytes, such as angiotensiogen, and an association between NEFA and 
blood pressure. Sympathetic nervous system activity is elevated in individuals with insulin 
resistance (Reaven, 2001), where infused insulin can augment SNS activity and provides 
evidence for a link between insulin resistance and hypertension (Moller & Kaufman, 
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2005). Insulin normally mediates vasodilation, however vascular tissues may become 
insulin resistant and thus non-responsive. Insulin acutely increases renal sodium retention, 
a further example of an organ retaining sensitivity to insulin, despite muscular insulin 
resistance (Reaven, 2001). Increased adipocyte mass leads to increased angiotensinogen 
production and angiotensin-converting enzyme (ACE), which both predispose to elevations 
in blood pressure, through their effects on renal function (Miranda et al., 2005). Systematic 
evidence suggests that circulating NEFA may also promote hypertension in insulin 
resistance, however the mechanism have not been elucidated, with suggestions including 
α1-adrenergic stimulation, endothelial dysfunction, increased oxidative stress or 
stimulation of vascular cell growth (Sarafidis & Bakris, 2007). 
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2.1.5 Emerging components 
The metabolic CVD risk factors associated with MetS do not appear to fully explain the 
elevated CVD risk associated with the syndrome, therefore other abnormalities may 
contribute (Sakkinen et al., 2000). Obesity leads to a pro-thrombotic and pro-inflammatory 
state that potentiates atherosclerosis (Moller & Kaufman, 2005). Elevations in plasma 
concentrations of fibrinogen and plasminogen activator inhibitor-1 (PAI-1) are associated 
with hypertriglyceridaemia and hypertension, and likely to be related to insulin resistance 
and compensatory hyperinsulinaemia (Reaven, 2001; Alberti et al., 2006). PAI-1 inhibits 
tissue plasminogen activator, which is a key regulator of the endogenous fibrinolysis 
system and thus thrombus formation, and PAI-1 is highly correlated with all components 
of MetS (Mertens et al., 2006). PAI-1 may even be any early marker of MetS and is 
secreted primarily by liver and endothelial cells, but also from adipose tissue, visceral 
adipose tissue in particular (Robinson & Graham, 2004). The greater the adipocyte and 
adipose tissue mass the greater the contribution to circulating PAI-1 because visceral 
adipose tissue has a greater capacity to synthesise PAI-1 than subcutaneous adipose tissue, 
which indicates the mechanism by which obesity may lead to impaired fibrinolysis (Skurk 
& Hauner, 2004). Where PAI-1 tends to cluster with BMI, fibrinogen, a strong risk factor 
for CHD (Yudkin et al., 2000), clusters with markers of inflammation (C-reactive protein; 
CRP), suggesting that it is a marker of underlying inflammation rather than pro-coagulant 
potential (Sakkinen et al., 2000). 
 
Inflammation plays an important role in the pathogenesis of atherosclerosis, where excess 
adiposity is associated with the release of inflammatory adipokines and contributes to an 
increase in CRP, which is an inflammatory marker and a CVD risk factor (Moller & 
Kaufman, 2005). Increases in circulating adipokines may mediate the obesity-induced 
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increases in fibrinogen and PAI-1 levels (Moller & Kaufman, 2005). Inflammatory factors 
that may be predictors or markers of CVD risk include CRP, IL-6 and TNF-α, where CRP 
predicts future CVD risk even in apparently healthy individuals (Yudkin et al., 2000). 
Associations between CRP with atherogenic dyslipidaemia in insulin resistance is 
mediated through increased fat mass and visceral adipose tissue accumulation, where CRP 
is significantly associated with fat mass and visceral adipose tissue and glucose tolerance, 
rather than blood lipid and lipoprotein profile in men with atherogenic dyslipidaemia 
(Lemieux et al., 2001). 
 
Microalbuminuria, hyperuricaemia and hyperhomocysteinemia are further parameters that 
have also been implicated with the presence of MetS. The involvement of 
microalbuminuria in MetS is considered by some to be controversial because there is no 
proven mechanistic evidence relating to an underlying cause for the elevated urinary 
albumin in MetS, however statistical associations have been found to suggest that 
microalbuminuria may be related to one of the observed manifestations of the syndrome 
(Alberti et al., 2006). Uric acid has also been implicated MetS because there is an 
association between coronary heart disease (CHD) and uric acid, which is also present with 
insulin resistance (Reaven, 2001). However, the relationship between uric acid and CHD 
appears to be an epiphenomenon, where kidneys retain insulin sensitivity, even when other 
organs of the body are insulin resistant, and respond to the day long elevations in insulin 
by decreasing urinary uric acid clearance. Due to the effects of insulin on renal function, 
increased sodium retention (pre-cursor for high blood pressure) is also associated with 
decreased renal uric acid clearance. Thus, elevated uric acid concentrations are merely 
markers of insulin resistance mediated through hyperinsulinaemia and impaired renal 
function. Homocysteine is an amino acid that has been implicated in MetS because 
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moderate hyperhomocysteinemia is an independent risk factor for atherosclerotic and 
thrombotic morbidity and mortality, through altering vessel wall connective structure and 
enhancing sympathetic activity (Garcin et al., 2006). However, it has only been weakly 
correlated with systolic & diastolic blood pressure and blood cholesterol & TAG, but not at 
all with BMI, WHR, blood glucose, insulin resistance, HDL-C and LDL-C. Therefore, 
despite hyperhomocysteinaemia being a useful risk marker in high-risk cardiovascular 
patients, it has little association with MetS. 
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2.1.6 Metabolic syndrome and cardiovascular disease 
Coronary artery disease (CAD) is a form of CVD specifically related to the circulation of 
the heart, where blood flow becomes impaired by atherosclerosis, which is a “multi-focal, 
smouldering, immuno-inflammatory disease of medium-sized and large arteries fuelled by 
lipids” that decreases the lumen of coronary arteries (Falk, 2006). Atherosclerosis-induced 
CAD may lead to coronary heart disease (CHD), a precursor for conditions such as 
myocardial infarction (MI), which is where perfusion is limited enough to cause permanent 
ischaemia and results in the area of myocardium that it supplies becoming infarcted. 
Atherosclerosis per se is rarely fatal, it is the thrombosis that occurs that forms on a 
ruptured plaque that precipitates the fatal cardiovascular events, such as stroke and MI 
(Falk, 2006). Risk factors for thrombosis include elevated levels of fibrinogen and PAI-1, 
an inhibitor of anti-coagulation processes, and thus decreased fibrinolysis (Libby & 
Theroux, 2005). Elevated serum cholesterol is sufficient to drive the development of 
atherosclerosis in the absence of other risk factors, however these risk factors, such as 
hypertension, type II diabetes mellitus and inflammatory markers, appear to accelerate a 
disease driven by atherogenic lipoproteins, particularly LDL-C. The accelerating properties 
of these risk factors may include increasing the atherogenicity of the LDL-C, i.e. particle 
size, number or composition, or increase the susceptibility of the arterial wall (Falk, 2006). 
Indeed, among patients with MetS, the progression of atherosclerotic stenosis has been 
shown to be twice as fast in patients with aortic stenosis (Briand et al., 2006). These risk 
factors are components of MetS, therefore it is clear that being diagnosed with MetS may 
be a strong indicator of CVD development, especially where MetS may increase the risk of 
cardiovascular death 2-4 fold and reduce life expectancy by 5-10 years (Libby & Theroux, 
2005). 
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A meta-analysis involving >300,000 participants has demonstrated that the adverse effects 
of overweight on blood pressure and blood cholesterol may account for a 45% increased 
CHD risk, both independently and addititively (Bogers et al., 2007). Stroke is the second 
highest cause of mortality worldwide and MetS has been implicated with stroke as well as 
CHD (Bang, 2006). Analysis of data from NHANES III demonstrated that ATPIII-defined 
MetS was significantly associated with future myocardial infarction (MI)/stroke 
development, where insulin resistance, hypertension, hypertriglyceridaemia and low HDL-
C were also independently related to MI/stroke (Ninomiya et al., 2004). The WHO (1998) 
definition of MetS has been found to identify individuals with increased risk of 
cardiovascular morbidity and mortality (Isomaa et al., 2001), as has the ATPIII definition, 
using participants involved in NHANES III (Alexander et al., 2003), which has also been 
demonstrated to predict new-onset diabetes (Sattar et al., 2003). However, evidence from a 
cross-ethnic population in west London comprising 2,346 Europeans, 1,711 South Asians 
and 803 African-Caribbeans suggests that the WHO (1998) and ATPIII (Cleeman, 2001) 
definitions of MetS provide an inconsistent picture of CVD risk across different ethnic 
groups and that ethnic-specific definitions should be developed (Tillin et al., 2005). The 
WHO (1998) and ATPIII (Cleeman, 2001) definitions of MetS predicted CVD prevalence 
in European and South Asian men, however the associations were weaker for African-
Caribbeans and inconsistent among European women. 
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2.1.7 Aetiology of metabolic syndrome - sedentariness 
Metabolic syndrome is a multi-factorial condition and consequently there are a multitude 
of possible causes, where just as the diagnosis of MetS requires a combination of risk 
factors (hypertension, insulin resistance, abdominal obesity & dyslipidaemia) there are also 
different lifestyle and genetic factors that encourage the development of MetS. Possible 
determinants of MetS include modifiable factors such as sedentariness – an inactive 
lifestyle – by promoting positive energy balance, and nutrition, through elevated energy 
consumption or an imbalanced intake of macronutrients, such as carbohydrates, which may 
increase energy balance and/or alter metabolism. Non-modifiable determinants of MetS 
include a genetic predisposition, gender (male), age (≥middle age), and more transient 
factors such as neuroendocrine imbalances and viral infections. Data from NHANES III 
suggests that when a combination of several low-risk lifestyle factors (physically active, 
non-smoking and moderate carbohydrate & fat consumption) are present in individuals 
with a BMI <30 kg·m2 those individuals are at a lower risk of developing MetS (Zhu et al., 
2004). These determinants may act independently, collectively or contribute to each other 
in a knock on effect. Due to the nature of this thesis the contribution of physical 
(in)activity will be discussed here. 
Sedentary behaviour impacts on MetS risk, where low levels of PA are associated with 
increased risk of obesity and its accompanying co-morbidities, such as hypertension, 
insulin resistance and dyslipidaemia, and performing less than 150 min·wk-1 of moderate-
vigorous leisure time PA increases the risk of developing MetS two-fold (Ford et al., 
2005). Decreased energy expenditure is the likely mediator between physical inactivity and 
increased MetS risk, where objectively measured PA energy expenditure (EE) has been 
demonstrated to predict the progression towards MetS, independently of OO2max and 
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obesity (Ekelund et al., 2005). The relationship between PA and MetS risk appears to be 
unaffected by OO2max or adiposity, suggesting that improvements in OO2max or decreases in 
adiposity are not absolutely necessary to decrease MetS risk, providing that PAEE 
increases. However, further studies are needed to confirm these slightly controversial 
findings, since men with a OO2max ≤29.1 mL·kg-1·min-1 are almost 7 times more likely to 
have MetS than those with a OO2max ≥35.5 mL·kg-1·min-1 (Lakka et al., 2003). Middle-
aged men performing less than 3 hrs·wk-1 of moderate-vigorous intensity leisure time PA 
are twice as likely to develop MetS compared to those performing more than 3 hrs·wk-1 of 
moderate intensity leisure time PA, and there is an even stronger inverse relationship 
between vigorous leisure time PA and MetS risk (Laaksonen et al., 2002). Men in the 
upper third of OO2max classification are 75% less likely to develop MetS than those in the 
lowest third. A subsequent study from the same research group demonstrated that men 
engaging in less than 1 hr·wk-1 of at least moderate intensity PA were at a 60% greater risk 
of developing MetS than those performing more than 3 hr·wk-1 of at least moderate 
intensity PA (Lakka et al., 2003). These findings are important because they indicate the 
crucial role of regaular PA on decreasing future MetS risk and treating those at risk or with 
current MetS, which is the basis for this thesis. 
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2.1.8 Summary  
The presence of MetS may be related in part to adiposity and fitness levels, but the over-
riding factor is likely to be of genetic origin, which predisposes individuals to some degree 
of impaired glucose tolerance, dyslipidaemia (↑ TAG & ↓ HDL), essential hypertension 
and a pro-coagulant and pro-inflammatory state (Reaven, 2006). Although the exact 
pathogenesis of MetS is not yet certain, it is generally postulated that a metabolic 
susceptibility, such as genetic insulin resistance, racial/ethnic factors, endocrine 
dysfunction, increased abdominal fat, physical inactivity and/or advancing age, may 
interact with obesity to present components of MetS (Grundy, 2006). Each of the 
individual components of MetS are independently related to increased risk of CVD, 
however when present in combination these components may lead to even greater CVD 
risk than the sum of their parts (Wilson, 2004). Therefore, MetS may be considered as an 
intermediary between discrete CVD risk factors and those who develop diabetes and CVD. 
The diagnosis of MetS requires the individuals to present a number of CVD risk factors, 
however, the classification of MetS is controversial since the World Health Organisation 
(WHO) (Alberti & Zimmet, 1998), National Cholesterol Education Panel Adult Treatment 
Panel III (ATPIII) (Cleeman, 2001), European Group for the Study of Insulin Resistance 
(EGIR) (Balkau & Charles, 1999) and International Diabetes Federation (IDF) (Alberti et 
al., 2006) have proposed subtly different classification criteria (Table 2.1). Generally, 
MetS represents a cluster of metabolic abnormalities, characterised by the presence of 3 or 
more of 1) abdominal obesity, 2) insulin resistance, 3) hypertension, 4) dyslipidaemia, and 
5) emerging risk factors, such as pro-thrombotic and pro-inflammatory states, which are 
each independent cardiovascular disease (CVD) risk factors.  
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Table 2.1 Definitions of MetS 
WHO (Alberti & Zimmet, 1998) EGIR (Balkau & Charles, 1999) 
• Impaired fasting glucose/impaired 
glucose tolerance/insulin resistance or 
diabetes, and 2 or more of:  
• Blood pressure – ≥160/90 mmHg 
• Plasma TAG – ≥1.7 mmol·L-1 and/or 
HDL-C <0.9 mmol·L-1 in men, and 
<1.0 mmol·L-1 in women 
• Waist:hip ratio – >0.90 in men, 
>0.85 in women, and/or BMI >30 
kg·m-2 
• Microalbuminuria – urinary albumin 
excretion rate ≥20 µg·min-1 or 
albumin:creatinine ratio ≥30 mg·g-1) 
• Hyperinsulinaemia – fasting insulin 
above the upper quartile in non-diabetics, 
and 2 or more of:  
• Hyperglycaemia – fasting plasma 
glucose ≥6.1 mmol·L-1 
• Hypertension – ≥140 and/or ≥90 
mmHg, or treatment for hypertension 
• Dyslipidaemia – plasma TAG ≥2.0 
mmol·L-1 and/or <1.0 mmol·L-1 or 
treatment for dyslipidaemia 
• Central obesity – waist circumference 
≥94 cm for men, ≥0.80 cm for women 
ATPIII (Cleeman, 2001) IDF (Alberti et al., 2006) 
• 3 or more of: 
• Waist circumference – >102 cm in 
men, >88 cm in women 
• Plasma TAG – ≥1.69 mmol·L-1 
• HDL-C – <1.04 mmol·L-1 in men, <1.29 
mmol·L-1 in women 
• Blood pressure – ≥130/≥85 mmHg 
• Fasting blood glucose – ≥6.1 mmol·L-1 
• Central obesity – waist circumference 
≥94cm for Europid men and ≥80cm for 
Europid women, plus any two of the 
following four factors: 
• Raised TAG – ≥1.7 mmol·L-1, or 
treatment for dyslipidaemia 
• Reduced HDL-C – <1.03 mmol·L-1 in 
males and <1.29 mmol·L-1 in females, 
or treatment for dyslipidaemia 
• Raised blood pressure – systolic BP 
≥130 OR diastolic BP ≥85 mm Hg, or 
treatment of previously diagnosed 
hypertension 
• Impaired fasting glucose – ≥5.6 
mmol·L-1, or previously diagnosed type 
2 diabetes 
WHO: World Health Organisation; EGIR: European Group for the study of Insulin 
Resistance; ATPIII: National Cholesterol Education Panel Adult Treatment Panel III; IDF: 
International Diabetes Federation. 
 
The WHO criteria were developed for research, whereas the ATP III criteria are useful in 
clinical practice. However, joint statements from the American Diabetes Association and 
the European Association for the Study of Diabetes published simultaneously questioned 
the relevance of the ‘syndrome’ related to insulin resistance based on a lack of certainty 
regarding its pathogenesis and a doubt regarding its value as a marker of CVD risk (Kahn 
et al., 2005a; 2005b). The basis of this argument was due to ambiguity of certain criteria, 
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i.e. whether to use systolic blood pressure and diastolic blood pressure, or either SBP and 
DBP, and whether this should be measured in the supine or seated position. Furthermore, 
waist circumference can be measured at a number of levels, therefore a specific protocol 
for measuring waist circumference should be specified. However, a recent prospective 
study has demonstrated that diagnosis of MetS by the WHO, ATPIII or IDF defined 
criteria impart similar diabetes and CVD risk, particularly in men aged ≥45 and women 
aged ≥55 (Lorenzo et al., 2007). 
 
Explaining the national and worldwide epidemiology of MetS has proven difficult due to 
differences in study design, sample selection, the precise definition of MetS criteria used 
and the gender & ages of the studied samples (Cameron et al., 2004). The overall 
prevalence of MetS is higher when using the WHO definition than with the ATPIII or 
EGIR definitions (Ford & Giles, 2003; Cameron et al., 2004). Using the ATPIII definition, 
Native American females and males demonstrated the highest worldwide MetS prevalence 
of 56.7% and 43.6%, respectively (Resnick, 2002), whereas French females and males 
demonstrated the lowest prevalence at 7.0% and 10%, respectively, and the mean 
worldwide prevalence of ATPIII-defined MetS is 27.9% for females and 22.8% for males 
(Cameron et al., 2004). Studies using the EGIR definition of MetS place older Italian men 
with the highest worldwide prevalence at 24.6% and Danish females at 16.0%, whereas 
Mauritian men (9.0%) (Cameron et al., 2003) and Dutch females (8.3%) (Balkau et al., 
2002) exhibit the lowest prevalence of EGIR-defined MetS, and the mean worldwide 
prevalence of EGIR-defined MetS is 10.9% for females and 16.1% for males (Cameron et 
al., 2004). The WHO-defined worldwide prevalence of MetS is 18.7% for females and 
28.2% for males (Cameron et al., 2004), with English males and females aged 40-65 
demonstrating the highest prevalence (>44.8 & 33.9%, respectively) and middle-aged 
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Italian males and females demonstrating the lowest prevalence (12.2 & 5.1%, respectively) 
(Balkau et al., 2002). Combined data from the San Antonio Heart Study and the 
Framingham Offspring Study, using either the WHO (1998) and ATPIII (2001) criteria, 
indicate that MetS affects ~20-30% of middle-aged Americans, and these individuals are at 
increased risk of diabetes and CVD than those without MetS (Meigs et al., 2003). Data 
from the Third National Health and Nutrition Survey 1988-1994 (NHANES III) show that 
the prevalence of MetS was 23.9% using the ATPIII definition and 25.1% using the WHO 
definition in 8,608 US adults and 86.2% of these were classified as having MetS under 
both definitions. Furthermore, the proportion of individuals in the US meeting the ATPIII 
MetS criteria increased from 24.1% reported in the NHANES III to 27.0% reported in the 
National Health and Nutrition Survey 1999-2000 (NHANES 1999-2000), primarily due to 
increases in waist circumference, hypertension and hypertriglyceridaemia, where 2000 
consensus data indicate that ~47 million US residents have MetS (Ford et al., 2002), and 
the increasing prevalence of MetS is likely to lead to future increases in diabetes and CVD 
(Ford et al., 2004). 
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2.2 Reverse cholesterol transport & physical activity 
2.2.1 Introduction 
The concept of reverse cholesterol transport (RevCholT) was introduced 40 years ago by 
John Glomset (1968), who proposed that lecithin-cholesterol acyltransferase (LCAT) was 
involved in the transport of cholesterol from the peripheral tissues to the liver. RevCholT is 
included in this discussion because each component of MetS – central adiposity, insulin 
resistance, elevated plasma triacylglycerol and hypertension – is associated with low levels 
of HDL-C (Lewis & Rader, 2005), which is a primary agent in RevCholT and a component 
of dyslipidaemia (Barter, 2004). Dyslipidaemia is a derangement in lipid metabolism that 
manifests itself in elevated levels of serum TAG, TC and LDL-C and suppressed HDL-C. 
This is not a benign disorder because such changes in the blood lipid profile, especially 
small dense LDL-C and lower HDL-C, are associated with increased cardiovascular 
mortality (Zhang et al., 2005; Clarke et al., 2007).  
 
Increased levels of LDL-C and decreased HDL-C create an environment that allows 
atherosclerotic plaques to form when LDL-C is oxidised into the tunica media of vessels, 
which increases the thickness of the arterial walls and narrows the lumen (Galle et al., 
2006). This can occur throughout the blood vessels of the body, however the greatest risks 
of atheroma are within the coronary and cerebral circulations, where decreased blood 
supply can increase the risk of ischaemia leading to myocardial infarction or 
cerebrovascular accident (Falk, 2006). Nevertheless, the body has the capability of 
reducing the risk of atheroma development through the process of RevCholT. This is the 
process by which cholesterol is removed from the circulation by HDL-C before it can be 
deposited in the artery walls (Figure 1) and also involves LCAT and cholesteryl ester 
transfer protein (CETP) (Fielding & Fielding, 1995). Other agents also involved include 
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lipoprotein lipase (LPL), phospholipid transfer protein (PLTP) and hepatic lipase, where 
increased LPL activity (LPLa) improves HDL-C concentration, whereas increased PLTP 
activity (PLTPa) and hepatic lipase activity impair HDL-C concentration.  
 
Fielding & Fielding (1995) 
 
 
Figure 2.1 RevCholT has five steps: 1) uptake of cholesterol from (cholesterol efflux), 
2) esterification of free cholesterol (FC) within HDL-C by LCAT, 3) 
transfer of cholesteryl esters (CE) to the apoB-containing lipoproteins 
(cholesterol transfer), 4) remodelling of HDL-C by CETP & PLTP and (5) 
uptake of cholesterol from HDL-C by the liver (cholesterol uptake). 
 
High-density lipoprotein (HDL-C) particles promote the efflux of excess cholesterol from 
peripheral tissues and return it to the liver for the production of bile in order to maintain 
cellular cholesterol homeostasis (Lewis & Rader, 2005). Apolipoprotein A-I (apoA-I) is 
secreted by the liver and intestines and represents ~70% of the apolipoprotein moiety of 
HDL-C and is present on the majority of HDL-C particles. When apoA-I is secreted it is 
lipid-poor and acquires cholesterol via lipid efflux of surface components of TAG-rich 
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lipoproteins in plasma. Low HDL-C is associated with insulin resistance, which causes 
hypertriglyceridaemia through increased hepatic production of very-low-density 
lipoprotein (VLDL) particles (Ji et al., 2005). The relationship between elevated TAG and 
decreased HDL-C may be explained by hyperinsulinaemia-blunted decreases in LPLa, thus 
decreasing TAG clearance and impairing maturation of HDL-C by enhanced CETP-
mediated exchange of TAG and cholesteryl esters between TAG-rich lipoproteins and 
HDL-C (Lewis & Rader, 2005). Combined with elevated hepatic lipase activity, the CETP-
mediated remodelling of HDL-C may result in enhanced hepatic apoA-I clearance. 
Furthermore, when HDL-C particles are TAG-rich they are poor acceptors of cholesteryl 
esters from LCAT and thus TAG-rich HDL-C particles are poor donors of cholesteryl 
esters to the liver, which further inhibits RevCholT (Skeggs & Morton, 2002). Therefore 
interventions, such as PA, that are known to decrease serum lipids and increase HDL-C 
concentrations are important in improving HDL-C function (See section 2.5.4 and Kodama 
et al. 2007 for review). 
 
Cholesterol ester transfer protein is an enzyme that impacts negatively on RevCholT, 
which circulates in plasma bound to lipoproteins and is produced by the liver and adipose 
tissue (Lewis & Rader, 2005). The main role of CETP is to redistribute hydrophobic lipids 
(cholesteryl esters & TAG) between HDL-C and apolipoprotein-B (apo-B) containing 
lipoproteins (intermediate-density lipoproteins (IDL), LDL-C, VLDL-C & chylomicrons). 
Cholesterol ester transfer protein enriches HDL-C with TAG and depletes them of 
cholesteryl esters, which reduces the size of the HDL-C particles (Skeggs & Morton, 
2002). Cholesterol ester transfer protein is rate-limiting during the transfer of lipids 
between HDL-C and TAG-rich lipoproteins, but not for cholesteryl ester transfer between 
LDL-C and HDL-C. Increases in CETP activity (CETPa), when exchanging cholesteryl 
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esters out of HDL-C in return for TAG, have the ability to reduce circulating HDL-C 
(Lewis & Rader, 2005).  
 
Lecithin-cholesterol acyltransferase is an enzyme that is bound to HDL-C particles and 
esterifies free cholesterol to form cholesteryl esters by transferring 2 acyl groups from 
lecithin to cholesterol. Cholesteryl esters are hydrophobic and thus remain within the 
HDL-C core, forming larger HDL-C particles (Sviridov & Nestel, 2002). However, the 
importance of LCAT in RevCholT has not been fully established because unesterified 
cholesterol can be directly transferred from HDL-C to the liver for excretion without the 
need for LCAT-mediated esterification (Lewis & Rader, 2005). Despite the equivocal 
importance of LCAT in RevCholT, it has been postulated that interventions to increase 
LCATa may be beneficial to health. Indeed, an in vitro study has demonstrated that 
increases in lipid-free apoA-I dissociation, such as decreased HDL-C particle density, was 
proportional to increased concentrations of VLDL-C, LDL-C and CETP, whereas HDL-C 
particle density returned to pre-intervention values when LCAT was introduced (Liang et 
al., 1994). 
 
Lipoprotein lipase is the enzyme principally responsible for TAG hydrolysis to form TAG-
rich lipoproteins into smaller TAG-depleted remnant particles and is found on the luminal 
surface of endothelial cells, particularly in adipose and muscle tissues (Lewis & Rader, 
2005). The process of TAG-rich lipoprotein hydrolysis releases surface lipids (free 
cholesterol and phospholipid) and apolipoproteins, which are added to HDL-C, thus 
increasing HDL-C and apoA-I concentrations. Decreases in LPLa may increase TAG-rich 
lipoproteins to such an extent that CETP-mediated lipid exchange of TAG to HDL-C 
would destabilise the particle, thus lowering HDL-C concentration and predisposing the 
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HDL-C to PLTP-mediated phospholipid exchange, creating lipid-poor apoA-I which can 
be cleared from plasma via hepatic lipase action in the liver. Phospholipid transfer protein 
exchanges surface phospholipids from TAG-rich lipoproteins to HDL-C and is responsible 
for the majority of phospholipid transfer in plasma (Lewis & Rader, 2005).  
 
Phospholipid transfer proteins remodel HDL-C into larger particles by merging smaller 
HDL-C, which results in one large HDL-C and the release of lipid-poor apoA-I (Ji et al., 
2006). TAG-rich HDL-C is most prone to remodelling due to the destabilisation of apoA-I 
with increasing TAG saturation, thus decreasing plasma HDL-C. Plasma HDL-C (apoA-I) 
are removed from the circulation by hepatic lipase. Hepatic lipase is synthesised by 
hepatocytes and predominantly converts HDL-C particles to smaller HDL-C remnants, 
pre-β HDL-C (marker of HDL-C production and acceptor of cellular cholesterol) and lipid-
poor apoA-I (Lewis & Rader, 2005). Increased CETP-mediated TAG-rich HDL-C 
enhances HDL-C remodelling by hepatic lipase, which commonly occurs in 
hypertriglyceridaemia because increased TAG concentrations destabilise HDL-C, causing 
the release of lipid-poor apoA-I which is excreted from the liver and reduces circulating 
HDL-C. Furthermore, plasma HDL-C is inversely proportional to hepatic lipase activity, 
and thus HDL-C is also a marker of dysfunctional lipid metabolism as well as having a 
direct role in RevCholT. Interventions to promote LPLa and to decrease the activity of 
PLTP and hepatic lipase could be beneficial to health because LPL facilitates RevCholT at 
the site of peripheral tissues, whereas PLTP and hepatic lipase inhibit the anti-atherogenic 
action of HDL-C (Ji et al., 2006). 
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2.2.2 Physical activity and reverse cholesterol transport 
Increasing physical activity (PA) has the potential to enhance RevCholT by decreasing 
CETPa, PLTPa and hepatic lipase activity, and increasing LPLa and LCATa, however 
there is little evidence for chronic adaptations in RevCholTran following PA intervention, 
despite evidence for increases in LPLa following a single exercise session (Gill et al., 
2003). The proposed association between systemic insulin resistance, hepatic insulin 
resistance and increased hepatic TAG-rich lipoprotein output provides a mechanism by 
which PA-induced changes may promote improvements in RevCholT. Insulin resistance is 
associated with obesity, particularly abdominal obesity, and PA of sufficient volume to 
decrease body fat should also affect insulin resistance. With the observed decreases in 
insulin resistance following PA (Katsanos, 2004) this would also decrease the hepatic 
lipase activity associated with insulin resistance. This is significant because hepatic lipase 
activity is partly responsible for the efflux of lipid-poor apoA-I from the plasma for biliary 
secretion, thus decreasing the plasma HDL-C, and this is a plausible mechanism by which 
increased PA may reduce HDL-C catabolism.  
 
A further effect of PA on RevCholT is on LPLa, particularly muscular LPL (Gill et al., 
2003). Physical activity significantly increases metabolism in the active musculature and 
lipolysis increases proportionally to PA intensity from rest until a threshold of ~65-70% 
OO2max, with the increases in lipolysis following PA being proportional to the PA-induced 
decreases in intramuscular triacylglycerol and glycogen stores (Seip & Semenkovich, 
1998). Following PA these must be restored, which results in increased uptake of TAG 
from the circulation. The increased need for blood-borne substrates increases LPLa, 
situated on the endothelium of the capillaries serving the active muscles, which is 
significant because LPL hydrolyses TAG-rich lipoproteins (LDL-C, VLDL-C & 
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chylomicrons). This is important for the maintenance of RevCholT because LPL removes 
TAG from the circulation before it can accumulate and destabilise HDL-C, resulting in the 
catabolism of HDL-C and its removal from the circulation.  
 
Lipoprotein-bound CETP is involved in the transfer of cholesteryl esters from HDL-C to 
TAG-rich lipoproteins and TAG from TAG-rich lipoproteins to HDL-C (Tall, 1993). As 
previously discussed, overloading HDL-C with TAG results in the destabilisation of HDL-
C with the net result of HDL-C catabolism. Therefore, if PA could influence CETPa, either 
through a direct effect or simply by lowering circulating TAG, then this provides a further 
mechanism for PA-induced increases in RevCholT. However, there is relatively limited 
literature describing the direct influence of PA/OO2max on reverse cholesterol transport, 
despite there being a wealth of data on the relationship between increased PA/OO2max and 
increased HDL-C concentrations, which is both an agent, and a rough marker, of 
RevCholT activity. Weight loss intervention programmes generally improve the blood 
lipid and lipoprotein profile (Purnell et al., 2000), therefore if physical activity intervention 
are sufficient to improve body composition then it is likely that they would have an effect 
on RevCholT through two mechanisms: 1) by increasing muscular TAG uptake, and 2) by 
alleviating the insulin resistance-mediated effect of excess body fat on hepatic lipase 
activity and PLTPa, that remodel and help to remove HDL-C from the circulation. 
 
The acute effects of exercise on factors relating to RevCholT have also been studied, such 
as HDL-C, LPLa, LCATa, CETPa and hepatic lipase activity (Zhang et al., 2002; 
Grandjean et al., 2000; Weise et al., 2005). The consensus of these studies was that a 
single session can potentially improve RevCholT in the short-term. However, despite 
reported positive increases in HDL-C, LPLa and LCATa for 48 hours, weaknesses in these 
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studies were that they failed to include control procedures within their study designs, 
therefore it is difficult to interpret the results compared to what may have happened 
naturally during the same period. 
 
The first published study investigating the influence of exercise training on plasma CETP 
was performed by Seip et al. (1993). The exercise training consisted of three to five 
sessions of supervised aerobic exercise (walking/jogging/stationary cycling) for 45-60 
minutes per week at ≤85% HRmax for 9-12 months. The main outcomes were that CETP 
concentrations fell and significantly in response to training, with the decreases in CETP 
concentration weakly associated with decreases in body fat. Pre-training CETP 
concentration predicted the training-induced increases in HDL-C, i.e. those with the lowest 
CETP concentrations gained the greatest increases in HDL-C and those with higher pre-
training CETP concentrations achieved the smallest increases in HDL-C. This is likely due 
to the destabilising effect of CETP on HDL particles through increased transfer of TAG 
into the HDL particle. 
 
In a cross sectional study of endurance athletes (33.6 ± 1.1 years; OO2max 53.4 ± 1.2 
mL·kg-1·min-1) versus moderately active controls (30.8 ± 1.0 years; OO2max 38.8 ± 1.0 
mL·kg-1·min-1), Olchawa et al. (2004) demonstrated that HDL-C, apoA-I, preβ1-HDL-C, 
LCAT activity and percentage cholesterol efflux from macrophages were each 
significantly greater in the athletes than the controls. However CETPa was similar. 
Furthermore, HDL-C, apoA-I and preβ1-HDL-C were significantly associated with OO2max 
in both groups up to a threshold of 51 mL·kg-1·min-1, which is consistent with other 
findings (Durstine et al., 1987). In a similar study, Brites et al. (2004) studied RevCholT in 
well-trained soccer players compared to sedentary medical students. The main findings 
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were that cholesterol efflux was greater in the soccer players than controls (20.5 ± 0.4% v 
15.0 ± 1.2%, respectively), which was directly associated with HDL-C, whereas LCAT 
and CETP activities were not influenced by PA level. Furthermore, cholesterol efflux was 
inversely correlated with waist:hip ratio (WHR) and LDL-C. However, while there is 
cross-sectional evidence demonstrating higher concentrations of LCAT in athletes 
compared to sedentary counterparts (Brites et al., 2004; Olchawa et al., 2004), there is no 
direct evidence that PA intervention can increase LCAT concentrations (Williams et al., 
1990) or LCATa (Bedgoni et al., 2002), despite significant decreases in body mass and fat 
percentage in these studies. 
 
In summary, the available evidence appears to suggest that PA has both an immediate and 
chronic impact on RevCholT, such as increased circulating HDL-C, mediated through 
decreases in circulating TAG. The immediate benefits of PA on RevCholT seem to be 
primarily exerted through increased LPL catabolism of TAG, whereas long term effects of 
PA may be mediated through decreasing hepatic insulin resistance, which decreases 
hepatic TAG-rich lipoprotein output, thus allowing HDL-C to transport cholesterol esters 
back to the liver more effectively without being saturated with TAG. Therefore, these 
mechanisms suggest the important role of PA in addressing dysfunctional blood lipid and 
lipoprotein profiles. 
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2.3 The management of metabolic syndrome with physical 
activity 
 
2.3.1 Introduction 
First-line therapies for the risk factors associated with the metabolic syndrome are weight 
reduction and increased PA (Cleeman et al., 2001). It has been suggested that the chronic 
effect of exercise on metabolic co-morbidities may be largely, but not entirely, as a 
consequence of body fat losses, especially of abdominal adipose tissue (Carroll & 
Dudfield, 2004). Cross-sectional evidence suggests that the relationship between fitness 
and the presence of MetS is mediated through lower adipose tissue, where the relationship 
between body fat percentage, visceral fat, subcutaneous fat and MetS components are 
stronger than the association between fitness and MetS components, and the effects of 
fitness on individual MetS components is mostly attenuated after controlling for total and 
abdominal obesity (Boule et al., 2005). Furthermore, evidence indicates that exercise does 
not significantly increase initial weight losses over and above that obtained with dietary 
intervention alone (Carroll & Dudfield, 2004). However, data substantiate the important 
role of exercise in the ‘mediation of a healthier bodyweight’ among overweight and obese 
adults without excessive energy deprivation, where the loss of only a few kilogrammes, 
particularly from visceral adipose tissue may lead to improvements in MetS components 
(Bussetto, 2001). Clinical trials have shown that modifying major components of the 
syndrome – atherogenic dyslipidaemia, hypertension and the prothrombotic state – will 
reduce CVD risk, yet few controlled studies have reported concurrently the effectiveness 
of exercise training alone for multiple metabolic risk factors (Carroll et al., 2004). 
 
Every 100 kcal·wk-1 expended by men participating in vigorous PA (≥7.5 METs) is 
associated with mean decreases of -0.36 mmol·L-1 in TC, -0.33 mmol·L-1 in TAG, -3 mm 
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Hg in diastolic blood pressure, -10 beats·min-1 in resting heart rate and -1.1 kg·m2 in BMI, 
and increases in HDL-C of 0.17 mmol·L-1 (Mensink et al., 1997). Furthermore, every PA 
session performed per week is associated with a decrease in TC of -0.014 mmol·L-1, -0.36 
beats·min-1 in heart rate, -0.093 kg·m2 in BMI, and serum lipids and BMI were more 
strongly associated with frequency than either intensity or duration of PA. Prospective 
evidence suggests that increasing PA routine after middle age even without active 
intervention is significantly associated with improvements in glucose control and HDL-C 
independently of changes in body mass compared to those who maintained their baseline 
PA levels over a 20 year follow-up period (Byberg et al., 2001). Furthermore, increased 
PA was also associated with decreases in pulse rate and serum TAG when the health 
outcomes were analysed without adjusting for weight change. However, despite cross-
sectional/prospective data to suggest that the presence of MetS is inversely associated with 
PA (Franks et al., 2004), there is relatively sparse data to demonstrate the independent 
benefit of PA without additional dietary intervention on components associated with MetS. 
This is despite recent reviews presenting many studies concerning the potential for 
increased PA to favourably influence the individual components associated with MetS, 
such as levels of total & abdominal obesity (Jakicic, 2003; Kay & Fiatarone Singh, 2006), 
insulin resistance & glucose tolerance (Henriksen, 2002; Yates et al., 2007), blood pressure 
(Pescatello, 2005), lipid and lipoprotein profile (Durstine et al., 2001) and markers of pro-
thrombotic & pro-inflammatory states (Imhof & Koenig, 2001; Kasapis & Thompson, 
2005).  
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2.3.2 Physical activity and weight control 
Obesity has classically been considered a problem of overeating, however persuasive 
evidence suggests that much obesity may be due to low energy expenditure rather than 
overeating (Prentice & Jebb, 1995). Excess fat deposition in the abdominal region, which 
is known to be independently associated with insulin resistance, glucose intolerance and 
dyslipidaemia, is a stronger predictor of CVD and T2D than overall adiposity (Abate, 
2000; Bonora, 2000). Dietary energy restriction has been the principal intervention strategy 
in attempts to reduce intra-abdominal fat and most current knowledge is based on energy-
restriction studies within obese adults, where it is apparent that for every kilogram of diet-
induced weight-loss there is an approximate 2-5% reduction in visceral fat (Kay & 
Fiatarone Singh, 2006). However, caloric restriction is associated with a decrease in resting 
metabolic rate (RMR) and thermic effect of feeding (TEF), thus resisting weight reduction 
or even maintenance of achieved weight loss, whereas a combination of caloric restriction 
with exercise enhances the maintenance of RMR and thus improves long-term results of 
weight reduction programmes (Eriksson et al., 1997). Resting energy expenditure in the 
obese is not related to BMI or insulin resistance, but is related to fat-free mass (FFM) (de 
Luis et al., 2005) and PA preserves lean body mass, unlike dieting alone, which is crucial 
since the major determinant of the 24hr EE is the fat-free body mass, accounting for about 
80% of the variance observed in 24hr EE between individuals (Pavlou et al., 1985; Horton, 
1986; Ravussin et al., 1986). However, the usefulness of increasing PA in order to lose 
weight has been somewhat controversial, mainly because: 1) intense long-duration PA has 
been prescribed to obese individuals, which is unrealistic in this population, 2) when PA 
weight-loss interventions alone have been compared to dietary weight-loss interventions, 
the dietary weight-loss interventions have been assumed to be more effective, but this is 
mainly due to greater energy deficits from the diet groups than that being expended in PA 
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groups, and 3) obese individuals tend to overestimate the amount of exercise and 
underestimate the amount of consumed food (Eriksson et al., 1997).  
 
A study by Katzel et al. (1997) examined the effects of sequential interventions of 9 
months of aerobic exercise training followed by weight loss (with continued training) on 
metabolic risk factors in obese middle-aged and older men, where PA increased maximal 
aerobic capacity by 14% but with no significant change in body weight or improvements in 
oral glucose tolerance responses, blood pressure and blood lipid & lipoprotein profile. 
However, evidence suggests that PA may have an independent effect on visceral and 
subcutaneous abdominal adipose tissue in overweight/obese individuals and an 8% weight 
reduction may reduce visceral fat mass by ~28%, and additional weight-loss intervention, 
without further fitness improvement, was associated with an 8% decrease in glucose, a 
30% decrease in insulinaemia during an oral glucose tolerance test (OGTT) and improved 
blood lipid & lipoprotein profile (Ross et al., 2000a; 2000b). Other studies have 
demonstrated that longer-term (≥12 months) PA, alone and combined with dietary 
intervention, has a significant impact on glucose-insulin homeostasis, blood lipid & 
lipoprotein profile and blood pressure in sedentary, overweight individuals at risk of MetS 
(Torjesen et al., 1997; Anderssen et al., 1998). The reductions in waist circumference 
(WC) significantly predict favourable changes in haemostatic parameters, blood lipid & 
lipoprotein profile and carbohydrate & lipid metabolism, independently of changes in 
physical fitness. In the Health Risk factors exercise Training And Genetics (HERITAGE) 
study including 621 sedentary African-American and Caucasian participants the 
prevalence of the ATP III-defined MetS was 16.9% and decreased to 11.8% following 
exercise training, where 30.5% of the 105 participants with MetS at baseline were no 
longer classified as having MetS and among these 32 participants, 28% decreased their 
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WC, 43% decreased TAG, 38% decreased blood pressure, 16% improved HDL-C and 9% 
improved fasting plasma glucose (Katzmarzyk et al., 2003). Evidence demonstrates that 
PA-induced reductions in total and abdominal fat are more strongly associated with 
improvements in blood pressure, blood lipid & lipoprotein profile and insulin sensitivity 
than the improvements in fitness (Stewart et al., 2005). However, both adiposity and 
fitness are important predictors of diabetes (Katzmarzyk et al., 2007). 
 
The frequency of PA is one of the most powerful determinants of successful weight 
maintenance because this facilitates the weekly accumulation of low-to-moderate intensity 
PA without the need for vigorous PA in order to achieve a satisfactory weekly EE and 
generally demonstrates good adherence to PA adoption (Jakicic, 2003). Data from ‘Studies 
of Targeted Risk Reduction Intervention through Defined Exercise’ (STRIDDE) 
demonstrate that six months of PA, consistent with CDC & ACSM guidelines (1995) 
(Section 2.8), was sufficient to prevent significant increases in visceral fat, however 
modestly increasing PA above these minimal recommendations (≥150 min·wk-1 moderate 
PA) significantly decreases visceral and abdominal fat without decreasing energy 
consumption (Slentz et al., 2005). The exercise prescription for improving body 
composition is related to creating a negative energy balance, whereby energy expenditure 
is greater than energy consumption, therefore daily moderate intensity PA sessions of at 
least 60 minutes may be required for this purpose in the obese (Pedersen & Saltin, 2006). 
The influence of increased PA on levels of obesity is created over a period of time, 
therefore the short-term benefits of PA on MetS risk factors associated with 
overweight/obesity may be mediated through mechanisms other than fat losses and these 
will be discussed within the subsequent sub-sections. 
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2.3.3 Physical activity and insulin resistance 
In addition to those with obesity, insulin resistance is often present in individuals who are 
not overtly obese, such as first degree relatives of T2D patients, where these ‘metabolically 
obese normal-weight’ individuals appear to be quite common in the general population, 
and they could be an important target population for exercise therapy for the prevention of 
MetS (Carroll & Dudfield, 2004). To achieve maximum benefit from modification of 
multiple metabolic abnormalities the underlying insulin-resistant state must become a 
therapy target (Minehira & Tappy, 2002) and it is now well established that bodyweight 
reduction improves insulin resistance in those that are overweight (Kelley & Goodpaster, 
1999; Ross et al., 2000b). Three major RCTs conducted in diverse countries, settings and 
incorporating various ethnic groups have confirmed that lifestyle intervention, including 
regular structured exercise can prevent or delay progression to T2D among high-risk 
groups with impaired glucose regulation (Tuomilehto et al., 2001; Knowler et al., 2002; Li 
et al., 2002).  
 
When endurance-trained individuals stop training, their enhanced insulin sensitivity is 
rapidly reversed (King et al., 1995), suggesting that this characteristic could partly be a 
consequence of the acute effects of their last bout of exercise. It has been demonstrated that 
acute exercise can normalise a defect in insulin-stimulated glucose transport-
phosphorylation in insulin-resistant subjects (Perseghin et al., 1996).  A single bout of 
acute exercise enhances insulin-mediated glucose disposal in normal subjects, in insulin-
resistant first degree relatives of T2D patients, in obese subjects with insulin resistance as 
well as in T2D patients. Exercising muscle may increase glucose clearance 7 to 20-fold 
(Wahren et al., 1971), where following an acute bout of exercise, glucose uptake into 
skeletal muscle is enhanced, which is partly an insulin-independent contractile effect and 
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may persist for several hours after the cessation of exercise (Henriksen, 2002). The 
enhanced post-exercise insulin sensitivity is most likely due to the need to replenish 
muscle glycogen, where glycogen-depleting exercise results in increased non-oxidative 
glucose disposal as measured 12 h after exercise (Henriksen, 2002). However, when an 
untrained leg was subjected to a single exercise bout there was no effect on insulin action 
in the untrained muscle, suggesting that ‘the effect of training on insulin-mediated glucose 
disposal in muscle is a genuine adaptation to repeated exercise… but is short-lived’ (Dela 
et al., 1992). Furthermore, in a study where one leg was trained over a period of 10 weeks 
and the other remaining untrained, GLUT-4 protein levels were 26% higher in the trained 
muscle, which was associated with an increase in insulin-stimulated glucose uptake in the 
trained leg (Dela et al., 1993). In addition to the glycogen-depleting effect of PA, reduced 
NEFA availability due to aerobic exercise may improve insulin sensitivity and glucose 
metabolism, where six weeks of PA at 60-85% OO2max for at least 60 minutes per week 
decreased circulating NEFA availability and improved insulin sensitivity, despite no 
changes in hepatic TAG or intramuscular TAG contents (Shojaee-Moradie et al., 2007). 
 
Data indicates that a threshold exercise intensity of 70% OO2max may be needed in order 
for short-term post-exercise improvements in insulin sensitivity, possibly due to the greater 
depleting effect of vigorous intensity PA on muscular glycogen stores (Thompson et al., 
2001). Indeed, data demonstrates that exercise increases insulin-stimulated glucose 
disposal through increased glycogen synthesis without affecting rates of glucose oxidation 
in both type II diabetic and non-diabetic participants and may last for at least 24 hours 
(Christ-Roberts & Mandarino, 2004). Possible mechanisms by which PA may improve 
insulin sensitivity include increased mRNA expression, increased glycogen synthase 
activity, decreased release of adipose tissue-derived NEFA and enhanced clearance of 
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NEFA and increased delivery of glucose and insulin to muscles through increases in blood 
flow (Pedersen & Saltin, 2006). In order to enhance muscular metabolism of glucose and 
NEFA the PA prescription should be of at least moderate intensity with the aim of 
increasing total levels of energy expenditure and evidence suggests that if exercise is to be 
effective in promoting insulin sensitivity, it should be regular, frequent and of sufficient 
volume, in terms of energy expenditure to maintain desirable level of body fatness in the 
long term (Kriska et al., 1994). This may be effectively achieved through the performance 
of 3-4 hours per week of moderate intensity PA, or 30 minutes of moderate intensity PA on 
a daily basis (Pedersen & Saltin, 2006). 
  41
2.3.4 Physical activity and dyslipidaemia 
The combination of hypertriglyceridaemia, low levels of HDL-C and small dense LDL-C 
particles have been named the ‘atherogenic lipoprotein phenotype’, ‘atherogenic 
dyslipidaemia’ or lipid triad (Grundy, 1998), which are associated with the purported 
central components of MetS (abdominal fat accumulation and insulin resistance). Intra-
abdominal fat is relatively insensitive to insulin and has a high lipolytic activity, partly due 
to its complement of adrenergic receptors (Björntorp, 1990) and hyperinsulinaemia and 
increased NEFA may affect several interconnected steps in lipoprotein-lipid metabolism 
(Carroll & Dudfield, 2004). Physical activity may improve the dyslipidaemic profile 
associated with MetS by increasing the ability of muscle tissue to take up and oxidize 
NEFA and increasing the activity of LPL in muscle (Pollare et al., 1991). Reductions in 
TAG and elevations in HDL-C are commonly associated with increased PA, however TC 
and LDL-C are infrequently affected (Durstine et al., 2001). Endurance-trained men and 
women demonstrate high rates of TAG clearance compared with sedentary controls, which 
may be related to the increased LPLa, the enzyme that hydrolyses TAG-rich lipoproteins 
(Kiens & Lithell, 1989). However, data suggests that the increases in TAG clearance 
associated with prior exercise are not related to improved insulin sensitivity (Gill et al., 
2002). This may benefit an atherogenic dyslipidaemic profile because circulating TAG 
concentrations are closely coupled with rates of HDL clearance and so an enhanced 
metabolic capacity for TAG may explain the high HDL-C levels in physically active 
people. In fact, in healthy trained men, a PA session expending 1,100 kcal may be 
sufficient to elevate HDL-C, however a lower PAEE threshold than this may be sufficient 
for sedentary individuals (Ferguson et al., 1998). Physically active individuals have higher 
levels of HDL-C and HDL2-C and lower levels of TAG, VLDL-C and small dense LDL-C 
compared to sedentary individuals (Haskell, 1984; Durstine & Haskell, 1994). Studies 
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concerning the effect of PA interventions on lipids and lipoproteins among subjects with 
the MetS remain scarce, partly due to the lack of precise definition of the syndrome. 
However, data indicates that over months, PA expending 1200-2200 kcal·wk-1 results in 
increases in HDL-C, which are even greater when the exercise programme is accompanied 
by weight loss (Durstine et al., 2001). Therefore, PA alone may not always be sufficient to 
normalise the atherogenic dyslipidaemia associated with MetS. Comparisons of two 
different interventions in sedentary overweight men and women – a hypo-caloric diet alone 
or the same diet plus PA (brisk walking and jogging) – showed that the addition of PA to 
the low-fat diet resulted in a greater reduction in WHR and more favourable changes in 
HDL-C than diet alone (Wood et al., 1991). 
 
The effects of acute PA on blood lipids are proportional to the energy expended, rather 
than meeting a specific EE threshold. However, despite those with the greatest TAG values 
having the potential for the greatest PA-induced reductions in blood TAG, unconditioned 
individuals may be unable to expend sufficient energy (Thompson et al., 2001). Evidence 
also suggests that PA may acutely increase blood HDL-C values, where an PAEE of 350-
400 kcal may be sufficient in moderately fit individuals. However, as with chronic training 
adaptations, changes in total cholesterol and LDL-C are more equivocal and potential 
favourable changes may be due to plasma volume expansion rather than changes in lipid 
metabolism (Thompson et al., 2001). A suitable exercise prescription for improving an 
atherogenic blood lipid and lipoprotein profile may be to aim to cover ≥20 km·wk-1 on foot 
(Pedersen & Saltin, 2006). 
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2.3.5 Physical activity and blood pressure 
Among normotensive adults, blood pressure values are inversely associated with insulin 
sensitivity, i.e. lower BP is related to greater insulin sensitivity, particularly among the 
relatively lean (Sowers et al., 2001). Furthermore, the insulin resistance of hypertension is 
often associated with a high rate of sodium/lithium counter-transport activity, salt 
sensitivity and microalbuminuria (Poppitt et al., 2002). However, several RCTs 
incorporating exercise only intervention groups have not been consistent in demonstrating 
improvements in blood pressure and postprandial insulin responses (Dengel et al., 1998; 
Blumenthal et al., 2000). It is possible that these inconsistent findings may stem from 
heterogeneity in the association between insulin sensitivity and blood pressure, which may 
help to explain the inconsistent blood pressure responses observed across PA intervention 
studies (Eriksson et al., 1997). Indeed, recent evidence from a cross-sectional study 
investigating the relationship between insulin sensitivity and hypertension suggests that 
adjusting for insulin sensitivity attenuates the relationship between habitual PA and 
hypertension in longitudinal exercise training studies (Foy et al., 2006). 
 
There may be certain subgroups of patients with hypertension who are more responsive to 
the blood pressure-lowering effects of PA, since the decrements in blood pressure 
associated with increased PA are not always sufficient to produce normotension in many 
studies (Eriksson et al., 1997). Despite the potential disparity, randomised controlled trials 
(RCTs) among overweight middle-aged and older subjects have also demonstrated the 
effectiveness of PA to lower blood pressure, with or without weight loss (Dengel et al., 
1998; Blumenthal et al., 2000). A 1999 meta-analysis of aerobic exercise training RCTs 
among overweight/obese participants, the blood pressure lowering effect of PA was small 
but statistically significant among normotensive study groups (baseline blood pressure 
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128/84 mm Hg) (Fagard, 1999) and a further meta-analysis showed modest weight loss (3-
9%) was associated with a significant reduction in mean systolic and diastolic blood 
pressures of approximately 3 mm Hg compared with non-intervention controls 
(Hermansen, 2000). The overall results of the published studies indicate that blood 
pressure reductions may be apparent within 10 weeks of hypertensive patients beginning 
participation in PA, with recent evidence to suggest that significant reductions are possible 
within 4 weeks (Collier et al., 2008) and blood pressure may continue to decline even 
further with prolonged maintenance of PA, which may occur independently of favourable 
changes in body composition (Hagberg et al., 2000). 
 
The reductions in blood pressure observed with regular PA may be due to the accumulative 
effects of single exercise bouts rather than to long term adaptations to PA (Kaufman et al., 
1987). The rationale for the exercise-induced decreases in blood pressure is that there is a 
marked dilation of blood vessels in active skeletal muscle decreasing resistance to flow 
during exercise, therefore the acute effects of exercise evident during recovery from 
individual bouts of exercise may be important, where the blood pressure of sedentary 
hypertensives may be reduced for up to 12 hours following a single exercise session 
(Pescatello et al., 1991; Brown et al., 1994). More recent data indicate that post-exercise 
hypotension may persist for up to 16 hours, thus PA may enable those with stage I 
hypertension to be normotensive for the majority of the day (Thompson et al., 2001).  
 
The immediacy by which post-exercise hypotension occurs suggests the hypotensive 
influence of regular PA may be partially an acute occurrence with the BP reductions 
accumulating as the training program continues (ACSM, 2004). Indeed, data from 
intervention studies suggest that longer training programmes may produce somewhat larger 
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reductions in blood pressure, suggesting that PA may impact on blood pressure control 
immediately and in the long term through separate mechanisms (Hardman, 1996). When 
the current ACSM recommendations for PA and hypertension were published the influence 
of the intensity and duration of PA sufficient to cause post-exercise hypotension was still 
unknown (ACSM, 2004). However, recent studies have demonstrated that although PAEE 
may be more important than either intensity or duration (Jones et al., 2007), it is now 
known that 15 minutes of PA at 40% OO2max is sufficient to promote post-exercise 
hypotension (Guidry et al., 2006). In order to achieve reductions in blood pressure, 
performing moderate intensity PA of at least 30 minutes on a daily basis should be 
sufficient to lower blood pressure, both in the immediate post-exercise period and for long-
term adaptations. 
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2.3.6 Physical activity, coagulation and inflammation 
The presence of MetS may predispose sufferers to an increased risk of thrombosis and 
inflammation, however both fitness (inversely) and fatness (directly) are associated with 
these disorders (Church et al., 2002). Despite this evidence, due to the limited number of 
studies involving the potential improvements in thrombotic and inflammation risk 
associated with PA, the exact PA dose to promote a favourable response is currently 
unknown. Metabolic processes within skeletal muscles may drive the anti-thrombotic 
effects of PA, where data demonstrates that the fibrinolytic activities of tissue plasminogen 
activator (tPA), and its endogenous inhibitor (PAI-1), were favourably altered in skeletal 
muscle and serum following 9 months of exercise training expending 2000 kcal·wk-1, as 
measured using the biopsy needle technique (Hittel et al., 2003).  
 
While TNF-α, IL-6 and PAI-1 have been the most studied inflammatory cytokines in 
lifestyle intervention studies to date (Bastard et al., 2000; Mavri et al., 2001; Bruun et al., 
2003), more recent attention has focused on adiponectin (Hulver et al., 2002; Faraj et al., 
2003) and CRP, a potent inflammatory mediator (Esposito et al., 2003). Analysis of data 
from the third National Health and Nutrition Examination Survey (NHANES III) appears 
to suggest that markers of inflammation (CRP, fibrinogen and white blood cell count) are 
decreased in association with increased participation in certain types of PA within the 
previous month, including jogging, swimming, cycling, aerobic dancing, callisthenics and 
resistance training compared to non-exercising controls (King et al., 2003). However, 
activities such as gardening were not associated with decreased inflammation, and the 
investigators conceded that due to only the frequency of activities being recorded, and not 
the intensity and duration of these activities, it was difficult to evaluate the relative value of 
each type of PA in terms of dose-responses. 
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Modulation of cytokines and other inflammatory mediators is achievable through lifestyle 
modification leading to weight loss in obese subjects (Robinson and Graham, 2004). 
Furthermore, individuals could still be classified as obese at the end of a study yet, in most 
cases, subjects still demonstrate significantly favourable improvements in inflammation-
related adipokines. Tumor necrosis factor-α is an inflammatory cytokine associated with 
obesity and Straczkowski et al. (2001) demonstrated a significant decrease in circulating 
TNF-α was not associated with insulin sensitivity after 12 weeks of exercise training in 
obese subjects, but the source of the TNF-α was not reported, and since fat mass and TNF-
α decreased by 7.9% and 19.6%, respectively, the effect of physical activity on circulating 
TNF-α appeared to be additive and independent of changes in body composition. Due to 
the paucity of studies of PA intervention on coagulation and inflammation, further studies 
are needed to clarify the association between level of obesity, prothrombotic & 
inflammatory markers and future risk for insulin-resistant conditions such as MetS and 
CVD. In most cases, plasma or serum cytokine protein concentrations have been measured, 
while adipose tissue mRNA and protein expression have been less studied (Robinson and 
Graham, 2004). It is difficult to distinguish possible independent effects of dietary factors 
and/or PA per se from the impact of weight loss itself. This may be an important 
consideration since the effects of exercise and weight loss on inflammation-related 
cytokines implicated in insulin sensitivity/resistance may function via different 
mechanisms 
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2.3.7 Current physical activity recommendations 
The current minimum PA recommendations are for 30 minutes of moderate intensity PA 
(at least 40/50% HRR) to be accumulated on 5 days of the week, 20 minutes of vigorous 
intensity PA (up to 85% HRR) to be performed on 3 days of the week, or a combination of 
the two sets of recommendations, such as 30 minutes of moderate intensity PA on two days 
of the week and a further two sessions of vigorous PA for 20 minutes (ACSM & AHA, 
2007). In each of the PA recommendations since 1978 there has been an appreciation of 
the trade-off between the intensity and duration of PA sessions, however the greatest 
emphasis on the benefit of performing moderate intensity PA for at least 30 min arose 
following the CDC & ACSM (1995) recommendations and has been maintained since. 
Another significant recommendation from this particular report was that PA may be 
accumulated throughout the day in sessions of at least 10 minutes instead of a single 
prolonged session of equivalent duration. The essence of the PA recommendations for 
health-enhancing PA have remained the same since 1995, however there has been greater 
clarification on the interaction between PA intensity, duration and frequency to provide the 
appropriate PA volume, such as performing high intensity PA for at least 20 minutes on at 
least 3 days of the week, or moderate intensity PA for at least 30 minutes on at least 5 days 
of the week, or combinations of the two (ACSM & AHA, 2007).  
 
Since the USGR (1996) was published, the ACSM (1998), CMO (2004) and ACSM & 
AHA (2007) have recommended that increasing PA volume through intensity, duration or 
frequency, or each, above the minimum recommendations may bring about greater 
reductions in the risk of CHD, diabetes, stroke, hypertension, obesity and certain cancers. 
The CMO report (2004) recommended that encouraging people to move from an inactive 
level to low to moderately active levels would produce the greatest reductions in risk and 
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that PA expenditures of 500-1000 kcals per week (~6-12 miles of walking for an average-
weight individual) should be sufficient. Physical activities such as walking/hiking, 
running/jogging, bicycling, swimming, rowing, rope skipping, skating, cross-country 
skiing and endurance-based games, dancing, walking during a round of golf, standing & 
casting whilst fishing, housework and gardening have been recommended as sufficient to 
promote health if performed for the recommended volume on a weekly basis. Since the 
mid-90s the accumulation of PA throughout the day has been encouraged to gain health 
benefits, where any increases in PA are better than none, however sessions of at least 10 
minutes per session adding up to at least 30 minutes per day are seen as a minimum target. 
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2.3.8 Summary 
Since there is a clustering of risk factors in association with MetS the treatment chosen 
should attempt to aim at as many of the metabolic abnormalities as possible, and this 
opportunity is provided by regular PA (Hardman, 1996; Carroll & Dudfield, 2004). Even 
though performing PA on fewer than two sessions a week at less than 50% OO2max and for 
less than 10 min/day may to be inadequate for developing and maintaining fitness for 
healthy adults, lower intensities and volumes may still be capable of inducing favourable 
changes in energy expenditure, muscle LPLa and blood pressure in sedentary or low active 
individuals (Eriksson et al., 1997). Evidence suggests that potential improvements in 
health outcomes related to MetS are inversely proportional to baseline health status, where 
those classified as ‘unhealthy’ are more likely to respond favourably than those classified 
as ‘healthy’ (Wilmore, 2001). 
 
Although most of the beneficial changes are well correlated with the loss of body 
weight/body fat, i.e. glucose homeostasis (Yates et al., 2007), increased PA may also 
stimulate metabolic improvements in the absence of weight loss, so failure to achieve this 
goal or improved fitness should not be interpreted to mean that no benefit has occurred 
(Ekelund et al., 2007). Long-term PA, without weight reduction, modestly decreases 
abdominal adipose tissue and improves insulin action among overweight/obese adults. 
Longer-term PA in middle-aged and older overweight/obese adults, even in the absence of 
clinically significant weight loss, is associated with modest, but clinically relevant 
improvements in the dyslipidaemic profile. This effect is created by lowering TAG and 
raising HDL-C and the most positive changes are evident among overweight/obese 
individuals with hypertension (Carroll & Dudfield, 2004). Perhaps, due to the potential 
negative health outcomes associated with MetS, such as CHD, diabetes and premature 
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mortality, individuals at risk of MetS are prescribed medication to control the individual 
components, such as statins for hypercholesterolaemia, beta-blockers for hypertension and 
metformin for T2D. However, despite performing PA above current public health 
recommendations (≥150 min·wk-1 moderate intensity PA) appearing to reduce such 
medication use (Williams & Franklin, 2007), there are currently insufficient data from non-
randomised and randomised exercise trials to establish dose-response relationships 
between intensity and volume of exercise and multiple metabolic abnormalities.  
 
The available data demonstrate a pattern between increased PA and decreased MetS risk, 
but well-designed RCTs are still required to establish the lower threshold for PA intensity 
and volume for favourable metabolic outcomes because there is presently limited evidence 
that lifestyle interventions, such as moderate intensity daily life physical activities, 
improve multiple metabolic abnormalities. Furthermore, the lower threshold of PA 
intensity and volume for promoting favourable acute responses in multiple metabolic 
abnormalities has yet to be established, therefore the influence of walking and 
accumulative PA on health outcomes will be discussed in the subsequent subsections 2.6 
and 2.7. 
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2.4 Walking for health 
2.4.1 Introduction 
For most (>99.5%) of the last 100,000 years walking has been modern homo sapiens’ main 
source of PA during ambulation and daily chores, however within the past 200 years daily 
PA levels have been systematically reduced by advancements in technology, such as cars 
and occupational instruments (Haskell & Torburn, 2006). In recognition that activities of 
daily living were decreasing, the notion of 10,000 steps per day originated from Japan in 
the 1960s and was exported to many countries in the late 1990s (Hatano, 1993; Haskell & 
Torburn, 2006). Very active individuals may still cover over 12,000 steps per day, with a 
sliding scale of active individuals (≥10,000 per day), somewhat active (7,500-9,999), low 
active (5,000-7,499) and sedentary individuals attaining less than 5,000 steps per day 
(Tudor-Locke & Bassett, 2004). Furthermore, studies evaluating how 10,000 steps per day 
equates to current public health recommendations (≥150 min·wk-1) found that 73% of those 
who attained ≥10,000 steps per day also reported performing 30 minutes of moderate 
activity per day (Welk et al., 2000). However, a more recent study demonstrated that 
walking for 30 minutes only required ~3,000 steps, indicating a deficit of 7,000 steps that 
needed to be met to fulfil the 10,000 daily steps required (Tudor-Locke et al., 2005a). 
Therefore, in order to meet the 10,000 steps per day target individuals must participate in 
other lifestyle activities on top of the structured 5 × 30 min sessions of brisk walking. 
 
Despite evidence to the contrary, many people believe that PA must be of vigorous 
intensity to be beneficial to health-related fitness, which is perhaps grounded in the 
exercise training for sporting performance paradigm, where improved fitness is associated 
with aspects of health (Timperio et al., 2000). However, even though vigorous PA is 
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beneficial to health, activities of daily life, such as walking, can be accumulated throughout 
the week to provide a large enough volume of PA to gain significant health benefits, 
evidence of which has been available for over 50 years (Morris et al., 1953). Sporting 
activities and structured exercise programmes are rarely part of many peoples’ lives due to 
age-related decreases in vigorous activity, the increase in sedentary occupations and lack 
of interest in participation in such activities (Haskell & Torburn, 2006). However ‘active 
transport’, which includes daily activities such as walking & cycling, and using stairs 
instead of escalators/lifts, has the potential to be a significant source of habitual PA for 
every able-bodied individual. The main premise of active transport is that travelling from 
A to B is a convenient way of increasing daily/weekly PA compared to automobile 
transportation and can also form part of leisure and recreational activities. This section will 
specifically refer to walking.  
 
Public health recommendations (ACSM, 1978 through to ACSM & AHA, 2007) have 
included walking as an aerobic activity, because it is dynamic, rhythmical and uses large 
muscle groups for prolonged periods. Brisk walking exerts a greater metabolic load on 
those with low OO2max and thus promotes improvements in OO2max that are directly related 
to walking speed (Haskell & Torburn, 2006; Duncan et al., 1991). Walking at 4.8 k·hr-1 on 
a level surface requires a OO2 of ~13 mL·kg-1·min-1, which may be less than 30% OO2max 
of a healthy 30-year-old man, whereas for the same individual at 75-years-old this could 
amount to over 60% OO2max due to age-associated declines in OO2max (Morris & Hardman, 
1997). Walking at any pace expends energy and at the least has potential for weight 
control, however when individuals are instructed to walk briskly they automatically select 
a pace that elicits an intensity of ~70% HRmax (~60% OO2max) and likely to improve 
cardiovascular fitness (Morris & Hardman, 1997; Murtagh et al., 2002). Furthermore, a 
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previous study also reported that habitual walkers, OO2max 35.7 ± 6.3 mL·kg-1·min-1, met 
the ACSM’s recommendations for improving OO2max (Spelman et al., 1993). Health risk 
factors that may be attenuated with regular moderate intensity PA, such as walking, 
include decreased arterial blood pressure, alteration in the lipoprotein profile, particularly 
decreases in TAG-rich particles and increases in HDL-C, enhanced glucose tolerance, 
lower tendency for thrombosis, decreased myocardial oxygen demand at rest and 
submaximal workloads and increased capacity of coronary circulation for vasodilation 
(Haskell & Torburn, 2006). 
 
Those individuals that public health recommendations are aimed towards, such as 
sedentary obese individuals, may also benefit the most from increased walking activity 
because this population appears to be less energy efficient during walking (Foster et al., 
1995; Chen et al., 2004), thus having greater implications for weight control, lessening the 
need for vigorous activity and also decreased risk of injury or sudden death. Furthermore, 
due to this reduction in movement economy there is an increased cardiovascular load, 
which means that the obese have greater potential to improve weight control and gain 
fitness from speeds equivalent to ‘walking for pleasure’ (Browning & Kram, 2005; Hills et 
al., 2006). A study by Williams (2005) demonstrated that this is possible whereby those 
who walked the least were most obese and those individuals had the greatest potential for 
declines in weight. 
 
Cross-sectional evidence has demonstrated that measures of obesity (BMI & fat%) are 
inversely related to ambulatory activity (Tudor-Locke et al., 2001; Yoshioka et al., 2005). 
In a relatively small-scale cross-sectional study of 150 older adults low rates of steps per 
day (<3100 steps·d-1) were associated with increased risk of some components of MetS, 
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including high TAG and central adiposity, whereas steps·d-1 were not predictive of the 
development of hypertension, impaired fasting glucose and low HDL-C (Strath et al., 
2007). However, overall in the Caucasian group, those accumulating <3100 steps·d-1 were 
96.8% more likely to have MetS than those accumulating >3100 steps·d-1. In a further 
epidemiological study, investigating the relationship between steps per day and WC & 
BMI, increased daily steps were associated with a decline in measures of obesity (Dwyer et 
al., 2007). Furthermore, an additional 2,000 steps per day was associated with a 2.8 cm 
decrease in waist circumference in those taking only 2,000 steps·d-1, yet only a 0.7 cm 
reduction in WC in those already taking 10,000 steps·d-1. Thus, the benefits of daily 
walking are logarithmic and those performing little habitual lifestyle PA have the greatest 
potential benefit from increased ambulation. Due to the cross-sectional nature of these 
studies causality of obesity due to ambulatory inactivity cannot be determined, therefore 
Williams (2007) performed a prospective study to investigate the role of ‘leanness’ in 
determining walking intensity and distance. The findings of the study were that although 
walking intensity and walking distance were both strongly associated with greater leanness 
the author concluded that distance was more causally related to leanness than intensity and 
should be encouraged for preventing/reversing weight gain. However, despite leanness 
being more causally associated with walking distance (Williams, 2007), when the impact 
of walking intensity and walking duration on all-cause mortality was investigated there 
was a significant inverse association between daily walking intensity and risk of death, 
whereas there was only a weak inverse association between daily walking duration and risk 
of death (Schnohr et al., 2007). 
 
Walking has been demonstrated to be at least as effective as equal volumes of more 
vigorous exercise in improving OO2max, where six months of six weekly 30 min sessions of 
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walking at 50% HRmax produced similar increases in OO2max (2.5 v 2.9 mL·kg-1·min-1) 
compared to four 30 min sessions per week of jogging without significant changes in body 
composition or lipid profile (Suter et al., 1994). Despite the improvements in OO2max from 
both groups not being associated with improvements in body composition or lipoprotein 
profile in that study, a more recent prospective study involving 73,743 postmenopausal 
women demonstrated that walking and vigorous exercise were associated with similar 
cardiovascular risk reductions on follow-up and a faster walking pace also predicted lower 
risk (Manson et al., 2002). Carrying on the theme that PA does not have to be vigorous to 
be effective, Duncan et al. (1991) demonstrated that although there was a dose-response 
effect between walking speed (4.8 v 6.4 v 8.0 k·hr-1) and improvement in OO2max following 
the performance of 4.8 km of walking per day on 5 days of the week for 24 weeks, HDL-C 
was equally affected by the low- and vigorous intensity walks. Therefore, indicating that 
energy expended during the walks, as indicated by the distance walked in each group (24 
km·wk-1), was key to the health improvements rather than walking speed.  
 
Walking is an activity that is usually performed on a daily basis in activities of daily living 
rather than part of a structured exercise programme. Due to the nature of activities of daily 
living they are not performed in a neat and single three hour session, but are accumulated 
throughout the day in numerous discrete sessions, therefore the various studies that used 
walking as the mode of PA to investigate the health benefits of accumulative walking will 
be discussed in Section 2.7 and the next two sub-sections will deal with the short-term and 
long- term health outcomes of walking. 
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2.4.2 Short-term responses 
Aside from the adaptations that take place following regular participation in walking 
activities, single walking sessions can have significant, although short-term, health benefits 
that may be maintained through regular PA. The potential effects of any form of PA 
intervention are limited in their short-term effects because not every health risk factor can 
respond immediately in the post-exercise period, i.e. reductions in body weight and its 
associated variables, therefore the majority of acute walking studies have focused on the 
influence of walking on postprandial lipaemia in particular, although some studies are 
available on the acute effects of walking on blood lipoproteins (Pronk et al., 1995; Ainslie 
et al., 2005), fibrinolysis (Ivey et al., 2003), inflammation (Murtagh et al., 2005a) and 
blood pressure (Park et al., 2006). Walking at 50% OO2peak for 40 minutes in a single 
session has been reported to decrease SBP by -5.6 ± 1.6 mm Hg and DBP by -3.1 ± 0.2 
mm Hg for 7 hours in pre-hypertensive adults and this effect was augmented when walking 
was accumulated in 4 × 10 min bouts, which caused SBP to decrease by 5.4 ± 1.7 mm Hg 
for 11 hours and DBP by 3.4 ± 1.3 mm Hg for 10 hours (Park et al., 2006). 
 
In a sample of stroke patients walking at 60% heart rate reserve (HRR) for 20 minutes 
resulted in a 79% increase in tPA activity and decreased PAI-1 activity by 18% 
immediately post-walk and plasma tPA activity remained elevated by 43% and PAI-1 
activity was depressed by 25% at least 1-hr post-walk (Ivey et al., 2003). These findings 
are significant because tPA dissolves excess fibrin clots, which may otherwise increase 
risk of thrombosis and PAI-1 is the main physiological inhibitor of tPA. An extension of 
this study would be to measure the activities of tPA and PAI-1 beyond 1-hr post-walk to 
determine the possible duration of effects, however these must be interpreted with the 
sample in mind since post-stroke patients are likely to have greater potential for 
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improvement than the apparently healthy population due to their predisposition for 
thrombosis. Due to the emerging importance of inflammatory mediators and the fact that 
these may alter acutely following intense exercise, the influence of walking at 60-70% 
HRmax on the inflammatory response has been investigated (Murtagh et al., 2005a). The 
main findings of a walking study on inflammation were that walking at 60-70% HRmax for 
45 min tended to decrease IL-6 from baseline (1.92 ± 0.29 mg·L-1) to 1.73 ± 0.18 mg·L-1 
and 1.76 ± 0.16 mg·L-1 immediately- and 1-hr post-walk (NS) respectively, however it was 
significantly decreased 24 hours post-walk (1.37 ± 0.14 mg·L-1). Samples were only 
collected up to 1-hr post-walk, therefore it was only possible to see changes in IL-6 at 24-
hr post-walk, which may have been apparent earlier. Furthermore, the study only employed 
a single trial, whereas a control trial may have highlighted other patterns. 
 
Plasma NEFA and glycerol concentrations can increase by ~31% and ~49%, respectively, 
following 1-hr of walking at 36% OO2peak compared to resting values, indicating increased 
rates of adipose tissue lipolysis and muscular oxidation (Kaminsky et al., 1986). 
Furthermore, plasma glycerol peaked at the end of exercise whereas plasma NEFA carried 
on increasing and peaked at 10 min post-exercise and plasma NEFA remained above 
resting values until at least 60 minutes post-exercise. Walking during the postprandial 
period has demonstrated decreases in alimentary lipaemia and especially during the post-
walk period in response to a high-fat meal. Acute exercise studies of postprandial lipaemia 
have used a variety of timings of exercise prior to or following the high fat meal. The 
effect of walking on postprandial lipaemia has been investigated by participants walking 
up to 1.5 hours into the postprandial period (Hardman & Aldred, 1995), 12 hours before 
(Tsekouras et al., 2007), 15 hours before (Aldred et al., 1994; Tsetsonis et al., 1996a; 
1996b), 18 hours before (Gill et al., 2003) and also over successive meals during the day 
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(Murphy et al., 2000). When normolipaemic young adults walked at 40% OO2max for 1.5 h 
following consumption of a high-fat test meal the 3-hour TAG area under the curve 
decreased by ~24% compared to resting control (Hardman & Aldred, 1995). The decrease 
in plasma triacylglycerol concentrations indicate increased alimentary TAG clearance, 
presumably through increased muscular TAG uptake, as previously mentioned in section 
2.3.  
 
The greatest decreases in postprandial lipaemia following walking occur from studies 
where walking is performed at least 12 hours prior to the high fat meal. Walking for 2 
hours at only 30.9 ± 1.6% OO2max 15 hours before the meal significantly decreased 
postprandial lipaemia (Aldred et al., 1994). Furthermore, 3 hours of low intensity walking 
(32 ± 1% OO2max) has been found to be as equally effective as 1.5 hours of moderate 
intensity walking (63 ± 1% OO2max) in reducing postprandial lipaemia compared to control 
(Tsetsonis & Hardman, 1996a). Indeed, it appears that the energy expended during walking 
was the key because a further study from this group found that walking for 90 minutes at a 
moderate intensity (61 ± 1% OO2max) was more effective than walking for the same 
duration at a low intensity (31 ± 1% OO2max) (Tsetsonis & Hardman, 1996b). It has been 
demonstrated that increases in LPLa are responsible for some of the reductions in 
postprandial lipaemia resulting from moderate intensity activities, such as walking, 
however LPLa does not explain all of the effects (Gill et al., 2003). 
 
In terms of ecological validity it is unusual for people to consume a meal excessively high 
in fat, as with the high fat test meals, and then fast for at least 6 hours, as is the case with 
many postprandial lipaemic exercise studies. Therefore in variation to the usual exercise 
study design for investigating postprandial lipaemia the effect of single and accumulative 
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bouts of walking on the postprandial lipaemic response to successive meals was studied to 
replicate every day lifestyle rather than fasting for ~6 hours (Murphy et al., 2000). The 
main findings of the study were that walking at 60% OO2max for either 30 minutes at the 
start of the day or for 10 minutes prior to each of the three prepared meals equally 
decreased postprandial lipaemia compared to controls and this effect was augmented 
following successive meals. A further study on postprandial lipaemia and of similar real 
life relevance investigated the effect of walking at 50% OO2max for 30, 60 and 90 minutes 
compared to control immediately followed by the ingestion of a mixed meal of moderate 
fat content, which was followed by another similar meal three hours later (Pfeiffer et al., 
2005). The main findings of the study were that although the 60 and 90 minute walking 
sessions reduced postprandial lipaemia by 14 & 15% respectively, these were not 
significant and indicate that either mixed meals are of insufficient fat content to overload 
fat uptake into the blood and thus provide walking intervention with limited potential for 
effect or that a longer timescale between walking and the meals was needed in order for 
adaptations to take place in the lipid handling processes, such as increased LPLa. 
Alternatively, it may have been that the walking was of insufficient volume (90 min at 
50% OO2max) to promote an effect. 
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2.4.3 Long-term adaptations 
Walking is the most common mode of exercise studied when investigating the efficacy of 
accumulative PA on factors of health-related fitness. However, physicians can sometimes 
be hesitant to recommend increasing lifestyle physical activities for improving health 
outcomes rather than more vigorous pursuits, which is not helped by the equivocal 
evidence from underpowered walking studies and those with small sample sizes. 
Therefore, a recent meta-analysis of 24 randomised controlled trials was performed to 
make use of the greater statistical power of multiple studies and provide evidence that 
regular brisk walking improves health outcomes in sedentary healthy individuals by 
significantly improving traditional cardiovascular risk factors; OO2max, body weight, BMI, 
percent body fat and resting diastolic blood pressure (Murphy et al., 2007). Eighteen of the 
studies included females only and four mixed, with a total of 193 men and 935 women 
with a drop-out rate of 20.2% and 12.4% from walking and control trials, respectively.  
 
The mean characteristics of the walking interventions were 38.3 ± 14.4 mins·session-1, on 
4.4 d·wk-1, giving a mean volume of 188.8 min·wk-1, for 34.9 ± 4.9 weeks, at a mean 
intensity 70.1 ± 9.1% HRmax (56.3 ± 7.1% OO2max) reported from 20 of the studies, and the 
mean rate of adherence was 87.8 ± 9.9%. Following the pooled walking interventions there 
was a mean increase in OO2max of 2.73 ± 0.35 mL·kg-1·min-1 (9%), mean decreases of -0.95 
± 0.61 kg (-1.4%) and -0.28 ± 0.20 kg·m-2 (-1.1%) and -0.63 ± 0.66% (-1.9%) in body 
mass, BMI and body fat percentage, respectively, compared to baseline. Each of these 
favourable changes were significant (P≤0.035) and although resting diastolic blood 
pressure was significantly decreased by -1.54 ± 0.79 mm Hg (-2%; P=0.026) systolic blood 
pressure was not favourably changed through walking intervention. However, relatively 
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few studies measured blood pressure pre & post (SBP=9; DBP= 6), thus decreasing the 
chances of a favourable outcome compared with the other measures. 
 
In a meta-analysis of 25 randomised controlled walking trials involving 18 women only 
trials, 2 male only trials and 5 mixed sex trials, 1,176 participants were studied to 
investigate the influence of walking on blood lipids and lipoproteins (Kelley et al., 2004). 
The walking studies were performed at 64.2 ± 9.4% OO2max for 38.4 ± 15.6 min·session-1 
on 4.8 ± 2.5 d·wk-1 for 23.2 ± 17.7 weeks and the rate of adherence was 83.4 ± 18.0%, The 
main findings of the analysis was that walking can significantly reduce LDL-C by ~5% 
and TC/HDL-C ratio by ~6% independently of reductions in body mass, and although no 
significant changes in TC, HDL-C or TAG were observed, the direction of change tended 
to be favourable. A secondary finding of the study was an increase in OO2max of 3.6 ± 0.5 
mL·kg-1·min-1, which equated to a 15% increase compared to controls, but body mass, 
BMI, percent body fat and lean body mass were not significantly altered. 
 
A study investigating similar health outcomes to those presented in section 3.0, such as 
measures of body composition and insulin resistance, demonstrated that by instructing 
sedentary obese Japanese participants to add 1,000 steps to daily walking activity at 
baseline for a 1-yr period, the increase in steps·d-1 was significantly correlated with 
reductions in visceral adipose tissue which was also associated with decreases in the 
homeostasis model assessment index (HOMA) (P<0.001) (Miyatake et al., 2002). 
Measures of changes in body composition also correlated significantly with decreases in 
HOMA index included body mass, BMI, WC, WHR, and subcutaneous & visceral fat area 
(all P<0.05), however body fat percentage was not. A prospective study investigating the 
efficacy of walking on future risk of developing T2D in 70,102 female nurses aged 40-65 
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years found that walking produced similar magnitudes in risk reduction as vigorous 
activity of equivalent energy expenditure and that increased walking pace was 
independently associated with decreased risk during 8-year follow up (Hu et al., 1999). 
These findings have significant health implications as all-cause mortality among US adults 
with diabetes was reported to be 39% lower in individuals who walk at least 2 h·wk-1 and 
those who walked 3-4 h·wk-1 had the lowest risk at 8-year follow up (Gregg et al., 2003).  
Participants with T2D that were instructed to walk >10,000 steps·d-1 on ≥5 d·wk-1 for 6 
weeks significantly increased HDL-C and resting energy expenditure, while significantly 
reducing PAI-1 activity compared to controls (Araiza et al., 2006). One of the few studies 
to investigate the influence of walking on coagulation demonstrated that walking at 73.5 ± 
7.2% HRmax for 18 weeks significantly decreased factor XIIa (FXIIa), the active form of 
FXII that is involved in coagulation, compared with sedentary controls, however there 
were no decreases in blood lipid profile and changes in OO2max were not reported (Woolf-
May et al., 2000). 
 
The total volume of PA is recognised as of greater importance for health benefits than 
intensity per se in epidemiological studies and reviews (Haskell, 1994), and to partly 
investigate this evidence in an intervention, the health benefits of different walking 
volumes were studied (Ready et al., 1996). This was performed over a duration of 24 
weeks and involved participants walking for 60 min·d-1 at 60% OO2peak for either 3 d·wk-1 
or 5 d·wk-1, or remaining sedentary and the main findings were that walking on 3 and 
5d·wk-1 significantly improved OO2peak by 12 & 14% and percent body fat by -1.1 & -
1.3%, respectively, however neither walking volume was sufficient to favourably alter 
serum lipids. A more recent study went a step further to investigate whether different 
walking intensities (45% v 55% OO2max) at different walking volumes (200 v 300 
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kcal·session-1) had variable effects on health outcomes (Asikainen et al., 2003). 
Participants were randomised to walk for 30 min·d-1 on 5 d·wk-1, expending either 200 
kcal·session-1 at either 45% OO2max or 55% OO2max (both 1000 kcal·wk-1) or expending 300 
kcal·session-1 at either 45% OO2max or 55% OO2max (both 1500 kcal·wk-1) for 24 weeks. 
The main findings were that OO2max improved irrespective of the walking intensity or 
volume compared to control, however none of the walking prescriptions significantly 
decreased body mass. Furthermore, it appears that despite the significant improvements in 
OO2max these were also not accompanied by significant favourable changes in blood 
pressure, blood lipoprotein profile or glucose tolerance. The power calculations for the 
study were based on OO2max changes, which may explain why this was the only health 
outcome to favourably change and that the study might have been underpowered. 
 
A study involving overweight pre-menopausal women investigated whether supplementing 
daily diet limited to 5-5.8 MJ with 5 × 30 min or 5 × 60 min of walking would promote 
favourable changes in body composition, blood lipids, blood pressure, OO2max, compared 
to dietary intervention alone (Bond Brill et al., 2002). The addition of walking to the 
dietary procedure did not enhance declines in body weight, body fat percentage, BMI, 
WHR, diastolic blood pressure TC, TAG and TC/HDL-C as all three programmes resulted 
in similar significant reductions, whereas WC, OO2max and LDL-C demonstrated greater 
improvements than diet alone, with no differences between walking volumes. Due to the 
dietary procedures, this was a rather ambitious study and a little difficult to draw a firm 
conclusion. However, it appeared that the addition of walking to a dietary procedure did 
not augment improvements in every health variable, but only in WC, OO2max and LDL-C. 
The improvements in OO2max indicate that PAEE was significantly greater in the walking 
groups compared to the diet group, which is the most likely explanation for the greater 
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decreases in WC. The likely reason why there were no differences between exercise groups 
was the energy compensation in the 60 min walk group who consumed an extra 1300 kJ 
per day than the 30 min walk group. It may also be speculated that the additional decreases 
in LDL-C were due to the additional EE in the walking groups rather than improvements in 
OO2max as the decreases in LDL-C tended to be greater in 60 min than 30 min, despite a 
tendency for greater OO2max improvement in 30 min. 
 
Studies of the effects of daily walking on cardiovascular health appear to have been 
equivocal, where 18 weeks of walking at ~74% HRmax and expending ~900 kcal·wk-1 
improved cardiovascular function by facilitating increases in the velocity of left ventricular 
relaxation and improved cardiovascular fitness in a study of 29 men and women (Woolf-
May et al., 1997), whereas 18 weeks of accumulative walking proved ineffectual in 
improving cardiac function in 64 men and women (Woolf-May et al., 2003). However, in a 
more recent study similar to that presented in section 3.0, which investigated the effect of 
accumulative brisk walking on MetS risk, primary care patients took part in a randomised 
controlled walking trial investigating the benefits of accumulating 30 min·d-1 of brisk 
walking on 5 d·wk-1 for 12 weeks on body composition, blood pressure, functional 
capacity, blood lipoprotein profile and 10-year CVD risk (Tully et al., 2005). The main 
findings of this study were that after the participants performed 27.72 ± 9.79 min·d-1 of 
walking for 12 weeks, systolic blood pressure, diastolic blood pressure, functional capacity 
and risk of stroke were favourably improved. However, there were no significant 
improvements in measures of body composition and lipoprotein profile. A further point to 
note was that the majority of the participants performed their walking in a single daily 
session and accumulative walking only accounted for 3.14% of the reported walking 
prescription.  
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The longest walking intervention included in this review investigated the influence of a 1-
year programme of brisk walking on cardiorespiratory function, body composition and 
blood lipoprotein profile in previously sedentary middle-aged men (Stensel et al., 1993; 
1994). The participants walked at 1.95 m·s-1 (68 ± 1% HRmax) for 28 min·d-1 and the main 
findings were that despite the long intervention period that required the participants to 
cover ~1,168 km in total, only cardiorespiratory function improved, whereas body 
composition and the blood lipoprotein profile were not favourably altered. However, the 
men participating in the study were relatively healthy, and thus had less potential gains to 
make from the intervention, and since dietary intake was only recorded for 7 days then 
there was also potential to compensation for energy expended during the walking activity 
through increased energy consumption. Evidence suggests that reductions in visceral fat 
are associated with improvements in OO2max, where sedentary obese women involved in a 
walking and weight loss programme who improved their OO2max by ~10% reduced visceral 
fat by ~20%, whereas those whose OO2max did not improve only reduced their visceral fat 
by ~10% (Lynch et al., 2001). However, despite dividing the study sample into quartiles 
based on OO2max changes, PA level did not appear to be taken into consideration, which 
impacts both OO2max and adiposity due to the direct relationship between PA and energy 
expenditure.  
 
Exercise studies of postprandial lipaemia tend to use an acute design in order to determine 
the immediate (24 hr) effects of a single exercise session on blood TAG clearance (Section 
2.6.2). A study that did investigate the ‘trainability’ of blood TAG clearance found that 
despite the experimental group walking at 1.76 ± 0.02 m·s-1 for 21 ± 1 min·d-1 for 12 weeks 
and improving OO2max, decreasing body fat and decreasing area under the insulin-time 
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curve compared with controls, postprandial lipaemia was unaffected (Aldred et al., 1995). 
The rationale for endurance training to attenuate postprandial lipaemia is the training 
induced increases in capillarisation, which is significant because LPL, the enzyme 
responsible for hydrolysing TAG-rich lipoproteins, is located on the luminal surface of 
capillaries. Therefore, using this premise in order for exercise training to enhance TAG 
clearance then OO2max must be significantly improved and it appears that if this is true then 
the threshold OO2max for improving TAG clearance was not attained by the females in the 
study. The same research group also demonstrated that favourable exercise-induced 
changes, including cardiorespiratory function, body fat percentage and HDL-C, occurred 
following 12 weeks of brisk walking in sedentary females and that these changes were 
reversed following a further 12 week period of detraining. These findings demonstrate that 
walking can create significant health benefits and that walking needs to be maintained to 
retain the associated health benefits (Hardman & Hudson, 1994). 
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2.4.4 Summary 
Evidence demonstrates that walking can promote favourable changes in CVD risk factors, 
both in the immediate post-exercise period and in response to long-term participation. 
However, the findings are equivocal at times, depending on the design of the study and the 
physiological variables being measured. In terms of the short-term responses to walking, 
blood pressure, fibrinolysis, inflammation and lipid metabolism may be favourably altered, 
while the health benefits that may be derived from long-term participation in walking 
include improvements in body composition (↓body mass, ↓ fat mass, ↓ body fat percentage 
& ↓ waist circumference), OO2max, blood pressure, blood lipid and lipoprotein profile and 
decreased risk of blood clotting. Data from the available studies suggest that these changes 
may be attained by walking at ~70% HRmax for 30 min·d-1 on 5 d·wk-1. This guidance 
provided the basis for the 24-week intervention described in section 3.0 investigating the 
influence of walking on a range of these risk factors, which characterise MetS. The shorter 
term effects of walking of different intensities and durations will also be assessed in 
section 4.0 because no published study has used this study design, particularly with MetS 
risk factors. 
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2.5 Physical activity accumulation 
2.5.1 Introduction 
Two common misconceptions regarding PA have been that it must be of vigorous intensity 
and performed in a single session to be of benefit to fitness and health. In order to address 
these misconceptions the joint statement by CDC & ACSM (1995) (See section 2.8.6) 
recommended that PA could be effectively accumulated in smaller bouts to produce similar 
improvements in health outcomes to single sessions of equal volume. Prior to these 
recommendations only two published studies had investigated the efficacy of accumulated 
PA on health. These studies investigated the influence of splitting running distance on 
cardiovascular endurance and blood lipids (Ebisu, 1985) and the effect of short vs. long 
bouts of exercise on OO2max (DeBusk et al., 1990). Since the 1995 PA recommendations 
were published, there has been a rapid increase in the number of studies performed to 
determine the efficacy of accumulating PA on a range of health outcomes in both acute and 
long-term studies. The health outcomes investigated by acute PA studies include the 
immediate effect of exercise on elevated post-exercise oxygen consumption 
(EPOC)/energy expenditure (EE) (Kaminsky et al., 1990; Fulton et al., 2001; Peterson et 
al., 2004), postprandial lipaemia (Murphy et al., 2000), postprandial lipaemia & blood 
pressure (Miyashita et al., 2006), blood lipid profile (Mestek et al., 2006), blood pressure 
(Padilla et al., 2005; Park et al., 2006) and glucose control (Baynard et al., 2005). 
 
Although the immediate responses to PA could potentially be important for the 
maintenance of good health, the majority of studies have focused on the adaptations that 
occur from long-term participation in accumulative PA compared to controls and/or equal 
volumes of exercise performed in prolonged single sessions. The combinations of health 
outcomes studied by these investigations include cardiorespiratory fitness & weight loss 
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(Jakicic et al., 1995; Schmidt et al., 2001; Asikainen et al., 2002), aerobic capacity, body 
composition, blood lipids & glucose control (Snyder et al., 1997), OO2max & body 
composition (Murphy & Hardman, 1998; Osei-Tutu & Campagna, 2005), OO2max (Thomas 
et al., 2001; Macfarlane et al., 2006), OO2max, blood lipids & body composition (Murphy et 
al., 2002), weight control (Sykes et al., 2003; Thompson et al., 2004), exercise adherence 
(Jacobsen et al., 2003), heart function (Woolf-May et al., 2003), cardiorespiratory fitness 
& blood lipids (Woolf-May et al., 1998; 1999; Boreham et al., 2005), glucose control 
(Eriksen et al., 2007; Venables & Jeukendrup, 2008), OO2max and HDL-C (Quinn et al., 
2006), aerobic capacity, blood pressure, blood lipids & glucose control (Asikainen et al., 
2003), body composition, blood pressure & blood lipids (Murtagh et al., 2005b) and 
aerobic capacity, blood pressure, blood lipids and body composition (Kennedy et al., 
2007). 
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2.5.2 Long-term physical activity accumulation 
In the first published study to challenge the dogmatic perception that PA must be 
performed in a single prolonged daily session in order to be effective, Ebisu (1985) 
demonstrated that splitting up running distance into smaller fractions had the same effect 
on cardiovascular function and blood lipids as performing the distance in a single bout. 
This study examined whether 10 weeks of progressive running had the same effect on the 
blood lipid profile and OO2max whether this was performed in one, two or three daily 
sessions compared to controls. The study employed an independent measures design where 
participants performed no activity, or ran for 3 miles·day-1 in weeks 1-3, 4 miles·day-1 in 
weeks 4-6 and 6 miles·day-1 in weeks 7-10. There were three running groups who 
performed the running in a single session, 2 sessions or in 3 sessions per day, i.e. 1 × 3 
miles, 2 ×1.5 miles and 3 × 1 mile, respectively during weeks 1-3 and so on. The main 
findings of this study were that 1.5 mile run time decreased and OO2max increased 
significantly following each pattern of running compared to control. However, HDL-C was 
only significantly increased following the pattern of splitting the running distance into 
three sessions during the day. A further finding of note was that there were no differences 
between running groups for any of the dependent variables, however no information was 
provided regarding adherence to the program, only that 53/60 completed, and no indication 
was given regarding the duration between the split sessions. 
 
A slightly more high profile study investigated the effect of performing ‘jogging’ in 3 
bouts of 10 minutes compared to 30 minutes on 5 days of the week at 65-75% peak 
treadmill HR (DeBusk et al., 1990). This study differed to that by Ebisu (1985) because it 
identified the exercise frequency (5 d·wk-1), exercise volume was prescribed as 150 
min·wk-1 rather than 3 miles·d-1 and lasted 8 weeks, however it did not include a control 
  72
group and only monitored measures of functional capacity, but adherence to the 
programme was recorded and the duration between multiple bouts was stated (≥4 hr). The 
main conclusion to this study was that “multiple short bouts of moderate intensity physical 
exercise produced significant training effects” (DeBusk et al., 1990). However, these 
significant training effects consisted of increases in OO2max, exercise test duration and 
decreased HR at submaximal exercise compared to baseline following the exercise period. 
The authors failed to explain why, despite the post-intervention increases in exercise test 
duration and decreases in submaximal HR being similar between exercise patterns, the 
multiple bouts only improved OO2max by 57% of the improvement observed in the single 
bouts (7.6% v 13.9%). 
 
A clear criticism of this study was that there was no control group, therefore single 
sessions of equal time were used as the benchmark for the efficacy of multiple bouts. A 
further unusual factor relating to the study was that participants with a mean baseline 
OO2max of 33 mL·kg-1·min-1 were reported to be jogging at only 70 & 71% HRpeak (54-56% 
OO2max), however in this group running at 5 mph would require 8.6 METs (91% OO2max) 
(LaFontaine & Robbins, 1991). This perhaps indicates that the participants performed brisk 
walking or jogged-walked during the sessions rather than jogged for the full duration of the 
sessions. It is important to bear in mind that, along with Ebisu (1985), it was the study that 
helped to break down the perception that PA had to be prolonged to be useful to health and 
provided the basis for PA recommendations for accumulating PA throughout the day in 
multiple shorter sessions (≥10 minutes) (CDC & ACSM, 1995) and prepared the 
groundwork for future studies in this area. In a similar study, Macfarlane et al. (2006) also 
investigated the efficacy of accumulating multiple smaller bouts of activity throughout the 
day, however these were ≤10 minutes. The study contained 45 participants (30 females) 
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who were randomly allocated to 30 min·d-1 of PA on 3-4 d·wk-1 (LB) or 6 min·session-1 for 
5 session·d-1 on 4-5 d·wk-1 (SB) for 8 weeks. Physical activity levels were 10-11 MET 
h·wk-1 and estimated using daily activity logs, which included time of day, duration, mode 
and RPE, and the activities were calculated from published values (Ainsworth et al., 1993), 
however no indication was provided regarding the nature of the PA, i.e. walking cycling. 
The main findings of the study were that OO2max improved significantly following both 
treatments (6.2% in LB & 4.1% in SB) with the improvements significantly higher in LB 
than SB, which were in agreement with the findings of Debusk et al. (1990).  
 
In a study published at the time of the new recommendations (CDC & ACSM, 1995), the 
effect of multiple bouts of walking in 10 minute sessions (SB) on OO2max and weight loss 
was performed for 20 week by sedentary overweight females (Jakicic et al., 1995). This 
study presented itself as a RCT, and has also been included in a list of RCTs (Asikainen et 
al., 2002), however there were no control participants and 28 of the 56 participants were 
allocated to the separate walking groups. Therefore, the health outcomes were only 
compared to walking for equivalent durations in single long bouts (LB) instead of using a 
control group, which does not allow comparison to the effects that may naturally occur 
over the course of 20 weeks. Furthermore, participants’ diets were restricted to 1200-1500 
kcal·day-1, thus clouding the discrete benefit of both patterns of walking on weight loss and 
consequently OO2max. During the walking intervention the participants were instructed to 
accumulate 4 × 10 minutes of walking, however the accelerometers and diaries that were 
used to monitor compliance indicated that those in the SB group preferred to accumulate 3 
× 15 minutes of walking instead. The main findings of that study were that walking 
performed in single or multiple sessions during the day produced similar increases in 
predicted OO2peak (5.6% v 5.0% for LB and SB, respectively), but there was a trend for 
  74
weight loss to be greater in SB (-8.9  ± 5.3 kg) v LB (-6.4 ± 4.5 kg; P=0.07). It must be 
emphasised that both patterns of walking induced such weight losses predominantly due to 
the dietary intervention to promote weight loss. However, suggestions as to why there was 
a trend for SB to achieve greater weight losses are that SB tended to walk for a greater 
volume (223.8 ± 69.5 min·week-1 vs 188.2 ± 58.4 min·week-1; P=0.08). Participants 
reported exercising on more days than LB and it may be speculated that this was due to 10 
minutes being easier to complete than 40 min and those in LB may not have attempted 
some sessions if they could not complete the entire 40 minutes. Furthermore, exercising in 
short bouts may influence calorie intake, i.e. reducing lunch hour or used to relieve 
boredom instead of food. 
 
A further similar study performed two years later also investigated the influence of 
accumulative walking in 13 sedentary moderately obese females who were asked to 
perform 5 x 30 min (3 x 10 min) of walking (‘walking briskly, yet comfortably’ at 50-65% 
HRR) for 32 weeks (Snyder et al., 1997). However, despite the long intervention period 
there were no significant changes in aerobic capacity, body composition, blood lipids, 
insulin or glucose. An issue with the design of this study was that there were no controls 
and not even a walking group performing the same volume of walking in single daily 
sessions, therefore no data was apparent to determine any relative changes, such as 
decreased fitness and increased body fat, which may have occurred naturally over the 
course of the 32 week period without the walking intervention.  
 
There has been an increase in the RCTs performed to assess the efficacy of accumulative 
PA on health outcomes. In fact many of these studies not only contain a control group but 
also a group that performs a similar daily PA volume in a single session. The design of the 
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study in section 3.0, a RCT involving a sedentary control group and a long session brisk 
walking group, not only compares the benefits of accumulative PA compared to the 
outcomes that may occur as a result of sedentariness, but also allows the determination of 
the effect of PA accumulation compared to longer single PA sessions. These are essential 
when studying accumulative PA in order to investigate the relative efficacy of 
accumulative PA per se. The essence of the argument for promoting accumulative PA is 
that the energy expended in PA is more important than the frequency, intensity or duration 
in particular. In this respect, and in variation to the majority of studies that investigate daily 
accumulative sessions, Sykes et al. (2003) studied the effect of two different patterns of 
accumulating PA during the week rather than daily PA accumulation. Thirty Singaporean 
females were randomly allocated to one of two 8-wk programmes of cycling & treadmill 
walking at “a moderate, comfortable intensity”, and the programmes involved either 5 
sessions·wk-1, each expending 400 kcal·session-1 (SB), or 2 sessions·wk-1, each expending 
1000 kcal·session-1 (LB). Food intake was recorded in diaries. The main findings were that 
body mass (-2.03kg [-3.2%] & -1.90 kg [-3.0%]), BMI (-0.78 kg·m-2 [3.2%] & -0.73 kg·m-2 
[3%]), body fat % (-1.37% [4.5%] & -1.19% [4.0%]) and WC (-2.62 cm [3.2%] & -2.34 
cm [2.7%]) were significantly decreased in both SB & LB, whereas lean mass & HC 
remained the same. These are significant findings that moderate-intensity exercise, 
performed for only 8 weeks, and irrespective of the frequency and duration of PA, 
produces similar positive effects on body composition. However, a weakness of the study 
was a lack of control group, which would have strengthened the study. 
 
In an earlier RCT, 34 women completed 10 weeks of brisk walking on 5 days of the week 
at 70-80% HRmax in either one 30 minute walk (LB) or three 10 minute walks per day 
(SB), or performed no walking as controls and participants were instructed to make no 
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dietary changes (Murphy & Hardman, 1998). The main findings of this study were that 
OO2max increased and sum of skin folds decreased significantly in both walking groups 
with no differences between walking groups relative to controls, however body mass and 
waist circumference decreased significantly only in the SB group. The authors also 
commented that body/fat mass gained by the controls contributed to the significant 
responses to the walking. Indeed this demonstrates the importance of including controls in 
such studies because although exercise intervention may not improve health outcomes, it 
can often prevent age-associated declines in health-related fitness, which are not 
necessarily demonstrated in non-controlled exercise trials.  
  
A further RCT of accumulative walking studied 49 males and females, who completed an 
18 week intervention where one group acted as non-exercising controls, one group 
performed single daily brisk walking sessions of 20-40 minutes (LB) and the other group 
accumulated the same duration of walking in 10-15 minute sessions throughout the day 
with ≥120 minutes between sessions (Woolf-May et al., 1998). Participants were instructed 
to perform 60 min·wk-1 of walking in the first week, which increased to 200 min·wk-1 by 
week 12. The main outcomes of the study were that aerobic capacity significantly 
decreased and factor XIIa, a marker of coagulation, significantly increased in the control 
group, however there were no significant changes in lipid profiles (TC, LDL-C, HDL-C 
and apos A-I, A-II & B) in the walking groups compared with controls. This was an 
important study because it was the first to compare the efficacy of accumulative walking 
sessions to walking of equal daily volume and to non-active controls, which fully 
examined the health benefits of accumulation per se relative to no activity and activity 
performed in single daily sessions. A further study by the same group performed a study of 
similar structure to that described above, however an additional group was added, in which 
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participants were instructed to perform brisk walking sessions in 5-10 minute bouts 
totalling 20-40 min·d-1 (Woolf-May et al., 1999). The main findings of this study were that 
each of the walking groups – long, intermediate and short duration – produced positive 
health outcomes compared to controls, however the long and intermediate groups 
demonstrated the more potent effects. Each of the walking groups promoted improvements 
in aerobic fitness, whereas only the intermediate and long sessions produced favourable 
improvements in the blood lipid profile compared to controls. 
 
In a study of different patterns of walking (Murphy et al., 2002), 21 participants (14 F) 
completed two different 6 week brisk walking programmes at 70-80% predicted HRmax in a 
cross-over design with 2 weeks in between. One programme involved brisk walking for 30 
minutes in a single daily session on 5 days of the week (LB) and the other involved 
accumulating 30 minutes of brisk walking in 3 × 10 minute sessions on 5 days of the week 
(SB). The study did not include a 6 week control period. The main findings were that both 
programmes increased plasma HDL-C, and decreased TAG & total cholesterol, despite no 
changes in body mass. However, SoS, WC & HC were reduced, indicating that increases in 
lean body mass may have accounted for decreases in adiposity. Predicted OO2max tended to 
increase following both programmes, but only significantly greater following SB. Despite 
the intervention being relatively short, the brisk walking interventions induced significant 
health benefits, which must be attributed to the high adherence to the programmes (88.2 ± 
1.1% in SB & 91.3 ± 4.1% in LB) and also to the relatively high intensity of the walking 
(70-80% predicted HRmax). 
 
In another RCT, 130 postmenopausal women completed single or double daily walking 
sessions, expending a total daily PA volume of 300 kcal·d-1 at 65% OO2max, or remained 
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sedentary for 15 weeks (Asikainen et al., 2002). The main outcomes of this study were that 
both single and multiple sessions of walking provided similar increases in OO2max (2.5 
mL·kg-1·min-1 for both walking groups) and decreases in fat% (1.7% in SB & 21.1% in 
LB). An extension of this study, looking at blood pressure, serum lipoproteins, fasting 
blood glucose and plasma insulin, and also glucose tolerance, was published shortly 
afterwards (Asikainen et al., 2003) and used the same study design and participants. The 
main findings of this study were that although diastolic blood pressure was not 
significantly reduced following walking in the discrete walking groups, when these were 
combined as a single group there was a mean decrease of -3 mmHg compared to controls. 
Furthermore, blood glucose was significantly reduced in both SB and LB and 2-hour 
glucose concentrations were decreased in both walking groups. However, despite 15 weeks 
of walking, neither the lipid profiles nor insulin concentrations changed. These data 
suggest that accumulative walking is at least as effective as walking in a prolonged single 
session of equal energy expenditure. 
 
The study requiring the lowest weekly accumulative walking volume was a RCT by 
Murtagh et al. (2005b), involving brisk walking for a total of 20 min·d-1 on 3 d·wk-1 for 12 
weeks, based on the absolute minimum PA recommendations, in 32 previously sedentary 
individuals. The three groups consisted of a control group, a group performing 20 min·d-1 
while another group performed 2 × 10 min·d-1, however the recommended PA volume 
appeared to be insufficient to promote improvements in health, even in sedentary 
individuals. Body mass, adiposity, blood pressure, waist & hip circumferences and lipid 
profile were measured and there were no significant responses in any of these variables 
following either walking pattern relative to control. It must be emphasised that it was not 
accumulation per se that was ineffective for promoting positive health outcomes because 
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the LB group also failed to demonstrate improvements. In terms of PA recommendations, 
these are important findings because they suggest that performing PA according to 
previous PA recommendations, such as the minimum frequency (3 d), mode and intensity 
(walking) and duration (20 min), is insufficient to decrease certain CVD risk factors. 
Furthermore, a study involving only a four week training programme demonstrated that 
exercising for 30 min·d-1 on 5 d·wk-1 and increasing by 10 min·d-1 until 60 min·d-1 at an 
intensity designed to elicit maximal fat oxidation was more effective in improving fat 
oxidation and insulin sensitivity than isocaloric exercise accumulated in five minute bouts 
(Venables & Jeukendrup, 2008). Fat oxidation increased by 44% and insulin sensitivity 
increased by 27% following the LB programme, whereas no changes were apparent 
following SB, and these improvements occurred despite no changes in body mass, WHR or 
body fat percentage. 
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2.5.3 Summary 
The results of studies investigating the efficacy of accumulating PA on health outcomes 
have been equivocal at times, however this is also true of exercise studies in general, and 
not specific to accumulated PA. The consensus from these studies is that, on the whole, the 
total PA volume is most important irrespective of the pattern of activity and this is why the 
most recent PA recommendations (ACSM & AHA, 2007), advocate that PA can be 
effectively accumulated throughout the day to promote good health. In the majority of the 
studies mentioned above, the common factor measured following accumulative PA was 
OO2max with a range of other independent health risk factors also measured to varying 
degrees. However, OO2max per se is not an actual risk factor and is only a marker for health 
based on the association between low OO2max and increased presence of health risk factors, 
such as overweight/obesity, insulin resistance, dyslipidaemia & hypertension (Blair et al., 
1996). This means that studies that only measure OO2max as the dependent variable simply 
infer improved health based on the relationship between OO2max and CVD risk factors 
rather than demonstrated within the results. However, those studies that investigate the 
influence of accumulative PA on other CVD risk factors, such as blood pressure and blood 
lipid & lipoprotein profile, enhance the value of those studies that only study OO2max, 
which assume positive health outcomes by proxy. Unusually, few of the studies of 
accumulative PA have specifically used only males in their studies, where females only, a 
mix of males and females or post-menopausal women have been used as research 
participants. Therefore, the study in section 3.0 will investigate the efficacy of 
accumulative walking in middle-aged men 
 
Interestingly, the majority of studies of accumulative PA have used walking as the PA 
medium of choice, but stair climbing appears to be gaining popularity (Boreham et al., 
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2005; Kennedy et al., 2007). However, this is most likely due to the target population 
being relatively sedentary and need a simple form of PA to encourage them to become 
more active on a daily basis. Furthermore, more vigorous forms of PA may be impractical 
because too much time during the day would be spent on washing and getting changed 
following this type of activity, thus missing the point of accumulative PA fitting neatly into 
daily living. 
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3.0 The influence of 24 weeks of accumulative brisk 
walking on risk factors associated with metabolic 
syndrome and reverse cholesterol transport 
 
3.1 Introduction 
As previously noted, MetS classifies the clustering of co-related cardiovascular disease risk 
factors, characterised by the presence of 1) abdominal obesity, 2) insulin resistance, 3) 
hypertension, 4) dyslipidaemia, and 5) emerging risk factors, such as pro-thrombotic and 
pro-inflammatory states (see section 2.1) (Wannamethee et al., 2005). This clustering of 
risk factors is reported to increase the odds ratio for cardiovascular and all-cause mortality 
above the risk associated with the individual components, where MetS may increase the 
risk of cardiovascular death 2-4 fold and reduce life expectancy by 5-10 years (Libby & 
Theroux, 2005). There are numerous definitions of MetS from international organisations, 
such as WHO (Alberti & Zimmet, 1998), ATPIII (Cleeman, 2001), IDF (Balkau et al., 
1999) and EGIR (Balkau & Charles, 1999) and the ATPIII definition has been used to 
classify the presence of MetS in this study (see table 2.1, section 2.1.6)
. 
Using the WHO 
definition of MetS (Alberti & Zimmet, 1998), the worldwide prevalence of MetS is 18.7% 
for females and 28.2% for males (Cameron et al., 2004), with English males and females 
aged 40-65 demonstrating the highest prevalence (>44.8 & 33.9%, respectively) (Balkau et 
al., 2002). 
 
Metabolic syndrome is a multi-factorial condition and consequently there are a multitude 
of possible causes, where lifestyle and genetic factors may predispose individuals to 
developing MetS. Possible determinants of MetS include modifiable factors such as 
sedentariness (Ford et al., 2005; Ekelund et al., 2005) and elevated energy consumption 
(Zhu et al., 2004; Liese et al., 2007) and when these lifestyle behaviours are combined 
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they may adversely affect vulnerabilities in the human genome (Bouchard, 2007), which 
are also influenced by gender (male) (Fox et al., 2007) and age (≥middle age) (Schubert et 
al., 2006). Therefore, therapeutic interventions to prevent or ameliorate symptoms of MetS 
are aimed towards those determinants that may be modified. Many of the interventions to 
decrease MetS risk involve complementary treatments, which include both dietary and 
exercise therapy, however few have investigated the benefits of increasing PA alone. 
Clinical trials have shown that modifying major components of the syndrome – 
atherogenic dyslipidaemia, hypertension and the prothrombotic state – will reduce CVD 
risk, yet few controlled studies have reported the effectiveness of exercise training alone 
for multiple metabolic risk factors (Carroll & Dudfield, 2004). Recent reviews present 
many studies concerning the potential for increase PA to favourably influence the 
individual components associated with MetS, such as levels of obesity (Jakicic, 2003), 
abdominal obesity (Kay & Fiatarone Singh, 2006), insulin resistance (Henriksen, 2002) & 
glucose tolerance (Yates et al., 2007), blood pressure (Pescatello, 2005), lipid and 
lipoprotein profile (Durstine et al., 2001) and markers of pro-thrombotic (Imhof & Koenig, 
2001) & pro-inflammatory states (Kasapis & Thompson, 2005) (see section 2.3).  
 
Cross-sectional evidence suggests that the relationship between fitness and the presence of 
MetS may be mediated through lower adiposity, where the relationship between body fat 
percentage, visceral fat, subcutaneous fat and MetS components are stronger than the 
association between fitness and MetS components, and the effects of OO2max on individual 
MetS components is mostly attenuated after controlling for total and abdominal obesity 
(Boule et al., 2005). In a 12 month intervention study involving 137 men with International 
Diabetes Federation (IDF)-defined MetS who were randomly allocated to control, diet, 
exercise or combined exercise/diet groups found that each intervention decreased the 
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presence of MetS symptoms compared to the control group (Anderssen et al., 2007). 
Following the interventions 76.5% in the exercise group (supervised aerobic exercise; 
3×60min·wk-1 at 60-80% HRpeak), 64.7% following 12 months in the diet group (dietary 
advice at 3, 6 & 9 months; energy restriction, reduced saturated fat & cholesterol and 
increased fish consumption) and 32.6% in the combined exercise and diet group still had 
MetS. An important aspect of MetS is the atherogenic blood & lipoprotein profile, 
however the body has an in-built capability to reduce some of the risk associated with 
dyslipidaemia through the process of reverse cholesterol transport (RevCholT), an 
emerging marker of MetS because each component of MetS – central adiposity, insulin 
resistance, elevated plasma triacylglycerol and hypertension – is associated with low levels 
of HDL-C (Lewis & Rader, 2005), which is a primary agent in RevCholT and a component 
of dyslipidaemia (Barter, 2004) (see section 2.2). However, there is relatively limited 
literature describing the direct influence of PA/OO2max on reverse cholesterol transport, 
despite there being a wealth of data on the relationship between increased PA/OO2max and 
increased HDL-C concentrations, which is both an agent, and a rough marker, of 
RevCholT activity (Kodama et al., 2007). Despite the limited studies of PA and 
RevCholTran, there is cross-sectional (Brites et al., 2004) and longitudinal (Seip et al., 
1993) evidence that PA may modulate improvements, with CETP and LCAT receiving the 
greatest attention.  
 
Even though vigorous PA is beneficial to health, activities of daily life, such as walking 
can be accumulated throughout the week to provide a large enough volume of PA to gain 
significant health benefits, evidence of which has been available for over 50 years (Morris 
et al., 1953). A recent meta-analysis of 24 randomised controlled trials found that walking 
for 188.8 min·wk-1 at a mean intensity of 70.1 ± 9.1% HRmax (56.3 ± 7.1% OO2max) 
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improved OO2max by 9%, decreased body mass, body mass index (BMI) and body fat 
percentage by -1.4%, -1.1% and -1.9%, respectively, and decreased diastolic blood 
pressure by -2% compared to baseline (Murphy et al., 2007) (see section 2.4). Walking is 
usually the PA medium of choice in the majority of studies of accumulative PA, and stair 
climbing appears to be gaining popularity (Boreham et al., 2005; Kennedy et al., 2007), 
which is most likely due to the target population being relatively sedentary and need a 
simple form of PA to encourage them to become more active on a daily basis. The results 
of studies investigating the efficacy of accumulating PA on health outcomes have been 
equivocal at times, however this is also true of exercise studies in general, and not specific 
to accumulated PA (see section 2.5). The consensus from these studies is that, on the 
whole, the total PA volume is most important irrespective of the pattern of activity (Woolf-
May et al., 1999; Murphy et al., 2002) and this is why the Centers for Disease Control and 
Prevention and American College of Sports Medicine (CDC & ACSM, 1995), and the 
most recent public health recommendations (ACSM & American Heart Association 
(AHA), 2007), advocate that PA can be effectively accumulated throughout the day to 
promote good health (see section 2.3.7).  
 
The current minimum PA recommendations are for at least 30 minutes of moderate 
intensity PA (at least 40/50% HRR) to be accumulated on 5 days of the week (ACSM & 
AHA, 2007). Therefore, the aims of the study were to determine whether walking briskly 
for 24 weeks on 5 days of the week and for 30 minutes each day could improve MetS risk 
factors and markers of RevCholTran compared to sedentary controls, and also whether 
accumulating the same volume of brisk walking during the day may be equally effective in 
improving risk factors associated with MetS. 
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3.2 Method 
3.2.1 Introduction 
Following a rolling programme of recruitment following a local media campaign involving 
editorials in newspapers, radio programmes and television news, 85 non-smoking 
sedentary males (age 54.0 ± 8.5 years), who were asymptomatic of cardiovascular disease 
and diabetes, volunteered and gave their informed consent to take part in the study, which 
was approved by the central NHS Research Ethics Committee (Appendix A.1; p242). 
Volunteers were recruited through a comprehensive and widespread advertising campaign 
(see 3.2.2). The volunteers were advised of the experimental procedures and possible 
discomforts (Appendix A.2; p275) and then signed the informed consent (Appendix A.3; 
p280), a pre-screening health questionnaire (Appendix C.1; p310), a physical activity 
questionnaire (Appendix C.2; p315) and gave permission for their General Practitioner to 
be contacted for approval of their entry onto the study (Appendix C.3.1; p319). The 
participants received written confirmation that they were under no obligation to begin or 
continue with the study and could withdraw at any time.  
 
3.2.2 Participant recruitment 
A priori power calculations based on change in serum CETP indicated that 156 participants 
were needed to complete the study, ie. 3 groups of 52 (see section 3.2.7). In May 2005 an 
editorial in a local newspaper and radio interview were used as the main methods for 
recruiting participants. However, this was only moderately successful and demonstrated 
that a large proportion of the suitable volunteers were prescribed cardiovascular 
medication and thus ineligible to partake according to the exclusion criteria at the out-set 
of the study (see section 3.2.3). With retrospect this was not surprising since MetS is 
recognised as being prevalent in those prescribed anti-hypertensive medication (Rantala et 
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al., 1999). The proportion of middle-aged men (40-59 years) with medication controlled 
hypertension and presenting symptoms of MetS was 35.3% for elevated BP & TAG, 
26.8% for elevated BP, TAG and insulin resistance, and 16.9% for those presenting T2D 
and elevated BP & TAG (Rantala et al., 1999). Furthermore, evidence has shown that even 
in middle-aged men who ran 0-15 km·wk-1, 6.05% and 5.39% of were prescribed with anti-
hypertensive and lipid-lowering medication, respectively (Williams & Franklin, 2007). 
Even still, this group of individuals would be too physically active/aerobically fit to meet 
the inclusion criteria of the present study, which were aimed toward non-smoking 
sedentary men presenting MetS. The randomised controlled aspect of the intervention was 
an additive methodological difficulty in recruiting participants because some potential 
participants did not want to volunteer in case they were randomised into the control group 
(personal communications, 2005).  
 
In response to these occurences, an application was made to the local NHS Research Ethics 
Committee in the summer of 2005 to allow volunteers prescribed with cardiovascular 
medication, ie. anti-hypertensive and lipid-lowering medication, onto the study and to 
allow participants allocated to the control group to enter their own 24-week walking 
intervention on completion of the study to optimise study numbers. Following the 
successful approval to the amendments to the study design, a further radio appeal was 
launched, emails were sent to local council personnel departments to circulated to staff, 
web-links from the University of Kent & Canterbury Christ Church University homepages 
were created aswell as handing out flyers at Canterbury and Ashford International train 
stations. Adverts were placed in GP surgeries, businesses, schools and colleges, libraries, 
supermarkets, taxi companies and bowling clubs throughout Kent. This was a direct 
marketing technique aimed towards our target sample of middle-aged men. Despite all of 
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these efforts there were still insufficient individuals fitting the criteria that were 
volunteering for the study (n=18). This particular demographic is especially problematic to 
engage since health behaviours, such as sedentariness, poor dietary choices and smoking, 
tend to cluster (Villegas et al., 2008). Figure 3.1 illustrates the withdrawal of participants 
based on medication and non-completion. 
 
Figure 3. 1 Participant exclusion/withdrawal flowchart 
 
The penultimate recruitment drive occurred just after the New Year in January 2006, where 
a large editorial was placed in a local newspaper to take advantage of those with New 
Year’s resolutions. This was by far the most successful avenue for recruiting, thus 
indicating that the timing of recruitment efforts may be more important than the type or 
    After withdrawal of medicated participants 
Participation in 24 weeks  
of post-control walking 
Withdrawal after non-compliance with study 
requirements/illness 
Participation in 24 hour walking study (Section 4.0) 
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variety of methods used for attracting volunteers (n=70 overall).  The final two recruitment 
efforts consisted of interviews on local radio stations in Kent and South East television 
news and in the match day programme at Kent County Cricket Club in April 2006. These 
efforts brought the final total of volunteers to 85 in 13 months.  
 
In the light of evidence stretching back over 30 years, it is perhaps unsurprising that this 
range of recruitment methods was relatively unsuccessful in attracting middle-aged men to 
volunteer (Wilson & Webb, 1976). Those that refrain from participation tend to be older 
males from lower socioeconomic groups, whereas those who volunteer are generally 
younger, more highly educated and likely to report healthier lifestyle patterns (Jancey et 
al., 2006; O’Neill et al., 1995). Therefore, with the target volunteers being placed in the 
former, there were always going to be difficulties in recruiting and retaining 156 sedentary 
overweight middle-aged men onto a 24 week physical activity intervention. Indeed, a study 
examing the recruitment and retention of participants on a 6-month walking intervention 
demonstrated that out of 7,378 potential volunteers being invited to participate via a 
postcard only 734 individuals responded (Jancey et al., 2006). Furthermore, out of this 
group 734 individuals only 573 completed a questionnaire at baseline (mean participation 
rate of 13.6%), 444 at 3 months and 413 at 6 months. This is despite the paper hailing itself 
as the “effective recruitment and retention of older adults in PA research” (Jancey et al., 
2006). 
 
3.2.3 Experimental design 
The study was a randomised controlled trial involving two exercise groups and a control 
group. Prior to the pre-exercise assessments, computer generated sequences (Clinstat, 
Martin Bland) were used to randomly allocate the participants into one of three groups: 
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 Normal lifestyle (unchanged diet or activity behaviour) (CON); 
 Single bout of brisk walking for 30 minutes on 5 days of the week (SBW); 
 Accumulative bouts of brisk walking for 30 minutes on 5 days of the week (ABW). 
Prior to and following the 24 week walking intervention all of the participants had a pre- 
and post-intervention health and fitness assessments.  
 
3.2.4 Pre-screening procedure 
Potential participants were pre-screened using a health questionnaire and their general 
practitioner was asked for their approval prior to participation. 
Inclusion criteria – Low active men (<150 min·wk-1>4METs ) aged 40 to 65 years with a 
waist circumference of at least 102 cm (~ 40 inches) or waist:hip ratio 
of at least 0.9. 
Exclusion criteria –  
a) Present cardiovascular disease 
b) Diabetes mellitus 
c) Tobacco smoking  
d) Waist circumference ≤102 cm (~ 40 inches) AND waist hip ratio of <0.9 
e) Physically active, i.e. moderate intensity PA for 30 minutes per day on 5 days 
of the week  
f) Their general practitioner was unable to provide health clearance for them to 
participate, or 
g) The participant was unable to understand the nature of the study. 
 
The original exclusion criteria included cardiovascular medication use, such as anti-
hypertensive and lipid-lowering agents, however despite the exhaustive recruitment efforts 
insufficient volunteers were medication-free. Therefore, to boost participant numbers those 
participants prescribed such medication were accepted, even though they were later 
precluded from the final analyses in order to report full data ranges without excluding case-
by-case on the basis of medication. 
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3.2.5 Health and fitness assessments 
3.2.5.1 Height, body mass, resting heart rate and resting metabolic rate 
After being allocated into a group, the participants arrived at the Sport and Exercise 
Science Laboratory following ~14 hour fast and received their health and fitness 
assessment, which included measures such as height, mass, body composition, blood 
pressure, blood test and aerobic fitness. Height was measured using a stadiometer to the 
nearest cm and mass to the nearest 100g using beam balance scales (both Seca, Hamburg, 
Germany). The participants then laid down in a supine position to rest for 5 minutes after 
which a 5 minutes expired air sample was collected using Douglas bags (Harvard 
Apparatus Ltd, Kent, UK) and resting heart rate (RHR) was also monitored during this 
period using a heart rate (HR) radio-telemetry system (Polar Beat, Polar Electro OY, 
Finland). The Douglas bags were then analysed (Servomex Series 1440, Servomex Group 
Ltd, Crowborough, UK) for oxygen and carbon dioxide concentrations and the volumes 
measured by a dry gas meter (Harvard Apparatus Ltd, Kent, UK). These values, plus 
ambient air temperature and barometric pressure were input into an MS Excel spreadsheet 
for the calculation of OO2 (Appendix F.2; p364). Resting metabolic rate (RMR) was 
calculated from oxygen consumption (OO2) by multiplying OO2 (L·min-1) by 5 (Montoye 
et al., 1996) and resting fat oxidation rates were calculated using f = 1.67* OO2 – 1.67* 
OCO2 – 1.92*n [where f = fat and n = urinary nitrogen] (Frayn, 1983) (See Appendix 
G.2.2.1 for RMR reliability, p422). 
 
3.2.5.2 Blood pressure and waist & hip circumferences  
Systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure 
(MAP) and pulse pressure (PP) were assessed after the participants had remained seated 
for at least 5 minutes in a chair with an arm rest. Three blood pressure measures were taken 
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from the participants’ right arm using an aneroid sphygmomanometer (Accoson Limpet, 
A.C. Cossor & Son Ltd, London, UK) 30 seconds apart and the mean values were 
recorded. Mean arterial pressure was calculated using (SBP-DBP)*0.33 + DBP from the 
mean of the SBP and DBP measures, and PP was calculated by the difference between the 
mean SBP and DBP values (See Appendix G.5.1 & G.6 for BP validity and reliability data, 
p474 & p495). The rate pressure product (RPP; index of myocardial workload) was 
calculated as RHR multiplied by SBP. The participants then stood in the anatomical neutral 
position and waist circumference (WC) was measured at the level of the umbilicus and hip 
circumference (HC) was measured at the largest circumference of the hips above the 
gluteal fold both to the nearest 1 mm using a self-tightening circumference tape measure 
(Seca, Hamburg, Germany). Three WC and three HC measures were taken and the mean 
values were recorded. The waist:hip ratio (WHR) was then derived from these measures 
(See Appendix G.4.1 for measures of body composition reliability, p454). 
 
3.2.5.3 Body composition and blood samples 
Body density (Db) was estimated from 7-site sum of skin fold thicknesses (chest, 
midaxillary, triceps, subscapular, abdomen, suprailiac and thigh (ACSM, 2000) and using 
skin fold callipers (Harpenden, British Indicators Ltd, Beds., UK). The participants stood 
in the anatomical neutral position whilst 3 skin fold measures were taken at each site, with 
the mean value being recorded. Body composition was then calculated using the Siri 
equation (1961) for white males aged 20-80 years [495/Db-450] (ACSM, 2000) (See 
Appendix G.4.1 for measures of body composition reliability, p454). This calculation 
provided a value for body fat percentage (BF%), which was then applied to the body mass 
of the participant for the determination of absolute fat mass (FM). Blood samples were 
collected from an antecubital vein into vacutainers (BD Systems, Oxford, UK) whilst the 
participants were in a seated position, following an overnight fast (~14 hours), for the later 
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analysis of triacylglycerol (TAG), non-esterified fatty acids (NEFA), total cholesterol 
(TC), high density lipoprotein cholesterol (HDL-C), glucose, insulin, fibrinogen, 
cholesteryl ester transfer protein (CETP) and lecithin:cholesterol acyltransferase (LCAT).  
 
3.2.5.4 Aerobic fitness 
A predictive treadmill test was used to avoid complications regarding maximally testing 
sedentary participants. The participants were then allowed sufficient time to familiarise 
themselves with the treadmill (Mercury Med., HP Cosmos, Nussdorf-Traunstein, 
Germany) and gas analysis equipment (Oxycon Pro, Jäeger, Würzburg, Germany), which 
involved walking on the level treadmill at 3 mph with the use of their hands until they 
could walk comfortably unaided. After resting, the participants performed the Stanford 
sub-maximal walking test (ACSM, 2000). The test consisted of walking at 3 mph 
throughout the test at five different gradients for two minutes at each stage (Table 3.1) (See 
Appendix G.2.1.1 for walking test validity & reliability, p391).  
Table 3. 1 Graded treadmill test protocol 
Speed (mph) Time (minutes) Gradient (%) 
3.0 2 2.5 
3.0 2 5.0 
3.0 2 7.5 
3.0 2 10.0 
3.0 2 12.5 
 
Expired air analysis (OO2) was performed using the online breath by breath gas analyser, 
HR was measured using a radio-telemetry system (Polar Beat, Polar Electro OY, Finland), 
which were both recorded every 5 sec. Ratings of perceived exertion (RPE; Borg 6-20 
scale) were recorded at the end of each 2-minute stage and a blood lactate sample was 
taken at the end of the test (10 minutes) using a Softclix lancet gun (Accuchek, Roche 
Diagnostics GmbH, Germany) and collected into a 20µL capillary tube (Kunststoff-
Kapillaire, EKF Diagnostics, Germany). The sample was then stored in freezer (Revco 
Ultra, Asheville, NC, USA) at -70oC for later analysis (Biosen 5030L, Industrie-Elektronik 
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GmbH, Madgeburg, Germany). Samples were collected one at a time and analysed in 
series of ten once ten samples had been taken from 10 participants. Following the test, the 
HR-OO2 relationship was calculated and this relationship was extrapolated up to the 
participants age predicted maximum heart rate (age-220 beats·min-1) to predict OO2max 
(Maritz et al., 1961). The HR-OO2 relationship was also used to estimate gross energy 
expenditure based on HRs recorded in the walking diaries using the heart rate flex method, 
where HRs recorded in the walking diaries were used to estimate VO2 during walking, 
from which PAEE was derived (Keytel et al., 2005). Similar health and fitness assessments 
were performed by all participants following the 24-week walking intervention. 
 
3.2.5.5 Validation and reliability procedures 
The studies presented in this thesis required a range of techniques for measuring/estimating 
health indicators and were used within a particular demographic – middle-aged men. 
Therefore, it was felt prudent to perform tests of validity and reliability of these measures 
on samples of the target population. The validity tests were important to indicate the 
degree of confidence in the measures being a true description of health risk and the 
reliability data were collected because the studies utilised repeated measures designs, thus 
relying on a strong degree of reproduceability.  
 
Physical activity is a behaviour that is not straight forward to measure due to its high 
variability and the available measurement tools. Walking diaries were the chosen recording 
medium in the 24 week walking intervention because they can be easily distributed at little 
expense, however they rely on the participants accurately recording their PA. Therefore, a 
comparison was performed between the walking diaries and walking activity recorded 
using an accelerometer during a seven-day period within the intervention. The main 
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findings of this study was that participants generally under-reported their walking activities 
in the diaries compared to that recorded by the accelerometer, with the greatest difference 
in those performing more than 150 min·wk-1 in ABW (Appendix G.1; p365). Furthermore, 
there was greater agreement between methods for recording walking activity in SBW than 
ABW, where those in ABW under-measured their walking duration compared to the 
walking duration objectively measured using the accelerometers. 
 
When measuring aerobic fitness the gold standard is the OO2max test, which is designed to 
take the participant to exhaustion. However, other tests have been developed in order to 
predict OO2max without taking sedentary/older individuals to exhaustion to avoid the 
potential risks associated with vigorous exercise (Raum et al., 2007). A predictive OO2max 
test was utilised for the studies in this thesis, therefore the validity and reliability of the 
submaximal walking fitness test was assessed, which demonstrated a high degree of 
reliability for measures of aerobic fitness with a slight over-estimation of OO2max 
(Appendix G.2; p391). Resting metabolic rate was also assessed as part of both of the 
studies in this thesis in repeated measures designs. Therefore to test-retest reliability, RMR 
was assessed twice during the same day and repeated the next day using the Douglas bag 
technique, which indicated that both the inter- and intra-day reliability of RMR were 
relatively strong (Appendix G2.2.1; p422).  
 
Indices of body composition formed a large proportion of the data collected in the 24-week 
study. Due to the nature of body composition analysis it needs to be estimated rather than 
directly measured. Sum of skin folds and body girths are commonly used methods to 
estimate body composition, however errors in validity and reliability of these measures can 
occur, thus adding error in a repeated measures design. Therefore, to test the validity of 
  96
body fat percentage, sum of skinfolds were compared to estimates using air displacement 
plethysmography, a surrogate for hydrostatic weighing (Gold standard) and reliability of 
body composition were estimated on two consecutive days to provide inter-day reliability 
(Appendix G.3; p433). Futhermore, waist and hip circumferences were assessed on two 
consecutive days to assess test-retest reliability of (Appendix G.4; p454). These studies 
found that despite separate principles of assessment the results obtained from seven-site 
sum of skin folds were similar to those using air displacement plethysmography. 
Furthermore, the reliability of measures of body fat percentage, waist circumference and 
waist:hip ratio were consistently high.  
 
Blood pressure can be highly volatile, illustrated by ‘white coat syndrome’ where blood 
pressure can change suddenly usually by increasing without known cause (Gerin et al., 
2006). Therefore, measures of blood pressure were assessed in order to observe the degree 
of difference between different measurement techniques and the repeatability of aneroid 
sphygmomanometry. Automated oscillometry was used to compare to the aneroid 
sphygmomanometry measures because aortic catheterisation is the gold standard and too 
invasive for the purposes of the research being performed (Appendix G.5; p474). The 
study found that although blood pressure measures were similar between aneroid 
sphygmomanometry and automated oscillometry, particularly for systolic blood pressure, 
these methods should not be used interchangeably. Intra- and inter-day blood pressure 
reliability were similar and demonstrated that changes in blood pressure can be volatile 
even when measured only 30 minutes apart, thus possibly contributing to the moderate 
statistical power observed for the blood pressure measures in the studies included in 
Sections 3.0 and 4.0 (Appendix G.6; p495).  The treadmill used in these studies was also 
  97
validated in Appendix G.7 (p503), which demonstrated that gradient, distance and speed 
were all highly valid with little variation between participants of various body mass. 
 
3.2.6 Walking intervention 
The participants were randomly assigned into their respective groups and the walking 
intervention required the participants in the walking groups to walk in their own time. The 
participants in the walking groups were advised about their heart rate training zone, heart 
rate palpation, walking briskly, and were also provided with walking diaries to record their 
daily walking activities (Appendices D.1.1 & D.1.2; pp321 & 331). The diaries were 
provided to motivate the participants and to monitor weekly walking activities. Participants 
in both of the walking groups (SBW & ABW) were instructed to walk for 30 minutes per 
day on five days of the week (150 min·wk-1) at an intensity eliciting >65% HRmax during 
the 24 week intervention, however the two groups differed in daily walking patterns. The 
SBW group were instructed to walk briskly for one single 30 minute daily bout, whereas 
the ABW group were instructed to accumulate 30 minutes of brisk walking in bouts of 3 × 
10 minutes or 2 × 15 minutes (See Appendix G.1.1 for walking diary method comparison, 
p365). ABW participants were advised to leave at least 2 hours between each daily 
walking session and all participants were instructed not to change their diets. 
 
To assess the efficacy of walking for 30 minutes on five days of the week, a group of 
participants were randomly allocated to the CON group so that differences over the 24 
week walking intervention could be measured in addition to differences from baseline. The 
CON group were instructed not to change their usual lifestyle, i.e. physical activity and 
dietary behaviours, over the course of the intervention. Following this 24 week period, the 
participants returned to the laboratory, where a post-intervention health and fitness 
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assessment was performed to assess changes in health and fitness over the previous 24 
weeks.  
 
Prior to returning to the laboratory all participants were advised not to exert themselves or 
consume alcohol on the day before the 24 week re-assessment. Sixty five participants were 
accepted onto the study with 19 allocated into CON, 22 into SBW and 24 into ABW after 
removing participants from the study due to the confounding effects of their anti-
hypertensive and/or lipid-lowering medication. 
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3.2.7 Blood sampling and analysis 
Blood was dispensed into a collection tube to form serum, a tube containing 0.05 mm 
trisodium citrate at a ratio of 9 parts blood to 1 part anticoagulant and a tube containing 
fluoride oxalate, both for the formation of plasma. The samples were then centrifuged at 
room temperature (Eppendorf 5804, Hamburg, Germany) and stored in a freezer (Revco 
Ultra, Asheville, NC, USA) at -70oC for later analysis. The serum samples were analysed 
for concentrations of TAG, TC and HDL-C (all Horiba ABX Diagnostics, Cambridge) 
using enzymatic colorimetry, insulin was analysed using chemiluminescence (Bayer Advia 
Centaur, Bayer Healthcare, Diagnostics Division, Tarrytown, NY.), the serum samples 
were diluted 1:20 with assay buffer for the analysis of CETPa and LCATa using activity 
assays (Roar Biomedical Inc, New York) on a fluorimeter (Safire XFLUOR 4 Version 4.4, 
Tecan, UK) (See Appendix E for more deailed biochemistry procedures, p344). Insulin 
sensitivity was estimated using the homeostasis assessment model ratio formula (HOMA-
IR; fasting serum insulin (µIU·mL-1) × fasting plasma glucose (mmol·L-1))/22.5) and 
insulin secretion was estimated using: fasting serum insulin (µIU·mL-1) × 20/fasting 
plasma glucose (mmol·L-1) – 3.5 (HOMA-β cell), both described by Matthews et al. (1985) 
and LDL-C was derived from serum TC – HDL-C – (TAG/2.2) (Friedewald et al., 1972). 
Insulin resistance and insulin secretion were estimated because measurement tests usually 
require an oral glucose tolerance test and invasive techniques such as hyperinsulinaemic 
clamping. The plasma collected in the fluoride oxalate tube was used to analyse glucose 
(Horiba ABX, Cambridge) and NEFA (Wako Ltd, Neuss, Germany) using enzymatic 
colorimetry and the plasma collected in the trisodium citrate tube was used for the analysis 
of fibrinogen using a modification of the Clauss clotting technique (Clauss, 1957) by 
adding prothrombin to the diluted plasma (PT-Fg technique) (Guideline, 2003). Pre- and 
post- samples were analysed next to each other within the same assay series to reduce 
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biochemical variability. The CVs for the assays, using low concentration quality control 
sera, were: glucose 2.24%; TC 3.82%; HDL-C 6.90%; TAG 8.04%; insulin 1.75%; 
fibrinogen 4.18%; CETP 8.2%; and LCAT 1.5%. [see Appendix F.1 for assay methods; 
p349]. 
 
3.2.8 Statistical analyses 
Power calculations were performed using the mean and standard deviation from previous 
studies looking at changes following exercise intervention and the sample size was decided 
from the health outcome that required the greatest number of subjects (CETP; mean 
difference 0.35 ± 0.55 ml·L−1). The results suggested that in order to have a 90% chance of 
finding significant differences, at an alpha of 0.05, a total sample size of 156 subjects 
would be required, including an estimated 20% subject drop out (controls n=52, ABW 
n=52 and SBW n=52). The results are presented as the mean ± SD, with their respective 
post-hoc statistical power and were analysed using SPSS version 13 software, with 
significance being accepted at P<0.05. Analysis of covariance (ANCOVA) was applied to 
the Pre- and Post-walking values using the Pre-walk values as the covariate, incorporating 
a Bonferroni correction, to determine differences in health outcomes between the groups. 
Baseline data were used as co-variates to overcome the slight heterogeneity within the 
groups. Non-normally distributed data were log-transformed and analysed using 
ANCOVA. If the data remained non-normally distributed the Kruskal-Wallis ANOVA was 
utilised and differences between the groups were analysed using Mann Whitney U tests. 
Post-hoc statistical power was also calculated. The data collected in the walking diaries 
were analysed parametrically using independent T-tests and data that could not be log-
transformed were analysed using Mann Whitney U tests. Pearson’s product moment 
correlation coefficients were used to explore relationships between factors.  
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3.3 Results 
The characteristics of the 65 men accepted onto the study were: age 52.7 ± 8.7 years; 
height 1.78 ± 0.07 cm; body mass 90.8 ± 12.2 kg; BMI 28.6 ± 3.6 kg·m-2; WC 102.5 ± 9.5 
cm; WHR 0.98 ± 0.05 and OO2max 36.3 ± 6.9 mL·kg-1·min-1 (Table 3.2). Of the 65 non-
medicated participants that were accepted onto the study 41 satisfactorily completed 24 
weeks; 4 did not satisfactorily complete CON due to illness (2) and not understanding the 
requirements of the study (2), leaving 15 participants that completed the control procedure 
(78.9%); 9 did not satisfactorily complete SBW, leaving 13 participants that completed the 
intervention (59.1%); finally 11 did not satisfactorily complete ABW due to not adhering 
to the accumulative pattern of walking (3) and not completing 24 weeks of walking (8), 
leaving 13 participants that completed the intervention (54.2%). Therefore, group data are 
based on CON=15, SBW=13 and ABW=13, unless otherwise stated, where participants’ 
data were omitted if there were problems with analysing the pre or post sample. 
Table 3. 2 Pre-intervention participant characteristics; mean ± SD 
Subject groups n Age (yrs) Height (m) Body mass (kg) 
CON 15 49.6 ± 7.3 1.77 ± 0.06 91.4 ± 10.5 
SBW 13 52.2 ± 7.8 1.79 ± 0.06 90.9 ± 8.4 
ABW 13 56.1 ± 7.2 1.78 ± 0.08 85.5 ± 12.0 
 
Pre-baseline physical activity levels were 0.75 ± 0.77 hrs·wk-1 ≥4 METs (CON 0.60 ± 0.89 
hrs·wk-1 ≥4 METs, SBW 0.80 ± 0.84 hrs·wk-1 ≥4 METs, and ABW 0.81 ± 0.75 hrs·wk-1 ≥4 
METs, as assessed using a 7-day PA questionnaire (Sallis et al., 1985), and there were no 
differences for any characteristics between groups at baseline (P=0.693). According to the 
ATP III criteria (Cleeman, 2001), 2 participants in CON (13.3%) were classified as having 
MetS, 1 in SBW (7.7%) and 1 in ABW (7.7%) at baseline. At completion of the 24-week 
intervention the presence of MetS increased to 5 participants in CON (33.3%), 3 
participants in SBW (23.1%) and the 1 participant remained in ABW (7.7%). 
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3.3.1 Walking data 
Table 3. 3 Walking diary data from the SBW and ABW groups; mean ± SD 
Mean walking pattern characteristics   SBW n=13 ABW n=13 
Weeks walked 23.5 ± 0.9 23.8 ± 0.4 
Total minutes walked 3623.0 ± 687.8 3532.5 ± 549.8 
Mean minutes walked per week 153.7 ± 27.9 148.3 ± 23.0 
Percentage of prescribed walking (%) 102.9 ± 18.0 98.1 ± 15.3 
Walking intensity (%HRmax) 64.5 ± 5.8 66.5 ± 8.0 
Walking intensity (%VO2max) 49.2 ± 7.2 50.7 ± 11.4 
Estimated walking gross energy expenditure (kcal·wk-1 ) 1196.2 ± 214.5 1326.6 ± 550.2 
Total estimated walking gross energy expenditure (MJ) 120.6 ± 26.4 132.8 ± 55.5   
Walking sessions per week ** 4.7 ± 0.3 9.4 ± 1.7 
Duration of each walking session (min) ** 32.9 ± 6.6 15.4 ± 2.7 
** Significantly different as determined by Mann Whitney U tests; P<0.001. 
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3.3.1.1 Walking intensity 
The allocated walking pattern did not influence either exercising HR or %HRmax recorded 
during the course of the walking intervention (Figure 3.2). The mean HR were 102.0 ± 
18.8 beats·min-1 and 107.4 ± 15.2 beats·min-1 for SBW and ABW, respectively, and mean 
%HRmax were 67.0 ± 11.1% and 65.3 ± 8.7% for SBW and ABW, respectively. 
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Figure 3.2 Mean walking intensity for SBW and ABW, expressed in absolute intensity 
(HR) and relative intensity (%HRmax). [No significant differences: No effect of 
walking pattern (ABW v SBW) on HR (F=0.404; P=0.839). No effect of walking pattern 
(ABW v SBW) on %HRmax (F=1.324; P=0.791)]. SBW=13; ABW=13. 
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3.3.1.2 Walking volume  
The allocated walking pattern did not significantly change for either total mins completed 
or mean min per week recorded during the course of the walking intervention (Figure 3.3). 
The mean total min completed were 3623.2 ± 687.8 min and 3532.5 ± 549.8 min for SBW 
and ABW, respectively, and mean min per week were 153.7 ± 27.9 min·wk-1 and 148.3 ± 
23.0 min·wk-1 for SBW and ABW, respectively. The mean estimated total gross energy 
expended during the walking programmes was 120.6 ± 26.4 MJ for SBW and  132.8 ± 55.5  
MJ for ABW, however despite the apparent trend for ABW to expend a greater total 
energy expenditure during the 24 week intervention, these were not significantly different 
(P=0.496). 
3623.0 3532.5
153.7
148.3
0.0
500.0
1000.0
1500.0
2000.0
2500.0
3000.0
3500.0
4000.0
4500.0
SBW ABW
Walking group
M
e
an
 
to
ta
l w
al
ki
n
g 
c
o
m
pl
e
te
d 
(m
in
s
)
120.0
130.0
140.0
150.0
160.0
170.0
180.0
M
e
a
n
 (m
in
s
·w
k
-1)
Total minutes completed Mean minutes per week
 
Figure 3. 3 Mean walking volume for SBW and ABW, expressed in total mins 
completed and mean mins per week. [No significant differences: No effect of 
walking pattern (ABW v SBW) on total mins (t=0.287; P=0.777). No effect of walking 
pattern (ABW v SBW) on mean mins (Z=-0.308; P=0.762)]. SBW=13; ABW=13. 
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3.3.1.3 Walking frequency 
The allocated walking pattern did not influence the mean weeks completed during the 
course of the walking intervention, however the mean sessions per week were significantly 
increased in ABW compared to SBW (Figure 3.4). The mean weeks completed were 23.5 
± 0.9 weeks and 23.7 ± 0.6 weeks for SBW and ABW, respectively, and mean sessions per 
week were 4.69 ± 0.33 sessions·wk-1 and 9.74 ± 1.73 min·wk-1 (P<0.001) for SBW and 
ABW, respectively. Only one participant that completed ABW chose to perform three 
sessions of 10 minutes for the entire intervention, whereas the majority of the group chose 
two 15 minute walking sessions on each walking day. 
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Figure 3. 4  Mean walking frequency for SBW and ABW, expressed in total weeks 
completed and mean sessions per week. [Significant differences: a Effect of 
walking pattern (ABW v SBW) on mean sessions per week (Z=-4.4334; P<0.001)].  
[No significant differences: b No effect of walking pattern (ABW v SBW) on mean weeks 
performed (Z=-0.429; P=0.762)]. SBW=13; ABW=13. 
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3.3.2 Anthropometric data 
Table 3. 4 Pre- and post-intervention values for anthropometric measures; mean ± SD 
Risk factor CON n=15 
Pre                    Post 
SBW n=13 
Pre                    Post 
ABW n=13 
Pre                      Post 
Between  
group P value 
Body mass (kg) 91.4 ± 10.5 92.6 ± 10.6 90.9 ± 8.4 90.5 ± 8.7 85.5 ± 12.03 84.4 ± 12.2* P=0.027 
Body mass index (kg·m2) 29.2 ± 3.4 29.6 ± 3.6 28.4 ± 2.5 28.2 ± 2.5 27.1 ± 3.6 26.8 ± 3.7 P=0.043 
Waist circumference (cm) 101.6 ± 9.5 103.8 ± 10.1 103.7 ± 7.3 102.6 ± 7.3** 97.3 ± 8.8 94.0 ± 8.9** P<0.001 
Waist:hip ratio 0.96 ± 0.06 0.99 ± 0.07) 0.99 ± 0.05 0.98 ± 0.05** 0.94 ± 0.04 0.92 ± 0.04** P<0.001 
Body fat (%) 28.2 ± 5.5 31.3 ± 4.4 27.4 ± 4.4 28.7 ± 3.6 27.4 ± 5.5 25.8 ± 6.7** P=0.001 
Change in value compared to CON as determined by post-hoc Scheffe test or Mann Whitney U test ; * P < 0.05; ** P < 0.01. 
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3.3.2.1 Body mass 
There was a main effect of group on body mass (P=0.027), where ABW significantly 
decreased body mass compared with CON (P=0.033; Figure 3.5). Body mass change in 
CON was 1.19 ± 2.75 kg, compared to losses of -0.46 ± 1.49 kg (NS) and -1.06 ± 1.77 kg 
in SBW and ABW, respectively. There was a significant effect of group on BMI 
(P=0.043), however neither ABW nor SBW significantly decreased BMI alone compared 
with CON (Table 3.4). BMI change in CON was 0.40 ± 0.87 kg·m-2, compared to 
decreases of -0.15 ± 0.48 kg·m-2 (NS) and -0.30 ± 0.56 kg·m-2 in SBW and ABW (NS), 
respectively. 
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Figure 3. 5  Mean pre- and post-intervention body mass values. [Significant differences: a 
Main of group on body mass (F=4.006; P=0.027). b Effect of ABW on body mass 
compared to CON (P=0.033)]. CON=15; SBW=13; ABW=13. Statistical power: 0.680. 
  108
3.3.2.2 Waist circumference 
There was a main effect of group on WC (P<0.001), with WC being significantly reduced 
in both SBW and ABW compared to CON (Figure 3.6). WC change in CON was 2.19 ± 
2.69 cm, compared to decreases of -1.12 ± 1.67 cm and -3.22 ± 3.38 cm in SBW (P=0.009) 
and ABW (P<0.001), respectively. 
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Figure 3. 6  Mean pre- and post-intervention WC values. [Significant differences: a Main 
effect of group (F=14.130; P<0.001). b Effect of SBW on WC compared to CON 
(P=0.009). c Effect of ABW on WC compared to CON (P<0.001)]. CON=15; SBW=13; 
ABW=13. Statistical power: 0.997. 
 
There was a main effect of group on WHR (P<0.001), with WHR being significantly 
reduced in both SBW and ABW compared to CON (Table 3.4). Waist:hip ratio change in 
CON was 0.03 ± 0.02, compared to decreases of -0.01 ± 0.02 and -0.02 ± 0.03 in SBW 
(P=0.005) and ABW (P<0.001), respectively. 
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3.3.2.3 Body fat percentage 
There was a main effect of group on BF% (P=0.001), with BF% being significantly 
decreased in ABW compared to CON (Figure 3.7). BF% change in CON was 3.08 ± 
2.40%, compared to an increase of 1.28 ± 2.69% in SBW and a decrease of -1.56 ± 5.13% 
in ABW (P=0.001). There were no significant differences between walking groups on 
BF% (P=0.558). 
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Figure 3. 7  Mean pre- and post-intervention body fat percentage values. [Significant 
differences: a Main effect of group on fat% (X2=13.127; P=0.001). b Effect of ABW on 
BF% compared to CON (Z=-3.386; P=0.001)]. CON=15; SBW=13; ABW=13. Statistical 
power: 0.959. 
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3.3.3 Cardiovascular data 
Table 3. 5 Pre- and post-intervention values for fitness parameters, resting heart rate and resting metabolism; mean ± SD 
Risk factor CON n=15 
Pre                Post 
SBW n=13 
Pre              Post 
ABW n=13 
Pre             Post 
Between  
group P value 
VO2max (mL·kg-1·min-1) 36.8  ±  7.4 36.6 ± 6.4 35.7 ± 4.6 39.4 ± 5.6* 38.9 ± 7.8 40.3 ± 5.9 P=0.005 
[La-] (mmol·L-1) 
CON=12, SBW=13, ABW=7 
4.6 ± 2.3 4.3 ± 2.0 4.4 ± 1.9 4.35 ± 1.6 6.2 ± 1.6 3.5 ± 1.3*# P=0.003 
SBP (mm Hg) 132.0 ± 17.1 131.4 ± 15.8 130.0 ± 15.5 124.6 ± 12.7 126.9 ± 13.7 121.3 ± 15.7 P=0.173 
DBP (mm Hg) 88.5 ± 8.6 89.2 ± 10.4 84.1 ± 8.8 83.5 ± 8.8 84.5 ± 10.3 83.1 ± 10.3 P=0.494 
MAP (mm Hg) 102.9 ± 10.8 102.3 ± 12.4 99.3 ± 10.6 97.1 ± 8.9 98.5 ± 11.0 95.7 ± 11.3 P=0.469 
PP (mm Hg) 43.4 ± 11.7 42.2 ± 10.9 45.9 ± 9.5 41.1 ± 10.5 42.4 ± 7.2 38.18 ± 10.9 P=0.974 
Resting heart rate 
(beats·min-1) CON=11, 
SBW=7, ABW=11 
61.5 ± 10.2 61.2 ± 8.2 57.4 ± 9.2 53.0 ± 6.5 61.0 ± 5.5 58.4 ± 6.5 P=0.132 
Rate-pressure product  
(RHR × SBP) CON=11, 
SBW=7, ABW=11 
8043 ± 1900 8056 ± 1656 7568 ± 1132 6635 ± 1231 7929 ± 1097 7013 ± 1147* P=0.019 
*Change in value compared to CON as determined by post-hoc Scheffe test; P<0.05; # compared to SBW; P<0.05. 
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3.3.3.1 Aerobic fitness 
There was a main effect of group on OO2max (P=0.005), where it was significantly 
increased following SBW compared to CON (P=0.004) (Figure 3.8). Change in OO2max 
following CON was -0.21 ± 2.54 mL·kg-1·min-1, compared to increases of 3.74 ± 3.18 
mL·kg-1·min-1 and 1.41 ± 3.65 mL·kg-1·min-1 in SBW and ABW (NS; P=0.180), 
respectively. The improvements in OO2max were not significantly different between ABW 
and SBW (P=0.459). 
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Figure 3. 8  Mean pre- and post-intervention OO2max values. [Significant differences: a Main 
effect of group on OO2max (F=6.161; P=0.005). b Effect of SBW on OO2max compared to 
CON (P=0.004)]. CON=15; SBW=13; ABW=13. Statistical power: 0.864. 
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3.3.3.2 Blood lactate 
There was a main effect of group on [La-] (P=0.022), which significantly decreased 
following ABW compared to CON (P=0.044) and SBW (P=0.028; Figure 3.9). Change in 
OO2max following CON was -0.25 ± 1.48 mmol·L-1, compared to decreases of -0.06 ± 1.80 
mmol·L-1·min-1 and -2.72 ± 1.20 mmol·L-1 in SBW and ABW, respectively. 
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Figure 3. 9  Mean pre- and post-intervention [La-] values. [Significant differences: a Main 
effect of group on [La-] (F=4.362; P=0.022). b Effect of ABW on [La-] compared to CON 
(P=0.044). c Effect of ABW on [La-] compared to SBW (P=0.028)]. Statistical power: 
0.707. 
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3.3.3.3 Systolic blood pressure 
Systolic blood pressure did not appear to change following the intervention period, with 
non-significant differences between groups (P=0.173; Figure 3.10). However, there was a 
trend for decreases in SBP following the SBW (-5.44 ± 7.59 mm Hg; P=0.427) and ABW 
(-5.62 ± 13.61 mm Hg; P=0.260) compared to a smaller decrease following CON (-0.58 ± 
8.35 mm Hg). 
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Figure 3. 10  Mean pre- and post-intervention SBP values. [No significant differences: No 
effect of group on SBP (F=1.843; P=0.173)]. CON=15; SBW=13; ABW=13. Statistical 
power: 0.359. 
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3.3.3.4 Diastolic blood pressure 
Diastolic blood pressure did not appear to change following the intervention period, with 
non-significant differences between groups (P=0.494; Figure 3.11). However, there was a 
trend for decreases in DBP following SBW (-0.62 ± 5.36 mm Hg; P=1.000) and ABW (-
1.44 ± 6.18 mm Hg; P=0.752) compared to CON (0.62 ± 5.22 mm Hg). 
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Figure 3. 11  Mean pre- and post-intervention DBP values. [No significant differences: No 
effect of group on DBP (F=0.485; P=0.494)]. CON=15; SBW=13; ABW=13. Statistical 
power: 0.162. 
 
Mean arterial pressure did not appear to change following the intervention period, with 
non-significant differences between groups (P=0.469) (Table 3.5). However, the trend was 
that the decreases in MAP following SBW (-2.21 ± 4.87 mm Hg; P=1.000) and ABW (-
2.82 ± 7.53 mm Hg; P=0.731) were slightly greater when compared to CON (-0.57 ± 7.12 
mm Hg). 
There were no effects of group on PP (P=0.974) with fairly uniform mean decreases in PP 
following CON (-3.60 ± 10.97 mm Hg), SBW (-4.82 ± 8.12 mm Hg; P=1.000) and ABW 
(-4.18 ± 11.64 mm Hg; P=1.000) (Table 3.5). 
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3.3.3.5 Rate-pressure product 
Resting heart rate was not recorded from the beginning of the study, therefore the first 12 
participants’ RHR were not included in the analyses (CON 4; SBW 6; ABW 2). There was 
no effect of group on RHR (P=0.132), where changes in RHR following CON were -0.27 ± 
6.96 beats·min-1, compared to decreases of -4.43 ± 5.47 beats·min-1 and -2.64 ± 4.99 
beats·min-1 in SBW and ABW, respectively (all NS) (Table 3.5). Resting heart rate was not 
recorded from the beginning of the study, therefore the first 12 participants’ RPP could not 
be calculated and were not included in the analyses (CON 4; SBW 6; ABW 2). There was 
a significant effect of group on RPP (P=0.019; Figure 3.12), where change in RPP 
following CON was 13 ± 51, compared to decreases of -933 ± 1503 and -916 ± 756 in 
SBW and ABW (P=0.031), respectively. 
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Figure 3. 12  Mean pre- and post-intervention RPP values. [Significant differences: a Main 
effect of group on RPP (F=4.681; P=0.019). b Effect of ABW compared to CON 
(P=0.031)]. Statistical power: 0.734. 
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3.3.4 Metabolic data 
Table 3. 6 Pre- and post-intervention values for fitness parameters, resting heart rate and resting metabolism; mean ± SD 
Risk factor CON n=15 
Pre                Post 
SBW n=13 
Pre              Post 
ABW n=13 
Pre             Post 
Between  
group P value 
Resting metabolic rate (kcal·day-1) 
CON=11, SBW=7, ABW=10 
2025 ± 318 1651 ± 438 2078 ± 360 1900  ± 197 1951 ± 320 1704 ± 392 P=0.366 
Resting fat metabolism (kcal·day-1) 898 ± 401 472 ± 345 418 ± 781 870 ± 567 648 ± 839 581 ± 729 P=0.060 
CON=11, SBW=7, ABW=10 
Resting percentage fat utilisation (%) 
CON=11, SBW=7, ABW=10 
 
43.3 ± 16.9 
 
28.4 ± 20.0 
 
15.9 ± 41.7 
 
44.6 ± 28.0* 
 
36.3 ± 37.4 
 
30.4 ± 34.7 
 
P=0.046 
Change in value compared to CON as determined by Mann Whitney U test; * P < 0.05. 
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3.3.4.3 Resting percentage fat utilisation  
Resting metabolic rate was not measured at the beginning of the study, therefore this data 
is not included for the first 12 participants (CON 4; SBW 6; ABW 2) (Table 3.6). There 
was a trend for RMR to decrease in each group over the course of the study, however there 
was no main effect of group (P=0.366). Mean change in fat oxidation rate following CON 
was -374.40 ± 377.71 kcal·day-1, compared to decreases of -177.94 ± 267.17 kcal·day-1 and 
-247.68 ± 271.30 kcal·day-1 in SBW and ABW, respectively (all NS). 
 
Resting fat metabolism was not measured at the beginning of the study, therefore this data 
is not included for the first 12 participants (CON 4; SBW 6; ABW 2). There was a trend 
for resting fat metabolism to decrease in CON and ABW, however there was no main 
effect of group (P=0.060) (Table 3.6). Mean change in fat metabolism following CON was 
-426.58 ± 401.03 kcal·day-1, compared to an increase of 452.47 ± 670.21 kcal·day-1 in 
SBW and a decrease of -67.18 ± 887.65 kcal·day-1 in ABW (all NS). 
  
Resting percentage fat oxidation was not measured at the beginning of the study, therefore 
this data is not included for the first 12 participants (CON 4; SBW 6; ABW 2). There was a 
trend for resting percentage fat oxidation to decrease in CON and ABW, and there was a 
main effect of group on resting percentage fat oxidation (P=0.046; Figure 3.13). 
Furthermore, rates were significantly increased in SBW compared to CON (P=0.012). 
Mean change in fat metabolism following CON was -14.98 ± 23.71 %, compared to an 
increase of 28.67 ± 33.19 % in SBW (P=0.012) and a decrease of -5.94 ± 42.21 % in ABW 
(NS). 
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Figure 3. 13  Mean pre- and post-intervention percentage fat utilisation. [Significant 
differences: a Significant differences between groups (X2=6.161; P=0.046). b Significant 
difference between SBW and CON (Z=-2.672; P=0.012)]. Statistical power: 0.635. 
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3.3.5 Blood data 
Table 3. 7 Pre- and post-intervention measures of blood MetS and markers of RevCholTran; mean ± SD 
Risk factor CON n=15 
Pre               Post 
SBW n=13 
Pre              Post 
ABW n=13 
Pre                Post 
Between  
group P value 
Fibrinogen (g·L-1)  
CON n=13, SBW n=11, ABW n=12 
2.93 ± 1.01 3.10 ± 0.72 3.07 ± 0.44 2.91 ± 0.38 2.96 ± 0.45 2.78 ± 0.68 P=0.249 
Insulin (µIU·mL-1)  
SBW n=12, ABW n=12 
13.07 ± 6.16 16.06 ± 4.72 11.36 ± 3.84 11.06 ± 3.80 11.35 ± 8.35 8.74 ± 6.09* P<0.001 
HOMA-IR (HOMA units) 
SBW n=12, ABW n=12 
2.92 ± 1.21 3.97 ± 1.21 2.67 ± 1.01 2.76  ± 1.06 2.87 ± 2.29 2.18 ± 1.68** P<0.001 
HOMA-β (%) 
SBW n=12, ABW n=12 
41.5 ± 20.5 52.9 ± 18.6 39.7 ± 13.5 36.1 ± 12.6 36.9 ± 27.9 27.9 ± 19.8* P=0.001 
Glucose (mmol·l-1) 
CON n=14, SBW n=12, ABW n=12 
5.45 ± 0.65 5.68 ± 0.48 5.25 ± 0.43 5.57 ± 0.34 5.56 ± 0.61 5.43 ± 0.53 P=0.072 
TAG (mmol·L-1)  
SBW n=12 
NEFA (mmol·L-1)  
CON n=13, SBW n=12 
TC (mmol·L-1)  
SBW n=12 
1.38 ± 0.59 
 
0.33 ± 0.17 
 
5.67 ± 0.94 
1.68 ± 0.90 
 
0.25 ± 0.14 
 
5.51 ± 0.98 
1.13 ± 0.36 
 
0.29 ± 0.10 
 
5.21 ± 0.84 
1.22 ± 0.75 
 
0.29 ± 0.13 
 
4.80 ± 0.73 
1.25 ± 0.52 
 
0.29 ± 0.14 
 
5.53 ± 0.82 
1.24 ± 0.60 
 
0.24 ± 0.10 
 
5.42 ± 0.82 
P=0.425 
 
P=0.271 
 
P=0.544 
HDL-C (mmol·L-1)  
SBW n=12 
1.38 ± 0.35 1.30 ± 0.39 1.27 ± 0.33 1.19 ± 0.31 1.37 ± 0.35 1.47 ± .44 P=0.165 
TC/HDL ratio 
SBW n=12 
4.33 ± 1.33 4.54 ± 1.36 4.23 ± 0.85 4.18 ± 0.84 4.19 ± 0.88 4.06 ± 1.09 P=0.154 
LDL-C (mmol·L-1)  
SBW n=12 
3.66 ± 0.85 3.45 ± 0.79 3.46 ± 0.73 3.06 ± 0.73 3.59 ± 0.67 3.39 ± 0.67 P=0.821 
CETP (pmol·hr-1)  
SBW n=12 
156.3 ± 70.0 146.5 ± 70.9 171.3 ± 99.3 151.3 ± 88.9 176.2 ± 94.5 180.5 ± 74.5 P=0.371 
LCAT (ratio 470/390nm of  
emission intensity) SBW n=12 
0.880 ± 0.024 0.880 ± 0.036 0.880 ± 0.035 0.880 ± 0.034 0.881 ± 0.034 0.887 ± 0.034 P=0.814 
Change in value compared to CON as determined by post-hoc Scheffe test; * P<0.05, ** P<0.001. 
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3.3.5.1 Plasma fibrinogen 
There was no main effect of group on plasma fibrinogen (P=0.249; Figure 3.14), where 
mean change following CON was 0.17 ± 0.69 g·L-1, compared to decreases of -0.16 ± 0.41 
g·L-1 and -0.18 ± 0.68 g·L-1 in SBW and ABW, respectively. 
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Figure 3. 14  Mean pre- and post-intervention plasma fibrinogen concentrations. [No 
significant differences: No effect of group on plasma fibrinogen (F=1.454; P=0.249)]. 
Statistical power: 0.288. 
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3.3.5.2 Insulin resistance 
Insulin resistance was estimated using the HOMA ratio formula and there was a main 
effect of group (P<0.001; Figure 3.15). Change in insulin resistance following CON was 
1.05 ± 1.29, compared to an increase of 0.09 ± 0.84 and a decrease of -0.69 ± 0.78 in SBW 
and ABW, respectively. There was a significant improvement in insulin resistance 
following ABW (P<0.001) compared to CON, and despite a slight increase in insulin 
resistance following SBW this was significantly less than following CON (P=0.012) and 
ABW and SBW were not significantly different (P=0.161).  
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Figure 3. 15  Mean pre- and post-intervention insulin resistance values (HOMA-IR). 
[Significant differences: a Main effect of group on insulin resistance (F=13.670; P<0.001). 
b Effect of SBW on insulin resistance compared to CON (P=0.012). c Effect of ABW on 
insulin resistance compared to CON (P<0.001).]. Statistical power: 0.996. 
There was a main effect of group on serum insulin (P<0.001), where change in serum 
insulin following CON was 2.99 ± 6.32 µIU·mL-1, compared to decreases of -0.30 ± 3.30 
µIU·mL-1 and -2.61 ± 3.04 µIU·mL-1 in SBW (P=0.020) and ABW (P=0.001), respectively, 
and the decreases in serum insulin were not significantly different between walking groups 
(P=0.384) (Table 3.7). 
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3.3.5.3 Insulin secretion rates 
Insulin secretion rates were estimated using the HOMA-β formula and there was a main 
effect of group (P=0.001; Figure 3.16). Change in insulin secretion following CON was 
11.41 ± 25.55%, compared to decreases of -3.64 ± 12.09% (P=0.024) and -9.01 ± 11.79% 
(P=0.001) in SBW and ABW, respectively.  
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Figure 3. 16  Mean pre- and post-intervention β-cell insulin secretion rate (HOMA- β). 
[Significant differences: a Main effect of group on β-cell insulin secretion (F=8.652; 
P=0.001). b Effect of SBW on β-cell insulin secretion compared to CON (P=0.024). c 
Effect of ABW on β-cell insulin secretion compared to CON (P=0.001)]. Statistical power: 
0.954. 
 
There was no effect of group on plasma glucose (P=0.072;), with only a slight increase in 
CON (0.23 ± 0.59 mmol·L-1), compared to an increase following SBW (0.33 ± 0.32 
mmol·L-1) and a decrease following ABW (-0.13 ± 0.39 mmol·L-1) (Table 3.7). 
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3.3.5.4 Blood Lipids 
Plasma NEFA was not significantly changed following walking compared to CON 
(P=0.271), where changes in plasma NEFA following CON were -0.08 ± 0.11 mmol·L-1, 
compared to an increase of 0.00 ± 0.11 and decrease of -0.05 ± 0.13 mmol·L-1 in SBW and 
ABW mmol·L-1, respectively. The changes in NEFA were not significantly different 
between walking groups (P=0.543) (Table 3.7). 
Serum TAG was not significantly altered between groups (P=0.425), however there was an 
increase following CON (0.30 ± 0.74 mmol·L-1), compared to a slight increase in SBW 
(0.08 ± 0.76 mmol·L-1) and a slight decrease following ABW (0.01 ± 0.42 mmol·L-1), all 
NS (Table 3.7). 
Serum TC concentrations were not significantly altered between groups following the 
intervention period (P=0.544). There was a general trend for serum TC to decrease in each 
group following the intervention, where there was a slight decrease in CON (-0.15 ± 0.79 
mmol·L-1), compared to decreases of -0.41 ± 0.63 mmol·L-1 and -0.10 ± 0.72 mmol·L-1 in 
SBW and ABW, respectively (Table 3.7). 
Serum HDL-C concentrations were not significantly altered between groups following the 
intervention period (P=0.165). Trends in HDL-C following the intervention were a slight 
decrease in CON (-0.08 ± 0.17 mmol·L-1), compared to a decrease of -0.09 ± 0.19 mmol·L-
1
 (P=1.000) and an increase of 0.10 ± 0.32 mmol·L-1 (P=0.144) in SBW and ABW, 
respectively (Table 3.7). 
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3.3.5.5 Serum TC/HDL-C ratio 
Serum TC/HDL-C concentrations were not significantly altered between groups following 
the intervention period (P=0.154; Figure 3.17). Trends in HDL-C following the 
intervention were a slight increase in CON (0.21 ± 0.50 mmol·L-1), compared to a mean 
increase of -0.05 ± 0.43 mmol·L-1 in SBW (P=0.434) and a decrease of -0.27 ± 0.69 
mmol·L-1 (P=0.080) in ABW. 
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Figure 3. 17  Mean pre- and post-intervention serum TC/HDL-C ratios. [No significant 
group differences (X2=3.740; P=0.154)]. Statistical power: 0.493. 
 
Serum LDL-C concentrations were not significantly altered between groups following the 
intervention period (P=0.821) (Table 3.7). There was a general trend for LDL-C to 
decrease during the study, where there was a slight decrease in CON (-0.21 ± 0.62 mmol·L-
1), compared to a mean increase of -0.40 ± 0.77 mmol·L-1 (P=0.683) and a decrease of -
0.20 ± 0.46 mmol·L-1 (P=0.751) in SBW and ABW, respectively. 
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3.3.6 Reverse cholesterol transport activity 
Serum CETP activity was not significantly altered between groups following the 
intervention period (P=0.371; Figure 3.31). Trends in serum CETP activity following the 
intervention were a slight decrease in CON (-9.80 ± 43.61 pmol·hr-1), compared to a mean 
decrease in SBW (-20.00 ± 96.69 pmol·hr-1; P=1.000) and an increase in ABW (4.31 ± 
53.94 pmol·hr-1; P=0.156). 
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Figure 3. 18  Mean pre- and post-intervention serum CETP activity. [No significant group 
differences (X2=1.980; P=0.371)]. Statistical power: 0.113 
 
Serum LCAT activity was not significantly altered between groups following the 
intervention period (P=0.814; Table 3.7). Trends in serum LCAT activity following the 
intervention were a slight decrease in CON (-0.0002 ± 0.0298 470/390nm ratio), compared 
to a mean decrease in SBW (-0.0001 ± 0.0160 470/390nm ratio; P=1.000) and an increase 
in ABW (0.0053 ± 0.0305 470/390nm ratio; P=1.000). 
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3.4 Discussion 
The aims of the study were to determine whether walking briskly for 24 weeks on 5 days 
of the week and for 30 minutes each day could improve MetS risk factors and markers of 
RevCholTran compared to sedentary controls, and also whether accumulating the same 
volume of brisk walking during the day may be equally effective. Of the 65 non-medicated 
participants that began the study 41 satisfactorily completed 24 weeks; 4 did not 
satisfactorily complete CON due to illness (2) and not understanding the requirements of 
the study (2), leaving 15 participants that completed the control procedure (78.9%); 9 did 
not satisfactorily complete SBW, leaving 13 participants that completed the intervention 
(59.1%); finally 11 did not satisfactorily complete ABW due to not adhering to the 
accumulative pattern of walking (3) and not completing 24 weeks of walking (8), leaving 
13 participants that completed the intervention (54.2%) (see Figure 3.1). These are greater 
than mean values from previous randomised walking trials, where mean percentage drop 
out rates were 20.2% among walkers and 12.4% for controls (Murphy et al., 2007) 
compared to a mean drop-out rate of 43.4% in ABW and SBW combined and 21.1% in 
CON in the present study. However, this was still within the range of those studies 
included in the meta-analysis: 0–53.8% and 0–38% among walkers and controls, 
respectively. 
 
The study recruited sedentary middle-aged men at risk of MetS and use of such 
medications is common in these groups (Rantala et al., 1999; Williams & Franklin, 2007). 
Following the recruitment period there were a number of participants that were excluded 
from the study due to their use of anti-hypertensive and/or lipid-lowering medication (8 
CON; 5 SBW; 5 ABW) in order to remove the confounding effects of these medications on 
the health outcomes being examined. In those who completed the study, the presence of 
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MetS increased in CON from 3 participants to 5 and in SBW from 1 participant to 3, 
whereas the participant with MetS in ABW remained in the MetS category as defined by 
ATPIII criteria (Cleeman, 2001). Considering that few of the participants began the study 
diagnosed with MetS, after exclusion of those using medication, it is conceivable that the 
relative good health of the participants precluded improvements in MetS components due 
to the walking, as those with greater health are known to derive less benefit from exercise 
than those of lower health status (Wilmore, 2001). At baseline the participants’ mean 
values for serum lipids and lipoproteins, RevCholTran enzymes, plasma fibrinogen, 
plasma glucose and serum insulin were within the normal ranges, while the participants’ 
mean aerobic capacity was in the ‘good’ classification for males of this age. However, 
mean blood pressure measures, WC and subsequent WHR values were towards high 
normal values. Therefore, in general, the participants could only have been considered to 
be pre-obese and borderline MetS at pre-intervention and perhaps not as likely as less 
healthy individuals to respond to PA treatment due to having less potential for 
improvement (Wilmore, 2001; Cleeman, 2001). However, exercise-only interventions have 
proven effective in reducing presence of MetS. Indeed, a 12 month intervention study 
involving 137 men with International Diabetes Federation (IDF)-defined MetS who were 
randomly allocated to control, diet, exercise or combined exercise/diet groups, found that 
each intervention decreased the presence of MetS symptoms (Anderssen et al., 2007). 
Following 12 months of the interventions 76.5% in the exercise group (supervised aerobic 
exercise; 3×60min·wk-1 @ 60-80% HRpeak), 64.7% following 12 months in the diet group 
(dietary advice at 3, 6 & 9 months; energy restriction, reduced saturated fat & cholesterol 
and increased fish consumption) and 32.6% in the combined exercise and diet group still 
had MetS.  
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In the present study the CON group were instructed to maintain their pre-intervention low 
levels of PA throughout the duration of the study and those in SBW and ABW were 
instructed to record their walking activities within diaries. These diaries indicated that 
there were no significant differences in the intensity of brisk walking in terms of mean 
HRmax and %HRmax (Figure 3.2) and volume of brisk walking in terms of minutes per 
week, total minutes performed or total estimated energy expenditure during the study 
(Figure 3.3 & Table 3.3). There were no significant differences between the walking 
groups for the number of weeks completed, however as would be expected ABW 
performed a significantly greater number of walking sessions during the course of the 
study than SBW (Figure 3.4). Compared to a meta-analysis of 20 randomised controlled 
walking trials (Murphy et al., 2007) the characteristics of the walking intervention in the 
present study were generally of lower duration (32.9 ± 5.8 mins·session-1 & 15.6 ± 3.0 
mins·session-1 for SBW & ABW, respectively), lower mean weekly volume (150.6 ± 25.1 
min·wk-1), shorter intervention period (23.6 ± 0.8 weeks) and at a lower relative intensity 
(66.2 ± 9.9% HRmax). However, walking frequency was similar to the pooled data in the 
meta-analysis (4.69 ± 0.33 sessions·wk-1 & 9.74 ± 1.73 min·wk-1 for SBW & ABW, 
respectively). The mean characteristics of the randomised controlled walking trials 
included in the meta-analysis were 38.3 ± 14.4 mins·session-1, on 4.4 d·wk-1, giving a mean 
volume of 188.8 min·wk-1, for 34.9 ± 4.9 weeks, at a mean intensity of 70.1 ± 9.1% HRmax.  
 
The accumulative brisk walking group (ABW) was associated with significant 
improvements in the majority of the anthropometric measures of obesity including body 
mass, WC, WHR and %BF compared to CON, however SBW only improved WC and 
W:H compared to CON (Table 3.4 & Figures 3.5-3.7). Blood [La-] was collected on 
completion of the submaximal walking test as an additional measure of cardiorespiratory 
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fitness to predicted OO2max as an indicator of metabolic changes due to walking. 
Interestingly, SBW improved OO2max compared to CON, whereas although there appeared 
to be a tendency for ABW to improve OO2max compared to CON, this did not attain 
statistical significance (P=0.180). However, the opposite was true for [La-], measured on 
completion of the submaximal walking test, where ABW decreased [La-] compared to both 
CON (P=0.044) and SBW (P=0.028) (Figures 3.8-3.9). It may be speculated that this 
difference was due to the pattern of walking where the longer duration bouts in SBW may 
have stimulated greater central cardiorespiratory adaptation, whereas the repetitive nature 
of the walks in ABW may have affected [La-] buffering capacity by the musculature of the 
legs being re-stimulated on multiple occasions on the same day and promoting peripheral 
metabolic adaptation. Change in OO2max appeared to be unrelated to changes in any of the 
health outcomes that were investigated. Indeed, evidence demonstrates that PA-induced 
reductions in total and abdominal fat are more strongly associated with improvements in 
blood pressure, blood lipid & lipoprotein profile and insulin sensitivity than the 
improvements in fitness (Stewart et al., 2005).  
 
Long-term adherence to PA may lower blood pressure independently of weight loss and 
may be related to increased vasodilation due to enhanced vagal tone and reductions in 
insulin resistance/hyperinsulinaemia-induced mechanisms, such as enhanced tubular 
sodium reabsorption, decreases in insulin resistant blood vessels, increased capillarisation 
and decreased secretion of vasoactive substances from adipose tissue (Pedersen & Saltin, 
2006). However, there may be certain subgroups of patients with hypertension who are 
more responsive to the blood pressure-lowering effects of PA, since the decrements in 
blood pressure associated with increased PA are not always sufficient to produce 
normotension in many studies (Eriksson et al., 1997). Despite the apparent disparity, RCTs 
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among overweight middle-aged and older subjects demonstrate the effectiveness of PA to 
lower blood pressure, with or without weight loss (Dengel et al., 1998; Blumenthal et al., 
2000). A 1999 meta-analysis of aerobic exercise training RCTs among overweight/obese 
participants, the blood pressure lowering effect of PA was small but statistically significant 
among normotensive study groups (baseline blood pressure 128/84 mm Hg) (Fagard, 1999) 
and a further meta-analysis showed modest weight loss (3-9%) was associated with a 
significant reduction in mean systolic and diastolic blood pressures of approximately 3 mm 
Hg compared with non-intervention controls (Hermansen, 2000).  
 
The overall results of the published studies indicate that blood pressure reductions may be 
apparent within 10 weeks of hypertensive patients beginning participation in PA, with 
recent evidence to suggest that significant reductions are possible within 4 weeks (Collier 
et al., 2008) and blood pressure may continue to decline even further with prolonged 
maintenance of PA, which may occur independently of favourable changes in body 
composition (Hagberg et al., 2000). In the present study, blood pressure tended to decrease 
slightly in each group throughout the duration of the study however it was not significantly 
augmented in either of the walking groups (Figures 3.10-3.11). Despite favourable changes 
in blood pressure, a primary MetS marker, these were not statistically significant, which 
was possibly at least partly due to the low statistical power, where changes of a similar 
magnitude have been reported in other exercise intervention studies and found to be 
significant (Wilmore, 2001). Therefore, it may be reasonable to state that both walking 
interventions appeared to be equally as effective as other interventions in reducing blood 
pressure, if non-significant. However, the trends for both BP (Figures 3.10-3.11) and 
resting heart rate (Table 3.5) to decrease during ABW and SBW compared to CON, 
resulted in significant differences in rate-pressure product following the 24 weeks of brisk 
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walking (Figure 3.12). This effect was evident for ABW compared to CON, however there 
was only a trend for the favourable effect of SBW compared to CON (P=0.077) and the 
favourable trends in SBP and RHR appear to have been additive to decrease RPP, in which 
changes were significantly associated with changes in WHR (P=0.018). 
 
There was an apparent trend for RMR to decrease in each group over the course of the 24 
weeks, however although the increase in resting fat oxidation in kcal·d-1 following SBW 
was not significant (Table 3.6), when resting fat oxidation was expressed proportionally to 
RMR, percentage resting fat utilisation was significantly increased following SBW 
compared to CON (Figure 3.13). However, this did not impact significantly upon body 
mass losses foloowing SBW. Change in body mass was associated with change in fasting 
serum insulin (P=0.007), a relationship that was also apparent between change in body 
mass and change in HOMA-IR (P=0.015) and HOMA-β (P=0.018). Change in body mass 
was also associated with change in DBP (P=0.014), BF% (P=0.013) and WC (P<0.001). 
However, change in WC was more strongly associated with [La-] (P=0.025), DBP 
(P=0.007) and fasting serum insulin (P=0.005). The changes in HOMA-IR and HOMA-β 
associated with changes in body mass appear to be mediated predominantly through 
changes in WC for HOMA-IR (P=0.001) and HOMA-β (P=0.013), even though change in 
BF% remained strongly associated with change in HOMA-IR (P=0.005). Improvements in 
glucose homeostasis occurred following both walking interventions compared to CON. 
Both fasting insulin secretion (Figure 3.16) and serum insulin (Table 3.7) tended to 
decrease compared to baseline in SBW and ABW, however the tendency for these 
measures to increase during CON increased the difference. Accumulative walking 
demonstrated a decrease in insulin resistance compared to baseline, whereas there was a 
trend for insulin resistance to increase slightly following SBW (Figure 3.15). However, 
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since serum insulin and insulin secretion were significantly lower following the walking 
intervention, this phenomenon is likely due to the slight increase in fasting plasma glucose 
that occurred following SBW (Table 3.7). These findings were similar to those of 
Miyatake et al. (2002) and showed greater improvement than the findings of Snyder et al. 
(1997). It is debatable whether hyperinsulinaemia is the primary defect that causes obesity 
or actually a response, however it is clear that reductions in abdominal adiposity and 
hyperinsulinaemia are related to increased PA and that increases in non-oxidative glucose 
disposal following chronic PA is likely to be responsible (Ross et al., 2000b). These 
favourable changes occur even in the absence of body mass losses, which indicates that 
improvements in muscle metabolism decreases abdominal adiposity and enhances insulin-
stimulated insulin uptake, however significant decreases in body fat may augment this 
effect (Kelley & Goodpaster, 1999; Ross et al., 2000b). 
 
Intra-abdominal fat is relatively insensitive to insulin and has a high lipolytic activity, 
partly due to its complement of adrenergic receptors (Björntorp, 1990) and 
hyperinsulinaemia and increased NEFA may affect several interconnected steps in 
lipoprotein-lipid metabolism (Carroll & Dudfield, 2004). Physical activity may improve 
the dyslipidaemic profile associated with MetS by increasing the ability of muscle tissue to 
take up and oxidize NEFA and increasing the activity of LPL in muscle (Pollare et al., 
1991). Reductions in TAG and elevations in HDL-C are commonly associated with 
increased PA, however TC and LDL-C are infrequently affected (Durstine et al., 2001). 
Endurance-trained men and women demonstrate high rates of TAG clearance compared 
with sedentary controls, which may be related to the increased LPLa, the enzyme that 
hydrolyses TAG-rich lipoproteins (Kiens & Lithell, 1989). This may benefit an 
atherogenic dyslipidaemic profile because circulating TAG concentrations are closely 
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coupled with rates of HDL clearance and so an enhanced metabolic capacity for TAG may 
explain the high HDL-C levels in physically active people. However, there was no 
apparent effect of brisk walking on blood lipid and lipoproteins, with plasma NEFA, serum 
TAG, serum total cholesterol, serum HDL-C, TC/HDL-C ratio and serum LDL-C 
remaining unchanged compared to CON following SBW and ABW (Table 3.7 & figure 
3.17). Changes in fasting serum TAG were associated with change in HOMA-IR 
(P=0.020) and HOMA-β (P=0.020), and change in plasma NEFA were also associated with 
HOMA-IR (P=0.022), while change in serum TAG was also associated with change in the 
TC/HDL-C ratio (P<0.001), with much of this effect being mediated through the 
relationship between change in serum TAG and serum HDL-C (P=0.031) rather than 
changes in serum TC (P=0.106).  
 
Two of the primary markers of MetS, TAG and HDL-C, were unchanged as a result of the 
intervention, which may have been due to insufficient PAEE. Evidence suggests that there 
is a weekly PAEE threshold of 1200-2200 kcal·wk-1 that needs to be met for increases in 
HDL-C to occur (Durstine et al., 2001) and although the mean estimated weekly PAEE in 
the present study was just over 1200 kcal·wk-1, the lack of change in serum HDL-C may 
have been due to the mean baseline blood lipid and lipoprotein profiles being in the fairly 
good category leaving little potential for favourable change (Wilmore et al., 2001). 
Furthermore, the participants in the walking groups only walked at ~50% OO2max, which 
is considerably lower than 75% OO2 max that has been shown to cause changes in blood 
lipid and lipoprotein profile (Durstine et al., 2001). In a meta-analysis of 25 randomised 
controlled walking trials, 1,176 participants were studied to investigate the influence of 
walking on blood lipids and lipoproteins (Kelley et al., 2004). The walking studies were 
performed at 64.2 ± 9.4% OO2max for 38.4 ± 15.6 min·session-1 on 4.8 ± 2.5 d·wk-1 for 23.2 
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± 17.7 weeks and the rate of adherence was 83.4 ± 18.0%, The main findings of the 
analysis was that walking can significantly reduce LDL-C by ~5% and TC/HDL-C ratio by 
~6% independently of reductions in body mass, and although no significant changes in 
mean TC, HDL-C or TAG were observed, the direction of change tended to be favourable. 
A secondary finding of the meta-analysis was an increase in OO2max of 3.6 ± 0.5 mL·kg-
1
·min-1, which equated to a 15% increase compared to controls, but body mass, BMI, 
percent body fat and lean body mass were not significantly altered. These findings are 
contradictory to the present study, where although the walking interventions in the present 
study were similar to the mean characteristics of those included in the meta-analysis, those 
studies generally demonstrated decreases in serum TC/HDL-C ratio and LDL-C without 
associated improvements in body composition. Furthermore, even though significant 
improvements in body composition were observed in the present study, these were not 
associated with significant decreases in serum LDL-C and TC/HDL-C ratio, despite 
favourable trends. However, even following meta-analysis, these were the only 
components of the lipid & lipoprotein profile that walking intervention significantly 
improved (Kelley et al., 2004). 
 
Serum CETPa and LCATa were measured to indicate mechanisms for potential changes in 
TAG-HDL-C dynamics as a result of the walking interventions. However, as with serum 
TAG and HDL-C concentrations, CETPa and LCATa remained unchanged, indicating that 
not only did blood lipid and lipoprotein profiles not favourably respond compared to CON 
following the brisk walking, despite significant reductions in anthropometric measures of 
abdominal adiposity in SBW and ABW, measures of RevCholTran remained unchanged 
(Table 3.7 & Figure 3.18). Therefore, aside from TC/HDL-C ratio there was no clear 
pattern for SBW or ABW to favourably influence the blood lipid and lipoprotein profile, 
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thus indicating that both walking interventions may have been collectively ineffective in 
improving this profile.  
 
Studies concerning the effect of PA interventions on lipids and lipoproteins among 
individuals with MetS remain scarce, partly due to the lack of precise definition of the 
syndrome. However, data indicates that over months, PA expending 1200-2200 kcal·wk-1 
results in increases in HDL-C, which are even greater when the exercise programme is 
accompanied by weight loss (Durstine et al., 2001). Therefore, PA alone may not always 
be sufficient to normalise the atherogenic dyslipidaemia associated with MetS without 
significant weight loss. Low HDL-C is associated with insulin resistance, which causes 
hypertriglyceridaemia through increased hepatic production of VLDL particles (Ji et al., 
2005). Hyperinsulinaemia-blunted decreases in LPLa have also been suggested to explain 
the relationship between elevated TAG and decreased HDL-C, thus decreasing TAG 
clearance and impairing maturation of HDL-C by enhanced CETP-mediated exchange of 
TAG and cholesteryl esters between TAG-rich lipoproteins and HDL-C (Lewis & Rader, 
2005). However, neither serum TAG, HDL-C or CETPa were favourably influenced 
following the walking interventions, despite increases in insulin sensitivity and decreases 
in serum insulin, particularly ABW. Cholesterol ester transfer protein enriches HDL-C 
with TAG and depletes them of cholesteryl esters, which reduces the size of the HDL-C 
particles (Skeggs & Morton, 2002). Reductions in CETPa have the ability to elevate 
circulating HDL-C through reductions in TAG-rich HDL-C (Lewis & Rader, 2005). The 
first published study investigating the influence of exercise training on plasma CETP was 
performed by Seip et al. (1993). The exercise training consisted of three to five sessions of 
supervised aerobic exercise (walking/jogging/stationary cycling) for 45-60 minutes per 
week at ≤85% HRmax for 9-12 months. The main outcomes were that CETP concentrations 
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fell and significantly in response to training, with the decreases in CETP concentration 
weakly associated with decreases in body fat. Pre-training CETP concentration predicted 
the training-induced increases in HDL-C, i.e. those with the lowest CETP concentrations 
gained the greatest increases in HDL-C and those with higher pre-training CETP 
concentrations achieved the smallest increases in HDL-C. As with the mean characteristics 
of randomised controlled walking trials mentioned above, the study by Seip et al., (1993) 
involved a greater PA volume than the present study, in terms of PA session duration, 
intensity and total intervention period, indicating that the present intervention may have 
been insufficient to promote favourable responses rather than being underpowered per se. 
Therefore, increasing PA intensity, session duration or total intervention period may have 
resulted in increases in CETPa and concomitant increases in HDL-C. 
 
Lecithin-cholesterol acyltransferase is an enzyme that is bound to HDL particles and 
esterifies free cholesterol to form cholesteryl esters by transferring 2 acyl groups from 
lecithin to cholesterol. While there is cross-sectional evidence demonstrating higher 
concentrations of LCAT in athletes compared to sedentary counterparts (Brites et al., 2004; 
Olchawa et al., 2004), there is no direct evidence that PA intervention can increase LCAT 
concentrations (Williams et al., 1990) or LCATa (Bedgoni et al., 2002), despite significant 
decreases in body mass and fat percentage in these studies. Therefore, it may be reasonable 
to speculate that the lack of change in LCATa may have been due to an insufficient PA 
volume. Furthermore, the importance of LCAT in RevCholT has not been fully established 
because unesterified cholesterol can be directly transferred from HDL-C to the liver for 
excretion without the need for LCAT-mediated esterification (Lewis & Rader, 2005). A 
combination of the equivocal importance of LCAT in RevCholTran and the lack of change 
in LCAT or LCATa following PA intervention substantiates the present findings that 
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LCATa remained similar between groups during the present study, despite greater 
concentrations in athletes compared to sedentary individuals (Brites et al., 2004; Olchawa 
et al., 2004). 
 
Neither ABW nor SBW appeared to significantly improve plasma fibrinogen 
concentrations, despite favourable trends in both walking groups compared to CON 
(Figure 3.14). However, due to the limited number of studies of the potential 
improvements in thrombotic risk associated with PA, the exact PA dose to promote a 
favourable response is currently unknown. Metabolic processes within skeletal muscles 
may drive the anti-thrombotic effects of PA, where data from the longitudinal ‘Studies of 
Targeted Risk Reduction Intervention through Defined Exercise’ (STRIDDE) 
demonstrated that the fibrinolytic activities of tissue plasminogen activator (tPA), and its 
endogenous inhibitor (PAI-1), were favourably altered in skeletal muscle and serum 
following 9 months of exercise training expending 2000 kcal·wk-1, as measured using the 
biopsy needle technique (Hittel et al., 2003). In the present study mean weekly estimated 
PAEE was only 1345.3 kcal·wk-1 in ABW and 1211.5 kcal·wk-1 in SBW over the course of 
~6 months, therefore well below the PAEE threshold achieved by STRIDDE. Therefore, 
since the exact PA dose required to improve fibrinolytic activity is yet to be defined, it is 
seems that the PAEE achieved in the current study was insufficient to significantly 
decrease plasma fibrinogen concentrations. 
 
A limitation of the outcome of the present study was that blood pressure and blood lipid & 
lipoprotein profile tended to be underpowered in contrast to anthropometric and aerobic 
fitness measures (>0.70), particularly for WC, WHR and BF%, with WC, WHR, OO2max 
and glucose homeostasis being the only health outcomes that were favourably improved 
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following SBW compared to CON. Despite relatively low statistical power for some of the 
health outcomes in this study it is possible that the walking interventions (walking intensity 
and volume) were insufficient to improve some of the health outcomes. Although walking 
at any pace expends energy, usually when individuals are instructed to walk briskly they 
automatically select a pace that elicits an intensity of ~70% HRmax (~60% OO2max), which 
likely to improve cardiovascular fitness (Morris & Hardman, 1997; Murtagh et al., 2002). 
Walking at 4.8 k·hr-1 on a level surface requires a OO2 of ~13 mL·kg-1·min-1, which could 
amount to over 60% OO2max for a 75-year-old due to age-associated declines in OO2max, 
but may be less than 30% OO2max of a healthy 30-year-old man (Morris & Hardman, 
1997). A study from the early 1990s reported that habitual exercise walkers, OO2max 35.7 ± 
6.3 mL·kg-1·min-1, met the ACSM’s recommended PA intensity for improving OO2max 
(≥70% HRmax; ≥60% OO2max) (Spelman et al., 1993). However, due to the mean age (52.71 
± 8.73 years) and mean OO2max (36.30 ± 6.84 mL·kg-1·min-1) of the participants in this 
study being categorised as fairly fit for their age, it is likely that the mean walking intensity 
(66.2 ± 9.9 HRmax), although generally sufficient to improve OO2max in the walking groups 
compared to CON, was of insufficient intensity to improve primary health outcomes, such 
as blood pressure and blood lipid and lipoprotein profiles. Furthermore, the characteristics 
of the walking interventions were generally lower than the mean values for those reported 
in the recent meta-analysis on the impact of walking on body composition, fitness and 
blood pressure (Murphy et al., 2007). 
 
Data from the available randomised controlled walking trials suggest that favourable 
changes in body composition, OO2max, blood pressure, blood lipid and lipoprotein profile 
and blood clotting may be attained by walking at ~70% HRmax for 30 min·d-1 on 5 d·wk-1 
(Woolf-May et al., 1998; Murphy & Hardman, 1998). Mean data pooled in a recent meta-
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analysis of randomised controlled walking interventions demonstrated mean increases in 
OO2max of 2.73 ± 0.35 mL·kg-1·min-1 (9%), mean decreases of -0.95 ± 0.61 kg (-1.4%) and 
-0.28 ± 0.20 kg·m-2 (-1.1%) and -0.63 ± 0.66% (-1.9%) in body mass, BMI and body fat 
percentage, respectively, compared to baseline (Murphy et al., 2007). Each of these 
favourable changes were significant (P≤0.035) and although resting diastolic blood 
pressure was significantly decreased by -1.54 ± 0.79 mm Hg (-2%; P=0.026) systolic blood 
pressure was not favourably changed through walking intervention, however relatively few 
of the walking studies measured blood pressure pre & post (SBP=9; DBP= 6), thus 
decreasing the chances of a favourable outcome compared with the other measures. These 
findings clearly suggest that walking may have its limitations for enhancing certain risk 
factors, where even in meta-analysis there are non-significant findings. Furthermore, 
despite including data for 116 participants between four walking groups, walking did not 
significantly improve body composition, blood pressure, blood lipoprotein profile or 
glucose tolerance despite increases in OO2max, which also suggested a lack of power 
Asikainen et al. (2003). 
 
Prior to the original PA recommendations for accumulating PA being published (CDC & 
ACSM, 1995) only two empirical studies had investigated the efficacy of accumulated PA 
on health. These studies investigated the influence of splitting running distance on 
cardiovascular endurance and blood lipids (Ebisu, 1985) and the effect of short vs. long 
bouts of exercise on OO2max (DeBusk et al., 1990). Subsequently, in a more eloquent RCT,  
the efficacy an 18 week intervention of accumulative walking was investigated 
incorporating a CON group, a single daily brisk walking involving 20-40 minute sessions 
(LB) and another group accumulated the same duration of walking in 10-15 minute 
sessions throughout the day with ≥120 minutes between sessions (Woolf-May et al., 1998). 
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The main outcomes of the study were that aerobic capacity significantly decreased and 
factor XIIa, a marker of coagulation, significantly increased in the control group, however 
there were no significant changes in lipid profiles (TC, LDL-C, HDL-C and apos A-I, A-II 
& B) in the walking groups compared with controls. This was an important study because 
it was the first study to compare the efficacy of accumulative walking sessions to walking 
of equal daily volume and to non-active controls, which more comprehensively examined 
the health benefits of accumulation per se relative to no activity and activity performed in 
single daily sessions, in comparison to the more simplistic studies of Ebisu (1985) and 
DeBusk et al. (1990).  
 
In close chronological proximity a RCT, involving 10 weeks of brisk walking on 5 days of 
the week at 70-80% HRmax in either one 30 minute walk (LB) or three 10 minute walks per 
day (SB), or performing no walking as controls, found that OO2max increased and sum of 
skin folds decreased significantly in both walking groups with no differences between 
walking groups, however body mass and waist circumference decreased significantly only 
in the SB group (Murphy & Hardman, 1998). The authors also commented that body/fat 
mass gained by the controls contributed to the significant responses to the walking, 
whereby the control participants decline in health parameters contributed to the effect of 
walking as much as the walking improved the health in the walking group. These findings 
are in slight contrast to the present study, where OO2max was only significantly increased 
following SBW and BF% was only significantly reduced following ABW, with both of 
these variables presenting relatively strong statistical power. These differences are despite 
the present intervention being of longer duration and of similar frequency, however the 
walks were performed at a greater mean relative intensity. 
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A further study from Woolf-May et al. (1999) used a similar design to their previous study 
(Woolf-May et al., 1998), but with an additional accumulative walking group, in which 
participants were instructed to perform brisk walking sessions in 5-10 minute bouts 
totalling 20-40 min·d-1. The main findings of this study were that each of the walking 
groups – long, intermediate and short duration – produced positive health outcomes 
compared to controls, however the long and intermediate groups demonstrated the more 
potent effects. Each of the walking groups promoted improvements in aerobic fitness, 
whereas only the intermediate and long sessions produced favourable improvements in the 
blood lipid profile compared to controls. These studies both agree and disagree with the 
findings of the present study, where OO2max tended to increase in this study too, yet blood 
lipid profile improved in the long and intermediate sessions in the second study by Woolf-
May et al. (1999), despite both interventions being shorter than the present study. 
However, a telling difference may be the intensity of the walking interventions, ~74% 
HRmax, compared to only ~66% in the present study. 
 
The influence of brisk walking on the risk factors associated with MetS has been slightly 
equivocal in the present study, with measures of body composition and insulin resistance 
responding positively, whereas certain other health outcomes, such as blood pressure and 
blood lipid and lipoprotein profile, did not appear responsive. However, in conclusion, the 
findings of this study clearly demonstrate that current recommendations for the 
accumulation of 30 minutes of physical activity throughout the day on at least 5 days of the 
week (ACSM & AHA, 2007), performed at an easily attainable walking intensity, was 
effective in reducing certain risk factors associated with MetS, particularly BMI, WC, 
WHR, BF%, fasting serum insulin and insulin resistance. These findings ar particularly 
significant and provide a mechanism by which walking >2 h·wk-1 is related to a 39% 
reduction in mortality (Gregg et al., 2003). Furthermore, accumulative walking also 
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showed favourable trends toward decreasing blood pressure, plasma fibrinogen and an 
increase in OO2max in men at risk of MetS, therefore this would be a useful strategy for 
reducing symptoms of MetS in those at risk. Future research may wish to re-investigate 
these health outcomes using participants of lower health status but still without medication 
or using a greater walking volume. Research should also be performed to investigate the 
short-term impact of single walking sessions on similar health outcomes to those studied 
here. Due to the apparent limited effect of the 24 weeks of walking on certain health 
outcomes it would be of interest to determine whether discrete walking sessions may have 
an effect and if so whether the intensity or duration of walking session may influence the 
magnitude or duration of any effects. 
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4.0 The 24 hour effect of different intensities and 
durations of brisk walking on risk factors associated 
with metabolic syndrome 
 
4.1 Introduction 
In follow-up to the study in the previous section and in slight contrast, the short term 
effects of walking on MetS risk factors was studied to discern whether the same health 
outcomes respond immediately or only following adaptation and if the non-responding 
health outcomes to chronic walking may be affected in the short-term.  
 
Sedentary behaviour impacts on MetS risk, where low levels of PA are associated with 
increased risk of obesity and its accompanying co-morbidities, such as hypertension, 
insulin resistance and dyslipidaemia, where performing less than 150 min·wk-1 of 
moderate-vigorous leisure time PA increases the risk of developing MetS two-fold (Ford et 
al., 2005). Decreased energy expenditure is the likely mediator between inactivity and 
increased MetS risk, where objectively measured PAEE has been demonstrated to predict 
the progression towards MetS independently of OO2max and obesity (Ekelund et al., 2005). 
The relationship between PA and MetS risk appears to be unaffected by OO2max or 
adiposity, suggesting that improvements in OO2max or decreases in adiposity are not 
absolutely necessary to decrease MetS risk, providing that PAEE increases.  
 
Public health problems occur in the least active 20-30% of the population (Hamilton et al., 
2004), where bed-rest models of physical inactivity demonstrate that as the stimulus for 
muscular protein synthesis decreases there are associated increases in insulin resistance 
and insulin secretion, which are associated with components of MetS (Biolo et al., 2005). 
Participation in regular PA is now promoted as one of the ‘best buys’ in the prevention and 
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management of physiological disorders, such as hypertension, dyslipidaemia, overweight 
and obesity, diabetes and heart disease. Indeed, long-term increases in PA alone have been 
shown to decrease the prevalence of MetS, which are further enhanced by combining 
dietary intervention with PA (Anderssen et al., 2007) (see section 2.3). It may also be 
possible that the benefits associated with PA may be partly as a consequence of the acute 
effects of the last bout of exercise rather than from favourable adaptations to chronic PA 
(Thompson et al., 2001). However, no published study appears to have investigated the 
potential for PA to impact on MetS risk factors in the immediate post-exercise period, 
despite evidence demonstrating short-term improvements in independent MetS risk factors, 
such as blood glucose control (Englert et al., 2006), blood pressure (Jones et al., 2007), 
lipid and lipoprotein profile (Ferguson et al., 1998), markers of pro-thrombotic (Ivey et al., 
2003) and pro-inflammatory states (Murtagh et al., 2005a) that may be gained from a 
single PA session. These are important questions both physiologically and in terms of PA 
promotion, since many individuals appear to like a ‘quick fix’.  
 
When the impact of walking intensity and walking duration on all-cause mortality has been 
investigated there was a significant inverse association between daily walking intensity and 
risk of death, whereas there was only a weak inverse association between daily walking 
duration and risk of death (Schnohr et al., 2007). Furthermore, data demonstrates that those 
whose walking speed exceeds 2.1 m·s-1 have 64% lower odds for anti-diabetic, 50% lower 
odds for anti-hypertensive and 47% lower odds for LDL-C lowering medication use 
compared with those whose walking speed is less than 1.2 m·s-1 (Williams, 2008). The 
current minimum PA recommendations are for 30 minutes of moderate intensity PA 
(≥40/50% HRR) to be accumulated on 5 days of the week or 20 minutes of vigorous 
intensity PA (up to 85% HRR) to be performed on 3 days of the week, or a combination of 
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these two sets of recommendations (ACSM & AHA, 2007). However, these 
recommendations are based on long-term adherence to these guidelines rather on the 
immediate health-enhancing effects that may be gained from a single session (see section 
2.3.7). Furthermore, the minimum volume of PA for affecting each aspect of MetS in a 
single session is currently unknown. 
 
Therefore the purpose of this study was to determine a) whether walking at 50% OO2max 
for 30 minutes may effect favourable changes in risk factors associated with MetS during 
the 24 hour post-exercise period compared to a control trial, and b) whether increasing the 
intensity of the walk to 65% OO2max for 30 minutes or maintaining the intensity at 50% 
OO2max and increasing the duration to 60 minutes would alter the magnitude or duration of 
these responses.  
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4.2 Method 
4.2.1 Introduction 
The study included 13 non-smoking middle-aged males (age 59.92 ± 6.64 years; height 
1.79 ± 0.05 cm; mass 94.1 ± 11.2 kg; BMI 29.37 ± 4.69 kg·m2; waist 104.0 ± 10.4 cm; 
waist:hip ratio 0.98 ± 0.05; OO2max 37.1 ± 6.1 mL·kg-1·min-1). The participants were 
recruited from the previous study (section 3.0) following its completion and were 
asymptomatic of cardiovascular disease and diabetes, and not prescribed cardiovascular 
medication (see Figure 3.1). There were at least 4 weeks between completing the 24 wek 
walking study and commencing this 24-hour study. The study was approved by the central 
NHS Research Ethics Committee (Appendix B.1; p281) and the participants were advised 
of the experimental procedures and possible discomforts (Appendix B.2; p299) and then 
signed the informed consent form (Appendix B.3; p304), a pre-screening health 
questionnaire (Appendix C.1; p310), and gave permission for their General Practitioner to 
be contacted for approval of their entry onto the study (Appendix C.3.2; p320). The 
participants received written confirmation that they were under no obligation to begin or 
continue with the study and could withdraw at any time.  
 
4.2.2 Pre-screening procedure 
Potential participants were pre-screened using a health questionnaire and their general 
practitioner was asked for their approval prior to participation. 
Exclusion criteria –  
a) Symptomatic of cardiovascular disease 
b) Diabetes mellitus 
c) Tobacco smoking  
d) Prescribed cardiovascular or diabetic medication 
e) Their general practitioner was unable to provide health clearance for them to 
participate, or 
f) The participant was unable to understand the nature of the study. 
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4.2.3 Experimental design 
The study employed a repeated measures design, where participants took part in all four 
trials and acted as their own controls. The main trials took place in a randomly assigned 
order and included: 
• Trial A: No exercise (CON) – 30 min lying in a semi-supine position on the couch 
• Trial B: 30 minute walk at 50% OO2max (30×50%) 
• Trial C: 30 minute walk at 65% OO2max (30×65%) 
• Trial D: 60 minute walk at 50% OO2max (60×50%) 
 
4.2.4 Initial assessments 
The initial assessment included height, mass, waist circumference (WC) and hip 
circumference (HC) measurements, and a sub-maximal walking test was performed to 
calculate the correct walking intensities during the brisk walking sessions. Initial 
assessments in this study were performed as part of the post-intervention assessments in 
the study in section 3.0. 
 
4.2.4.1 Height, body mass and waist & hip circumferences 
Height was measured using a stadiometer to the nearest cm and mass to the nearest 100g 
using beam balance scales (both Seca, Hamburg, Germany). The participants then stood in 
the anatomical neutral position and waist circumference was measured at the level of the 
umbilicus and hip circumference was measured at the largest circumference of the hips 
above the gluteal fold both to the nearest 1 mm using a self-tightening circumference tape 
measure (Seca, Hamburg, Germany). Three WC and three HC measures were taken and 
the mean values were recorded. The WHR was then calculated from these measures. 
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4.2.4.2 Submaximal walking test 
The test consisted of walking at 3 mph throughout the test at five different gradients for 
two minutes at each stage (Table 4.1). 
Table 4. 1  Graded treadmill test protocol 
Speed (mph) Time (minutes) Gradient (%) 
3.0 2 2.5 
3.0 2 5.0 
3.0 2 7.5 
3.0 2 10.0 
3.0 2 12.5 
 
To assess aerobic fitness the participants performed the Stanford sub-maximal walking test 
(ACSM, 2000) on a motorised treadmill (Mercury Med., HP Cosmos, Nussdorf-
Traunstein, Germany) while oxygen consumption (OO2) was analysed using an online 
breath by breath gas analyser (Oxycon Pro, Jäeger, Würzburg, Germany). Heart rate (HR) 
was also recorded using a radio-telemetry system (Polar Beat, Polar Electro OY, Finland), 
which was recorded every 5 seconds with oxygen consumption. Ratings of perceived 
exertion (RPE; Borg 6-20 scale) were recorded at the end of each 2-min stage. Following 
the test, the HR-OO2 relationship was calculated and this relationship was extrapolated up 
to the participants age predicted maximum heart rate (220-age) to predict OO2max (Maritz 
et al., 1961). The treadmill gradient required to elicit 50% and 65% OO2max was 
interpolated from the HR-OO2 relationship. 
 
4.2.5 Pre-trial dietary records and health assessments 
On the day prior to each trial, the participants recorded the food they consumed in a food 
diary (Appendix D.2; p341) so that this same diet could be replicated on the first day of the 
subsequent trials. This was in order to reduce the confounding effect of diet. The data from 
the diaries were analysed using DietMaster Pro (Version 6 Software, Lifestyles 
Technologies Inc, Valencia, CA). Following this the participants fasted for at least 14 
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hours (i.e. from 7.00 PM until after the post-1 hr assessment the following morning) and 
again for the same period the following night, before the 24 hour post-walk assessment on 
the second morning. All assessments included a blood test, blood pressure, resting 
metabolic rate/fat oxidation and resting heart rate. 
 
Day one 
Pre               
 
 
 
0 min  30/60min* Post     1-hr       4-hr 
 
Day two   24 hr 
 
 
 
Key 
 
   Cannula inserted    Blood sample, RMR, BP & RHR 
 
 
   Treadmill walk    Breakfast  
 
Figure 4. 1 Timescale for each trial 
 
These assessments were performed immediately prior to walk (Pre), immediately post-
walk (post), 1 hour post-walk (1-hr), 4 hours post-walk (4-hr) and 24 hours post-walk (24-
hr) (Figure 4.1). The participants were required to fast until after the 1-hr assessment when 
breakfast was provided (See section 4.2.6). Following the 4 hour post-walk assessment on 
the morning of the first test the participants recorded the food they consumed for the 
duration of the day in the food diary. 
 
4.2.5.1 Blood sampling, blood pressure, resting heart rate and resting 
metabolic rate 
On arrival in the Sport and Exercise Science Laboratory the participants lay in a semi-
supine position and a cannula (Venflon, BD, Oxford) was inserted into a forearm vein of 
* CON = 30 min 
   30×50% = 30 min 
   30×65% = 30 min 
   60×50% = 60 min 
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the participants to allow the series of blood samples to be collected and was kept patent 
using saline solution (0.9% w/w, BD, Oxford). Systolic blood pressure (SBP), diastolic 
blood pressure (DBP), mean arterial pressure (MAP) and pulse pressure (PP) were 
assessed after the participants had remained in the semi-supine position for 5 minutes. 
Three blood pressure measures were taken using an aneroid sphygmomanometer (Accoson 
Limpet, A.C. Cossor & Son Ltd, London, UK) each 30 seconds apart from the opposite 
arm to where the cannula was inserted and the mean values were recorded. MAP was 
calculated using (SBP-DBP)*0.33 + DBP, and PP was calculated by the difference 
between the mean SBP and DBP values.  
 
For the assessment of resting metabolic rate (RMR) and fat oxidation rates, the participants 
remained in a supine position while a five minute expired air sample was collected using 
Douglas bags (Harvard Apparatus Ltd, Kent, UK) and resting heart rate (RHR) was also 
monitored during this period using a heart rate radio-telemetry system (Polar Beat, Polar 
Electro OY, Finland). Rate-pressure product (RPP) was calculated from RHR and SBP 
measures. The Douglas bags were then analysed (Servomex Series 1440, Servomex Group 
Ltd, Crowborough, UK) for oxygen and carbon dioxide concentrations and the volumes 
were measured using a dry gas meter (Harvard Apparatus Ltd, Kent, UK). These values, 
plus ambient air temperature and barometric pressure were input into an MS Excel 
spreadsheet for the calculation of OO2 (Appendix F.2; p364). Resting metabolic rate was 
calculated from OO2 by multiplying L·min-1 by 5 (Montoye et al. 1996) and resting fat 
oxidation rates were calculated using f = 1.67* OO2 – 1.67* OCO2 – 1.92*n [where f = fat 
and n = urinary nitrogen] (Frayn, 1983). 
  151
4.2.6 Treadmill walk and breakfast 
Prior to the walking trials, the participants performed a standard warm up on the treadmill 
to prepare them for the walking session ahead (Table 4.2). When the participants 
performed the main test, the speed of the treadmill remained at 3 mph throughout, with the 
intensity being dictated by the gradient. The gradient of the treadmill was set to elicit either 
50% or 65% OO2max, depending on the trial, and the treadmill walks lasted for either 30 or 
60 minutes. Exercising HR and ratings of perceived exertion (RPE; 6-20) were monitored 
at five minute intervals, while OO2 was measured during the final 5 minutes of each 
treadmill walk using the online gas analysis equipment to validate the actual walking 
intensity and to allow the calculation of energy expenditure (EE) by multiplying OO2 
(L·min-1) by 5 (Montoye et al., 1996). Oxygen consumption was also measured using the 
online system during the 30 min CON period for the purpose of calculating EE during 
CON. 
Table 4. 2 Standard warm up 
Time (mins) Speed (mph) Gradient (%) 
2 3 0.0 
2 3 2.5 
1 3 5 
 
Breakfast was supplied to the participants relative to body mass, consisting of muesli, milk 
and orange juice, each provided at 1g·kg-1BM, which were measured to the nearest 1g 
using electronic scales (Ohaus  LS500, Ohaus Scale Corporation, NJ). The mean energy 
content of the meal was 541.4 ± 62.6 kcal (protein 53.2 ± 8.1 kcal; carbohydrate 438.8 ± 
45.5 kcal; fat 49.3 ± 9.0 kcal) and water was consumed ad libitum following the 1-hr 
assessment. 
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4.2.7 Blood sampling and analysis 
Blood was dispensed into a collection tube to form serum and a tube containing fluoride 
oxalate for the formation of plasma. The samples were then centrifuged at room 
temperature (Eppendorf 5804, Hamburg, Germany) and stored in a freezer (Revco Ultra, 
Asheville, NC, USA) at -70oC for later analysis. The serum was analysed for 
concentrations of TAG, TC and HDL-C using enzymatic colorimetry (all Horiba ABX, 
Cambridge), and insulin by chemiluminescence (Bayer Advia Centaur, Bayer Healthcare, 
Diagnostics Division, Tarrytown, NY.). The plasma collected in the fluoride oxalate tube 
was used to analyse glucose (Horiba ABX, Cambridge) and NEFA (Wako Ltd, Neuss, 
Germany) using enzymatic colorimetry (See Appendix E for more detailed biochemistry 
procedures, p344). Insulin resistance was estimated using the homeostasis assessment 
model ratio formula (HOMA-IR): fasting serum insulin (µIU·mL-1) × fasting plasma 
glucose (mmol·L-1))/22 5) and insulin secretion (HOMA-β cell) was estimated using: 
fasting serum insulin (µIU·mL-1) × 20/fasting plasma glucose (mmol·L-1) – 3.5, both 
described by Matthews et al. (1985) and LDL-C was derived from the Friedewald et al. 
(1972) equation using the TC, HDL-C and TAG values. The samples were analysed within 
the same assay series to reduce variability within the biochemical analytical procedures 
and were then corrected for changes in plasma volume (Dill & Costill, 1974). Changes in 
plasma volume were calculated from finger prick haemoglobin and haematocrit samples 
(see Appendices F.1.13 and F.1.14; pp 462-3). The coefficients of variations for the assays, 
using low concentration quality control sera, were: glucose 0.25%; NEFA 2.40%; TC 
5.81%; HDL-C 8.24%; TAG 7.09%; insulin 4.61%; (See Appendix F.1 for the Assay 
principles, p349). 
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4.2.8 Statistical analyses 
The number of research participants to be recruited was calculated using data from 
Tsetsonis & Hardman (1996b), which was similarly structured to the present study. The 
mean differences and SD for serum TAG were input into a programme (Clinstat, Martin 
Bland) for the calculation of sample size with an alpha of 0.05 at 80% power, which 
indicated that eight participants were required to avoid a type II error. However, that study 
utilised 12 participants, therefore the aim was to recruit at least 12 participants onto the 
study. Post-hoc power was also calculated for each health outcome between treatments. 
The descriptive data are presented as the mean ± SD and differences between treatments 
were analysed using two-way ANOVA with a Bonferroni correction (See Appendix B.4 
for tabulated mean data, p305). The data was analysed using SPSS version 13 and 
significance was accepted at P<0.05. Non-normally distributed data were log-transformed 
and analysed using two-way ANOVA. The energy expended during the intervention 
sessions were analysed using one-way ANOVA and the HR & %HRmax data recorded 
during the exercise sessions were analysed using two-way ANOVA. Friedman’s ANOVA 
for ranks was used to analyse the intensity of the walks (%OO2max). Friedman's two-way 
ANOVA for ranks was used to analyse the RPE data recorded during the exercise sessions 
because it remained non-normally distributed after log-transformation. The data recorded 
from the food diaries was analysed using one-way ANOVA. Friedman's ANOVA for ranks 
were employed if the data remained non-normally distributed. Pearson’s product moment 
correlation coefficients were used to explore relationships between factors, with an alpha 
of 0.05 level of statistical significance.  
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4.3 Results 
The mean intensity of each session was 49.1 ± 3.6% OO2max during 30×50%, 65.2 ± 3.6% 
OO2max during 30×65% and 49.0 ± 3.6% OO2max during 60×50%. The higher intensity 
walk was at a significantly greater intensity than both of the lower intensity walks 
(X2=15.200; P=0.001), whereas both of the lower intensity walks were of similar intensity 
(Z=-0.941; P=0.347). The arrow on the graphs     indicates when breakfast was consumed 
following 1-hr. Breakfast was initially not included in the proposed study, but it was a 
stipulation by the research ethics committee, and unfortunately influenced some data, 
particularly the metabolism, glycaemic and lipaemic data 
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4.3.1 Walking intensity  
4.3.1.1 Sessional energy expenditure 
There were significant differences in EE between CON and each of the walking sessions 
(P<0.001) (Figure 4.2). Energy expenditure during CON was just 47.63 ± 1.97 
kcal·session-1, compared to 248.80 ± 11.34 kcal·session-1 during 30×50% and 335.51 ± 
14.67 kcal·session-1 during 30×65%, with the greatest expenditure of 501.57 ± 18.02 
kcal·session-1 in 60×50%. 
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Figure 4. 2  Mean energy expenditure of each exercise trial. [Significant differences: a Main 
effect of walking session on EE (F=212.471; P<0.001). b EE significantly higher than CON 
(P<0.001). c EE significantly higher than 30×50% (P<0.001) d EE significantly higher than 
30×65% (P<0.001)]. 
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4.3.1.2 Heart rate, Percentage HRmax and Perceived Exertion 
Exercising heart rate was significantly different between walking sessions (P<0.001). HR 
in 30×65% was significantly higher than 30×50% and during both the 1st and 2nd 30 min of 
60×50% (P<0.001), furthermore HR in the 2nd 30 min of 60×50% was significantly higher 
than 30×50% (P=0.003) and the 1st 30 min of 60×50% (P<0.001). HR during 30×50% and 
1st 30 min of 60×50% were similar (P=0.519). Mean final HR during 30×50% was 99.2 ± 
10.0 beats·min-1, 127.8 ± 11.8 beats·min-1 during 30×65%, 97.9 ± 9.9 beats·min-1 at 30 min 
during 60×50% and 103.3 ± 9.8 beats·min-1 at 60 min of 60×50%. 
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Figure 4. 3  Mean %HRmax values recorded during each trial. [Significant differences: a Main 
effect of intensity × time (F=13.317; P<0.001). b %HRmax significantly higher between 5 & 
30 mins, and 35 & 60 mins (F=55.741; P≤0.012). c %HRmax significantly higher than 
30×50% (F=74.403, P≤0.015). d %HRmax significantly higher than 60×50% (1st 30 min) 
(F=74.403; P<0.001). e %HRmax significantly higher than 60×50% (2nd 30 min) (F=74.403; 
P<0.001)]. 
 
Exercising %HRmax was significantly different between walking sessions over time 
(P<0.001; Figure 4.3). %HRmax in 30×65% was significantly higher than 30×50% and 
60×50% (P<0.001), furthermore %HRmax in the 2nd 30 min of 60×50% was significantly 
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higher than 30×50% (P=0.002) and the 1st 30 min of 60×50% (P<0.001). %HRmax during 
30×50% and 1st 30 min of 60×50% were similar (P=0.509). Mean final %HRmax during 
30×50% was 62.0 ± 6.2 %, 79.8 ± 6.4 % during 30×65%, 61.2 ± 5.9 % at 30 min during 
60×50% and 64.6 ± 5.9 % at 60 min of 60×50%. 
RPE was significantly different between walking sessions over time (P<0.001). RPE in 
30×65% was significantly higher than 30×50% and 60×50% (P<0.05), furthermore RPE in 
the 2nd 30 min of 60×50% was significantly higher than 30×50% (P<0.05) and the 1st 30 
min of 60×50% (P<0.05). %HRmax during 30×50% and 1st 30 min of 60×50% were similar 
(P=0.161). Mean final %HRmax during 30×50% was 11.46 ± 1.90, 14.08 ± 1.50 during 
30×65%, 11.00 ± 1.68 at 30 min during 60×50% and 12.31 ± 1.75 at 60 min of 60×50%. 
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4.3.2 Dietary records 
4.3.2.1 Macronutrient intake prior to day 1 
 
Food intake was recorded on the day prior to each trial and there were no significant 
differences in energy consumption, carbohydrate, fat or protein (each kcal·day-1) between 
trials (Figure 4.4). 
840.04 856.20 969.38
1017.74
565.22 586.03
647.44 683.39
347.53 345.51
365.47
365.47
0.00
500.00
1000.00
1500.00
2000.00
2500.00
CON 30×50% 30×65% 60×50%
Trial
M
ac
ro
n
u
tr
ie
n
t i
n
ta
ke
 
(kc
al
·
da
y-1
)
CHO Fat Protein
 
Figure 4. 4  Mean macronutrient intake during the day prior to day 1 of each trial. [No 
significant differences in macronutrient energy intakes prior to day 1 between trials; CHO: 
F=0.551; P=0.651, Fat: F=0.619; P=0.617, Protein: X2=4.080; P=0.253, & Total Energy: 
F=0.702; P=0.557]. 
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4.3.2.2 Macronutrient intake prior to day 2 
 
Food intake was recorded for the rest of the first day of each trial prior to the second day, 
and there were no significant differences in energy consumption, carbohydrate, fat or 
protein (each kcal·day-1) between trials (Figure 4.5). There were no significant differences 
in enery consumption between day 1 and day 2 across the four trials (P=0.551). 
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Figure 4. 5  Mean macronutrient intake during the day prior to day 2 of each trial. [No 
significant differences in macronutrient energy intakes prior to day 1 between trials; CHO: 
F=0.838; P=0.481, Fat: F=0.489; P=0.692, Protein: F=0.160; P=0.922, & Total Energy: 
F=0.628; P=0.602]. 
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4.3.3 Cardiovascular responses 
4.3.3.1 Systolic blood pressure 
SBP decreased significantly for ≥4 hours following 30×50% (P≤0.023), SBP was only 
significantly lowered at 1 hour post-walk following 30×65% (P=0.032) and not 
significantly different to Pre values by 4 hours, and SBP was lowered for at least 1 hour 
but less than 4 hours following 60×50% compared to Pre (P≤0.006; Figure 4.6). Mean SBP 
increased by up to 9.2 ± 13.4 mm Hg (at 4-hr) following CON, compared to significant 
decreases of ≥-8.7 ± 7.7 mm Hg following 30×50%, ≥-11.0 ± 10.8 mm Hg following 
30×65% and ≥-10.4 ± 8.0 mm Hg following 60×50%. Moreover, SBP was significantly 
lower following 30×65% and 60×50% than CON at Post-walk (P≤0.026), significantly 
lower in 30×50%, 30×65% and 60×50% than CON at 1-hr (P≤0.043) and significantly 
lower in 30×50% & 60×50% than CON at 4-hr (P≤0.007), but there were no significant 
differences between 30×50%, 30×65% and 60×50% throughout. 
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Figure 4. 6  Mean systolic blood pressure values during each trial. [Significant differences: a 
Main effect of intensity × time on SBP (F=3.620; P=0.006). b Main effect of intensity 
compared to CON [30×50% & 60×50%] (P≤0.005). c 30×50% significantly lower than 
CON (P≤0.007). d Effect of time following 30×65% only at 1 hr (P=0.032). e 60×50% 
significantly lower than CON (P≤0.006)]. Statistical power: 0.991 
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4.3.3.2 Diastolic blood pressure 
There was a significant effect of time on DBP during the trials, however there was no 
direct effect of intensity between walking groups compared to CON (Figure 4.7). This 
effect occurred immediately post-walk and is likely due to the additive effect of the three 
walking intensities compared to CON (P=0.038). However, there was a trend for DBP to 
be lowered for at least 1 hour post-walk following 30×50% & 60×50%, and immediately 
post-walk following 30×65% (each NS). 
70
75
80
85
90
95
100
Pre post 1-hr 4-hr 24-hr
Time period
D
BP
 
(m
m
 
H
g)
CON 30×50% 30×65% 60×45%
a
b
 
Figure 4. 7  Mean diastolic blood pressure values during each trial. [Significant differences: 
a Main effect of time on DBP (F=4.399; P=0.010). b Main effect of time: Post-walk 
significantly lower than Pre-walk (P=0.038)]. Statistical power: 0.443. 
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There was an interaction between walking intensity over time over the course of the 24 
hour period, with 60×50% significantly lowering MAP for at least 4 hours post-walk 
(P=0.007; Figure 4.10), whereas this effect was not apparent following the more intense 
30×65%. MAP decreased significantly by at least -5.9 ± 4.4 mm Hg for at least 1 hour 
following 30×50% (P≤0.018) but for less than 4 hours (-4.7 ± 5.0 mm Hg; P=0.052) and by 
at least -5.7 ± 6.1 mm Hg, but for less than 1 hour following 60×50% (P=0.022). SBP did 
not significantly change over the 24 hour period following CON. MAP returned to Pre 
values by 4-hr in all trials. 
There was an interaction of intensity and time on PP (P=0.015) and a main effect of 
intensity on PP (P<0.05). PP appeared to rise slightly until at least 4-hr (9.6 ± 13.0 mm Hg; 
NS), whereas each of the walking trials appeared to slightly reduce PP (≤8.5 ± 9.4 mm 
Hg). PP was reduced at 1-hr following 30×65% & 60×50%, which lasted until 4-hr in 
60×50% only, by which time MAP was also decreased following 30×50%. PP at 4-hr 
during CON was significantly higher than post (6.2 ± 6.2 mm Hg; P=0.036), whereas PP 
significantly lower at 4-hr than pre in 30×50% (-6.0 ± 5.9 mm Hg; P=0.043). PP returned 
to Pre values at 24-hr for each treatment. 
 
4.3.3.6 Rate-pressure product 
RHR was highly variable throughout the treatments, with the post-walk RHR creating the 
greatest source of variation (≥7.2 ± 4.3 beats·min-1; P≤0.046) and the elevations in post-
walk RHR were apparent for >1-hr, particularly in 30×65% & 60×50% (≥4.9 ± 3.5 
beats·min-1; P≤0.005; Figure 4.12). RHR was also elevated above Pre at 4-hr in CON, 
therefore there may have been a post-prandial or circadian effect because RHR was not 
different between treatments at 4-hr. RHR returned to Pre values at 24-hr. Rate-pressure 
product remained relatively stable during the cours
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particularly so in 30×50% where there was only a marginal increase in RPP post-walk 
(260.3 ± 815.0) (Figure 4.8). Neither 30×50% nor 60×50% significantly influenced RPP 
throughout the 24-hr period, however 30×50% prevented the spike in RPP experienced in 
the other three trials, where 30×65% was significantly greater than 30×50% at 4-hr (7980 ± 
1851 v 7156 ± 1916; P=0.033). The largest fluctuations in RPP arose post-walk in 30×65% 
(1354.9 ± 806.7; P=0.001) and RPP also increased at 4-hr in CON compared to post & 1-hr 
(≥695.8 ± 572.9; P≤0.005). All values returned to Pre values at 24-hr. 
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Figure 4. 8  Mean rate-pressure product values during each trial. [Significant differences: a 
Main effect of intensity × time on RPP (F=3.135; P=0.011). b Main effect of intensity on 
RPP in 30×65% compared to 30×50% (P=0.045). c RPP in CON significantly higher than 
Post & 1-hr (P≤0.005). d RPP in 30×65% significantly higher than pre, 1-hr & 24-hr 
(P≤0.010). e RPP in 30×65% significantly higher than CON, 30×50% & 60×50% 
(P≤0.020). f RPP in 30×65% significantly higher than 30×50% (P=0.033)]. Statistical 
power: 0.680. 
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4.3.4 Metabolic responses 
4.3.4.1 Resting metabolic rate 
There was a main effect of intensity and time on RMR over the 24-hr period with the 
greatest fluctuations post-walk (≥160.6 ± 181.6 kcal·day-1; P≤0.025) and 4-hr (≥132.9 ± 
369.3 kcal·day-1; P≤0.005) (Figure 4.9). RMR was only significantly different at 4-hr in 
CON, whereas RMR was significantly greater in post than pre & 1-hr in 30×65% & 
60×50%. Furthermore, RMR was greater in 30×50% than CON and was also significantly 
greater in 30×65% than 30×50%. RMR returned to Pre values at 24-hr. 
1800
2000
2200
2400
2600
2800
3000
Pre post 1-hr 4-hr 24-hr
RM
R 
(kc
a
l·d
a
y-1
)
Time period
CON 30×50% 30×65% 60×50%
a
c
b, f, i
d
e
g
h
 
Figure 4. 9  Mean resting metabolic rate values during each trial. [Significant differences: a 
Main effect intensity × time on RMR (F=2.542; P=0.043). b Main effect of time on RMR 
(P≤0.025). c Main effect of time on RMR (P≤0.005). d RMR in CON significantly higher 
than pre, 1-hr & 24-hr (P≤0.05). e RMR in 30×50% significantly lower than post & 4-hr 
(P≤0.041). f RMR in 30×65% significantly higher than pre & 1-hr (P≤0.005). g RMR in 
60×50% significantly higher than pre (P=0.020). h RMR in 30×50% & 30×65% 
significantly higher than CON (P≤0.031). i RMR in 30×65% significantly higher than 
30×50% (P=0.044)]. Statistical power: 0.484. 
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4.3.4.2 Resting rate of fat oxidation 
The pattern of resting fat oxidation throughout the 24-hr period was relatively uniform 
throughout, except for the spikes in oxidation rates following 30×50% & 60×50% at 1-hr 
(NS). There was a main effect of time on resting fat oxidation rate, with the main effect 
taking place at 4-hr. Rates of fat oxidation following the 30×50% & 30×65% were 
significantly decreased at 4-hr compared to post-walk & 1-hr, whereas rates were only 
significantly lower than post-walk in 60×50%. There were no significant differences 
between treatments at any stage and resting fat oxidation rates returned to Pre values at 24-
hr. 
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4.3.4.3 Percentage fat utilisation 
There was no interaction of intensity and time on percentage fat oxidation, however 
intensity (P=0.034) and time (P=0.001) each had discrete effects, where there was a main 
effect of intensity between 30×65% & 60×50% and CON (P≤0.049; Figure 4.10). The 
greatest effect of walking appeared to occur at 1-hr following 30×65% (P≤0.027), however 
the walking sessions could not counteract the decrease in percentage fat oxidation that 
occurred at 4-hr. Percentage fat oxidation rates were not significantly different between pre 
and 24-hr. 
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Figure 4. 10  Mean percentage fat oxidation values during each trial. [Significant differences: 
a Main effect of intensity on percentage fat oxidation (F=4.102; P=0.034). b Main effect of 
time on percentage fat oxidation (F= 24.189, P<0.001). c Main effect of intensity between 
30×65% & CON (P=0.049). d Main effect of intensity between 60×50% & CON 
(P=0.046). e Percentage fat oxidation in CON significantly lower at 4-hr than post & 1-hr 
(P≤0.035). f  Percentage fat oxidation significantly lower in 30×50% at 4-hr than pre, post 
& 1-hr (P≤0.011). g Percentage fat oxidation in 30×65% significantly higher than post & 4-
hr (P≤0.027). h Percentage fat oxidation in 60×50% significantly lower than post, 1-hr & 
24-hr (P≤0.017)]. Statistical power: 0.260 
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4.3.5 Blood responses 
Hydration status remained relatively stable between walking sessions and over the duration 
of each test, with the exception of a slight and non-significant rise in the post-walk 
assessment in CON. 
 
4.3.5.1 Plasma glucose 
There was no significant effect of treatment or time on plasma glucose during the study, 
with glucose remaining stable throughout (Figure 4.11). The only interesting pattern to 
note was the non-significant spikes in glucose at 4-hr in the 30×65% & 60×50% 
treatments, which required the greatest energy expenditures during the walks. 
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Figure 4. 11  Mean plasma glucose values during each trial. [No significant differences 
between walking sessions over time (F=1.255; P=0.295)]. Statistical power: 0.111. 
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4.3.5.2 Serum insulin dynamics 
There was a main effect of time on serum insulin, where it remained elevated at 4-hr 
following the post-1-hr meal (P≤0.004) and there was no effect of treatment at any point. 
Elevations in serum insulin at 4-hr were 44.2 ± 47.5 µIU·mL-1 in CON, 45.4 ± 78.7 
µIU·mL-1 in 30×50%, 48.2 ± 59.9 µIU·mL-1 in 30×65% and 52.2 ± 63.7 µIU·mL-1 in 
60×50%. There was a main effect of time on insulin resistance, which fluctuated to a 
similar extent as serum insulin (P≤0.001). The pattern in CON was for insulin resistance to 
steadily increase until 1-hr, whereas there was a non-significant trend for insulin sensitivity 
to decrease between immediately post-walk, following each walking intensity, before 
reaching parity with CON at 1-hr. Insulin resistance increased significantly at 4-hr 
following the post-1-hr meal (P≤0.003), however there was no effect of walking compared 
to CON. Increases in insulin resistance at 4-hr compared to 1-hr were -11.3 ± 12.7 in CON, 
14.7 ± 30.2 in 30×50%, 17.0 ± 24.7 in 30×65% and 17.7 ± 25.5in 60×50%. 
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4.3.5.3 Insulin secretion 
There was a main effect of time on β-cell insulin secretion rates, where insulin secretion 
mirrored serum insulin (P≤0.001; Figure 4.12). The pattern in CON was for insulin 
secretion to steadily increase until 1-hr, whereas there was a non-significant trend for 
insulin secretion to decrease between immediately post-walk, following each walking 
intensity, before reaching parity with CON at 1-hr. Insulin secretion increased significantly 
at 4-hr following the post-1-hr meal (P≤0.003), however there was no effect of walking 
compared to CON. Increases in insulin secretion at 4-hr were 157.7 ± 159.5 in CON, 127.9 
± 181.8 in 30×50%, 128.7 ± 130.3 in 30×65% and 144.4 ± 141.8 in 60×50%. 
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Figure 4. 12  Mean β-cell insulin secretion rates (HOMA-β) during each trial. [Significant 
differences: a Main effect of time on insulin secretion (F=36.529; P<0.001). b Effect of 
meal (4-hr) on insulin resistance compared to pre, post, 1-hr & 24-hr in CON, 30×50%, 
30×65% & 60×50% (P≤0.001). c Effect of time on insulin secretion between post-walk & 
1-hr (P=0.022)]. Statistical power: 0.270. 
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4.3.5.6 Plasma non-esterified fatty acids 
There was an effect of intensity over time on plasma NEFA (P=0.011) and also an effect of 
walking compared to CON post-walk (P≤0.05; Figure 4.13). There was a tendency for 
NEFA to increase post-walk compared to Pre and this effect was proportional to the energy 
expended during the walk with 60×50% exhibiting the most significant increase of 0.5 ± 
0.4 mmol·L-1 (P=0.001) and  a non-significant increase in 30×50% of 0.2 ± 0.2 mmol·L-1 
(P=1.000). Plasma NEFA were back to Pre levels at 1-hr and significantly decreased in all 
treatments at 4-hr following the post-1-hr meal (P≤0.003). There were no significant 
differences between walking sessions. 
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Figure 4. 13  Mean plasma NEFA values during each trial. [Significant differences: a Main 
effect of intensity × time on plasma NEFA (F=3.856; P=0.011). b Main effect of walking 
sessions compared to CON (P≤0.05). c Plasma NEFA significantly lower than pre, post, 1-
hr & 24-hr in all treatments (P≤0.003). d. Effect of 30×65% on plasma NEFA compared to 
pre & 1-hr (P≤0.006). e Effect of 30×65% on plasma NEFA compared to post & 4-hr 
(P<0.001). f Effect of 60×50% on plasma NEFA compared to pre, 1-hr, 4-hr & 24-hr 
(P=0.001). g Effect of 60×50% on plasma NEFA compared to post, 4-hr & 24-hr 
(P≤0.005). h plasma NEFA significantly greater following 30×65% & 60×50% than CON 
(P<0.001). i plasma NEFA significantly greater following 30×50% than CON (P<0.041)]. 
Statistical power: 0.837. 
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4.3.5.7 Serum triacylglycerol 
There was no effect of treatment or time on serum TAG, where the only pattern was that it 
remained relatively similar throughout between treatments (Figure 4.14). The apparent 
interaction of treatment and time appears to have been due to the stable pattern in TAG 
following 30×50% compared to the fluctuations in TAG in CON, 30×65% & 60×50%. 
This effect is most apparent at 4-hr where TAG remained stable during 30×50%, whereas 
the other three treatments demonstrate a spike, with the mean CON value peaking the 
greatest at 1.4 ± 0.6 mmol·L-1 (P<0.050). The mean difference between CON and 30×50% 
at 4-hr was -0.3 ± 0.5 mmol·L-1 (P=0.017). 
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Figure 4. 14  Mean serum TAG values during each trial. [Significant differences: a Main effect 
of intensity × time on serum TAG (X2=40.651; P=0.003). b Effect of 30×50% compared to 
CON (P=0.017)]. Statistical power: 0.256. 
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4.3.5.8 Serum lipids 
There was no effect of treatment or time on serum TC, where the only pattern was that it 
remained relatively similar throughout between treatments. There was no effect of 
treatment or time on serum HDL-C, where it was similar to serum TC and remained 
relatively similar throughout between treatments. There was no effect of treatment or time 
on the TC/HDL-C ratio, where this measurement mirrored that of serum TC and HDL-C, 
where it remained relatively similar throughout between treatments. There was no effect of 
walking or time on serum LDL-C during the study, which was unaffected by either 
walking, or at 4-hr following the morning meal. There was no significant change despite 
there appearing to be a depression in LDL-C at 1-hr in 30×65% compared with the other 
treatments (P=1.000).  
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4.4 Discussion 
The purpose of this study was to determine a) whether walking at 50% OO2max for 30 
minutes (30×50%) may produce favourable changes in risk factors associated with MetS 
during the 24 hour post-exercise period compared to a control trial, and b) whether 
increasing the intensity of the walk to 65% OO2max for 30 minutes (30×65%) or 
maintaining the intensity at 50% OO2max and increasing the duration to 60 minutes 
(60×50%) would alter the magnitude or duration of these responses. The mean intensity of 
each session was 49.1 ± 3.6% OO2max during 30×50%, 65.2 ± 3.6% OO2max during 
30×65% and 49.0 ± 3.6% OO2max during 60×50% and EE during CON was just 47.63 ± 
1.97 kcal·session-1 compared to 248.80 ± 11.34 kcal·session-1 during 30×50% and 335.51 ± 
14.67 kcal·session-1 during 30×65%, with the greatest expenditure of 501.57 ± 18.02 
kcal·session-1 in 60×50% (Figure 4.2). Despite the intensity of the treadmill walks 
remaining constant throughout, where 30×65% was significantly greater than both 30×50% 
and 60×50%, mean HR rose significantly in a linear fashion between 5 minutes and 
completion of the walks (Figure 4.3). Exercising HR increased by 5.7 ± 3.3 beats·min-1 
from 5 to 30 minutes in 30×50%, by 16.7 ± 5.9 beats·min-1 in 30×65% and by 10.0 ± 3.9 
beats·min-1 in between 5 to 60 minutes 60×50%, where the final HR in 60×50% was 
significantly greater than the final HR in 30×50%. The rise in HR during 30×65% was 
significantly greater than 30×50% (P<0.001) and 60×50% (P=0.004), while 60×50% 
tended to induce a greater increment in HR than 30×50% (P=0.059). The rise in 
participants self-rated RPE also increased in a similar fashion to HR, with RPE 
significantly greater during 30×65% than both 30×50% and 60×50% and RPE at 60 
minutes in 60×50% was significantly greater than 30 minutes in 30×50% (P<0.001). These 
data demonstrate that irrespective of walking intensity, both HR and RPE rise significantly 
for the duration of each of the walks, thus highlighting that using HR or RPE to monitor 
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walking and/or exercise intensity might be dependent on the intensity and duration of the 
session, ie. is the prescription of walking intensity based on HR/RPE at the beginning or 
towards the end of the session. 
 
Even though the energy cost of habitual PA rarely accounts for more than 20% of the total, 
it is the only way in which energy expenditure can be increased voluntarily, yet to expend 
the energy stored in 1 kg of adipose tissue would mean walking or running 93 miles or 146 
miles for individuals with a body mass of 80 kg or 50 kg. This makes PA appear to be an 
unattractive strategy for weight loss, however there is an alternative way of looking at this 
relationship, where walking one extra mile every day for a year may expend approximately 
2.5-4 kg of adipose tissue (Hardman, 1996). The energy stored in 1 kg of adipose tissue 
equates to ~7700 kcals, therefore for this group of men to lose 1 kg of fat the mean number 
of sessions required would be 30.9 sessions of 30×50%, 23.0 sessions of 30×65% and 15.4 
sessions of 60×50%. If these were performed according to current PA recommendations 
(ACSM & AHA, 2007; 30 min·d-1 on 5 d·wk-1) the mean number of weeks required to lose 
1 kg would be 6.18 weeks in 30×50%, 4.6 weeks in 30×65% and 3.08 weeks in 60×50%. 
In gross terms, not taking dietary practices, additional activities, improvements in OO2max 
and decreases in body mass into consideration, this would produce annual gross body mass 
losses of 8.4 kg in 30×50%, 11.3 kg in 30×65% and 16.9 kg in 60×50%. Furthermore, for 
every kilogram of weight-loss there is an approximate 2-5% reduction in visceral fat (Kay 
& Fiatarone Singh, 2006), therefore visceral adipose tissue losses of 16.8-42%, 22.6-56.5% 
and 33.8-85.5% may mathematically be expected by performing 30×50%, 30×65% and 
60×50%, respectively according to the recommended pattern for a year. Indeed, data from 
the STRRIDE study demonstrate that six months of PA, consistent with CDC & ACSM 
guidelines (1995), was sufficient to prevent significant increases in visceral fat, and 
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modestly increasing PA above these minimal recommendations (≥150 min·wk-1 moderate 
PA) significantly decreases visceral and abdominal fat without decreasing energy 
consumption, which is of benefit to those at risk of MetS (Slentz et al., 2005). 
 
Data from the two-day food record diaries indicated that there were no significant 
differences between dietary intake between CON, 30×50%, 30×65% and 60×50% for total 
energy, carbohydrate, protein or fat consumption during the days prior to days one or day 
two of each trial, therefore dietary intake should not have been a confounding factor during 
the study (Figure 4.4 & 4.5). Statistical power ranged from 0.071 for TC/HDL-C ratio to 
0.991 for SBP. Favourable changes in SBP, DBP, MAP, PP, RHR, RPP, RMR, fat 
oxidation, percentage fat utilisation, plasma NEFA, and serum TAG were detected, 
however there appeared to be no effect of walking on glucose homeostasis or blood 
lipoprotein profile.  
 
More than 85% of individuals with MetS have elevated blood pressure or hypertension 
(Franklin, 2006) and data indicates that individuals with MetS and elevated blood pressure 
demonstrate greater carotid atherosclerosis compared with those who present aspects of 
MetS but not elevated blood pressure (Irace et al., 2005). There was a main effect of 
walking on blood pressure, with this effect most evident on SBP, where each of the 
walking trials exerted an effect (Figure 4.6). However, the more vigorous 30×65% only 
exerted a lowering effect on SBP for less than 4 hours, whereas both lower intensity walks 
(30×50% & 60×50%) exerted a SBP-lowering effect for at least 4 hours compared to CON, 
with 60×50% tending to exert a greater magnitude of SBP reduction than 30×50% (NS). 
However, the most interesting finding was that only 30×50%, the lowest walking volume 
(intensity × duration), decreased SBP compared to Pre-walk at 4-hr. A limitation in the 
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measurement periods within this study was the large gap between 4-hr and 24-hr, due to 
the unavailability of ambulatory blood pressure monitors, therefore the exact duration of 
the SBP-lowering effect of the lower intensity walks could not be established. Despite the 
favourable responses of SBP to the walking trials compared to CON, the effect of walking 
on DBP appeared to be less substantial. The statistical analyses demonstrated a main effect 
of time on DBP, where there was a tendency for DBP to be decreased Post-walk compared 
to Pre-walk following each of the walking trials, whereas DBP tended to rise slightly 
during this period during CON (NS) (Figure 4.7). However, the walking-induced 
reductions in DBP were not as dramatic as those observed for SBP and MAP, where DBP 
tended to remain lower at 1-hr following the two lower intensity walks (30×50% & 
60×50%) compared to CON and Pre-walk. Due to the modest effects of the walks on DBP 
and the more substantial SBP response there was a main effect of the walks on MAP, 
which remained relatively constant throughout CON, but was significantly decreased Post-
walk compared to Pre and CON in each of the walking trials and this reduction was 
maintained at 1-hr in the two lower intensity walks (30×50% & 60×50%). However, 
although there was a tendency for MAP to be reduced at 4-hr in 30×50% and 60×50% 
compared to Pre and CON, these were non-significant. Walking also exerted an effect on 
PP, which was significantly reduced at 1-hr and 4-hr in 60×50%, but only at 1-hr following 
30×65% and at 4-hr following 30×50% compared to CON. These are clinically significant 
findings because a 1 mm Hg reduction in blood pressure may reduce MI risk by 2-3% 
(Libby & Theroux, 2005). 
 
These results extend the work of a previous study, which found that walking at 50% 
OO2peak for 40 minutes in a single session has been reported to decrease SBP by -5.6 ± 1.6 
mm Hg and DBP by -3.1 ± 0.2 mm Hg for 7 hours in pre-hypertensive adults and this 
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effect was augmented when walking was accumulated in 4 × 10 min bouts, which caused 
SBP to decrease by 5.4 ± 1.7 mm Hg for 11 hours and DBP by 3.4 ± 1.3 mm Hg for 10 
hours (Park et al., 2006). When the current ACSM recommendations were published 
(ACSM, 2004) the influence of the intensity and duration of PA sufficient to cause post-
exercise hypotension was still unknown. However, recent studies have demonstrated that 
although PAEE is more important than either intensity or duration (Jones et al., 2007), it is 
now known that a minimum of 15 minutes at 40% OO2max is sufficient to promote post-
exercise hypotension (Guidry et al., 2006). During the 90 minute post-exercise period 
following cycling for 45 minutes at 30%, 50% and 75% OO2peak, only the 50% and 75% 
OO2peak sessions significantly decreased blood pressure in normotensives compared to the 
control session, and were associated with a decrease in systemic vascular resistance and 
increased cardiac output (Forjaz et al., 2004). However, a similarly designed study, that 
recorded for a longer post-exercise period (9 hours) and used hypertensive participants, 
demonstrated that reductions in systolic blood pressure were similar between cycling for 
15 minutes at 40% or 60% OO2max or for 30 minutes at 40% or 60% OO2max (Guidry et al., 
2006). Thus, reinforcing the benefits of performing short bouts of PA at a low intensity, 
however the exact PA dose needed to lower blood pressure remains to be identified. 
Furthermore, it may be possible that a threshold intensity of only 40% OO2max may be 
required to elicit a hypotensive effect and only three training sessions for this effect to 
become chronic (Thompson et al., 2001).  
 
Further data appears to support the significance of PAEE over PA intensity for the 
mediation of post-exercise hypotension, where isoenergetic PA sessions at either 40% or 
70% OO2peak produced ‘clinically similar’ reductions in blood pressure during the 20min 
post-exercise period (Jones et al., 2007). The immediacy by which post-exercise 
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hypotension occurs suggests the hypotensive influence of regular PA may be partially an 
acute occurrence with the BP reductions accumulating as the training program continues 
(ACSM, 2004). Indeed, data from intervention studies suggest that longer training 
programmes may produce somewhat larger reductions in blood pressure, suggesting that 
PA may impact on blood pressure control immediately and in the long term through 
separate mechanisms (Hardman, 1996). The rationale for the exercise-induced decreases in 
blood pressure is that there is a marked dilation of blood vessels in active skeletal muscle 
that decreases resistance to flow during exercise, therefore the acute effects of exercise 
evident during recovery from individual bouts of exercise may be important, where the 
blood pressure of sedentary hypertensives may be reduced for up to 12 hours following a 
single exercise session (Pescatello et al., 1991; Brown et al., 1994). Post-exercise 
hypotension may persist for up to 16 hours, thus PA may enable those with stage I 
hypertension to be normotensive for the majority of the day (Thompson et al., 2001). The 
mechanisms by which PA may acutely modulate post-exercise hypotension include 
sympathoinhibition, where sympathetic nerve fibre activity-induced vasoconstriction of the 
musculature becomes inhibited, and increases in circulating vasodilator substances, such as 
nitric oxide, which attenuate the vasoconstrictor response to α-adrenergic receptor 
stimulation, and these responses are not fully offset by increases in cardiac output during 
post-exercise hypotension (Halliwell, 2001). It may be speculated that the increases in 
SNSa associated with more vigorous exercise may have overcome the increases in vagal 
tone that may have been responsible for some of the effects of the lower intensity walks on 
post-exercise hypotension. Furthermore, the increases in HR associated with 30×65% 
compared to 30×50% and 60×50% may have been sufficient to overcome the walking-
induced vasodilation that may have occurred during the post-walk period. 
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Despite the favourable effects of the walking trials on blood pressure, significant increases 
in resting (recovery) HR were present following the walking sessions compared to CON. 
These effects were particularly evident following the higher intensity 30×65% and longer 
duration 60×50%, which elevated HR ≥1-hr post-walk compared to CON and for ≥4-hr 
post-walk compared to Pre, whereas HR was only elevated above CON and Pre 
immediately Post-walk following 30×50%, which was significantly lower than HR 
following 30×65% immediately Post-walk. However, the magnitude and duration of the 
decreases in SBP associated with walking were sufficient to offset some of the walking-
induced elevations in HR to produce similar levels of RPP compared to CON (Figure 4.8). 
An exception to this pattern was the higher intensity 30×65%, which increased RPP 
significantly above the lower intensity 30×50%, particularly immediately Post-walk and at 
4-hr following the breakfast meal. Furthermore, although RPP was not significantly 
different between the lower intensity 60×50% and 30×50% there was a pattern for RPP to 
remain reduced following 30×50% compared to the more energetic walks at 4-hr and 24-
hr. These findings have great significance because increased myocardial workload, 
estimated by RPP, often precedes cardiac events (Mittleman et al., 1993; Willich et al., 
1993; Raum et al., 2007) therefore low-moderate intensity walking may be recommended 
to reduce the risk of acute coronary events in apparently healthy populations both during 
walking and in the post-walking period. Perhaps more crucially these findings may have 
significant implications for the promotion of regular walking from healthcare professionals 
to cardiac patients, such as angina and post-myocardial infarction patients, and this area 
must now be further researched. 
 
Resting metabolic rate was not significantly different between treatments at Pre, 1-hr, 4-hr 
and 24-hr, however RMR in 30×65% and 60×50% were si
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CON, with RMR in 30×65% also significantly elevated above 30×50% Post-walk (Figure 
4.9). There were main effects of time on RMR, such as Post-walk in each of the walking 
trials and at 4-hr in each treatment following the breakfast meal, which was consumed 
immediately following the measures at 1-hr, demonstrating the thermic effect of food. 
However, there was no effect of walking on changes in postprandial RMR, which was 
significantly higher at 24-hr following 30×65% than following 30×50%. In contrast to 
RMR there was relatively little change in fat oxidation rates, where only the consumption 
of the breakfast meal significantly effected fat oxidation, which was significantly lower in 
each treatment at 4-hr, with none of the walking treatments exerting a significant effect on 
absolute fat oxidation. However, when absolute fat oxidation rates were expressed relative 
to RMR there was a significant effect of 30×65% and 30×50% compared to CON on 
percentage fat utilisation (Figure 4.10). It may be speculated that these differences may 
have occurred at 1-hr, 4-hr and 24-hr, where there was a tendency for percentage fat 
utilisation to be depressed during CON relative to each of the walking trials (NS). 
 
Acute exercise also has the potential to reduce plasma volume, which may impact upon 
blood biochemistry values (Kargotich et al., 1998), therefore despite no significant changes 
in hydration status throughout the duration of the study the plasma and serum samples 
were corrected for any changes in plasma volume that may have occurred. The walking 
trials did not significantly affect plasma glucose compared to CON (Figuure 4.11). Despite 
concentrations remaining relatively constant following CON and 30×50%, plasma glucose 
tended to be augmented at 4-hr following the breakfast meal, particularly in 30×65% and 
60×50%, which required the greatest energy expenditures during the walks. However, 
these were only tendencies rather than significant differences. Serum insulin 
concentrations remained relatively stable throughout the study, with the exception of 4-hr 
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in each treatment where serum insulin spiked significantly compared to Pre, Post, 1-hr and 
24-hr due to control the glycaemic load consumed following the 1-hr measurements. The 
homeostasis assessment models (HOMA-IR & HOMA-β) were used to predict insulin 
resistance from fasting glucose and insulin concentrations (Matthews et al., 1985). All 
measures within this study were from fasting blood samples, with the exception of those 
taken at 4-hr, which were collected following a ~2.5 hr fast. Due to this, those HOMA 
measures recorded at 4-hr are not valid and appear to demonstrate increased fasting insulin, 
whereas this is due to the normal hyperinsulinaemia that occurs in response to meals 
containing a moderate volume of carbohydrate. Therefore, non-surprisingly there was an 
apparent increase in ‘insulin resistance’ as determined by HOMA and this phenomenon 
tended to be increased following 30×65% and 60×50%, but less so following 30×50% and 
even less during CON (NS). There was a trend for insulin secretion to decrease slightly 
from Pre to Post during CON (NS), and to increase from Pre to Post during each of the 
walking sessions (NS) (Figure 4.12). Consequently, insulin secretion decreased 
significantly, predominantly following the walking sessions between Post and 1-hr. The 
rise in glycaemia between and 1-hr and 4-hr stimulated increases in β-cell insulin secretion 
following each treatment, however there was a non-significant trend for the walking 
sessions to effect a decreased insulin secretion relative to CON. 
 
When endurance-trained individuals stop training, their enhanced insulin sensitivity is 
rapidly reversed (King et al., 1995), suggesting that this characteristic could partly be a 
consequence of the acute effects of their last bout of exercise. It has been demonstrated that 
acute exercise can normalise a defect in insulin-stimulated glucose transport-
phosphorylation in insulin-resistant subjects (Perseghin et al., 1996).  A single bout of 
acute exercise enhances insulin-mediated glucose disposal in normal subjects, in insulin-
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resistant first degree relatives of T2D patients, in obese subjects with insulin resistance as 
well as in T2D patients, where exercising muscle may increase glucose clearance 7 to 20-
fold (Wahren et al., 1971). Following an acute bout of exercise, glucose uptake into 
skeletal muscle is enhanced, which is partly an insulin-independent contractile effect and 
may persist for several hours after the cessation of exercise (Henrisksen, 2002). The 
enhanced post-exercise insulin sensitivity is most likely due to the need to replenish 
muscle glycogen, where glycogen-depleting exercise results in increased non-oxidative 
glucose disposal as measured 12 hours after exercise. However, when an untrained leg was 
subjected to a single exercise bout there was no effect on insulin action in the untrained 
muscle, suggesting that ‘the effect of training on insulin-mediated glucose disposal in 
muscle is a genuine adaptation to repeated exercise … but is short-lived’ (Dela et al., 
1992). 
 
Possible explanations for the lack of effect of the walks on insulin sensitivity include 
insufficient exercise stimulus and the predominant use of fasting blood samples rather than 
post-exercise oral glucose tolerance tests (OGTTs). Data indicates that a threshold exercise 
intensity of 70% OO2max may be needed in order for short-term post-exercise 
improvements in insulin sensitivity, possibly due to the greater depleting effect of vigorous 
intensity PA on muscular glycogen stores (Thompson et al., 2001). Indeed, data 
demonstrates that exercise increases insulin-stimulated glucose disposal through increased 
glycogen synthesis without affecting rates of glucose oxidation in both type II diabetic and 
non-diabetic participants and may last for at least 24 hours (Christ-Roberts & Mandarino, 
2004). Possible mechanisms by which PA may improve insulin sensitivity include 
increased mRNA expression, increased glycogen synthase activity, decreased release of 
adipose tissue-derived NEFA and enhanced clearance of NEFA and increased delivery of 
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glucose and insulin to muscles through increases in blood flow (Pedersen & Saltin, 2006). 
Furthermore, the observation of the response to a glucose load may provide greater insights 
into the effects of prior exercise on glucose homeostasis rather than measuring static 
measures of glucose metabolism in the fasting state, as was the case in the present study. 
 
Unfavourable metabolic changes in sedentary individuals may be partly mediated by 
inactivity-induced down-regulations in LPLa (Hamilton et al., 2004), which is bound to the 
capillaries of muscles and responsible for the hydrolysis of TAG-rich lipoproteins and thus 
decreases in LPLa may promote an atherogenic blood lipid and lipoprotein profile, 
primarily through elevations in TAG-rich lipoproteins. However, studies demonstrate that 
low muscular LPLa can be reversed through a single session of walking at a moderate 
intensity, thus suggesting that the maintenance of the residual effects of the previous bout 
of lifestyle PA, such as walking, may enhance metabolic health (Bey & Hamilton, 2003). 
Plasma NEFA and glycerol concentrations have been shown to increase by ~31% and 
~49%, respectively, following 1-hr of walking at 36% OO2peak compared to resting values, 
indicating increased rates of adipose tissue lipolysis and muscular oxidation (Kaminsky et 
al., 1986). Furthermore, plasma glycerol peaked at the end of exercise whereas plasma 
NEFA carried on increasing and peaked at 10 min post-exercise and plasma NEFA 
remained above resting values until at least 60 min post-exercise. In the present study, 
plasma NEFA concentrations demonstrated much greater fluctuations following the 
walking sessions compared to glucose, where each of the walking sessions exerted an 
effect on plasma NEFA compared to CON, despite only small statistical power (0.256). 
Plasma NEFA increased significantly following 30×65% and 60×50% compared to Pre, 1-
hr and CON, however despite plasma NEFA being slightly raised compared to CON 
following 30×50% this was non-significant (Figure 4.13). Plasma NEFA returned to Pre 
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values by 1-hr in each treatment and were significantly decreased at 4-hr compared to all 
other time points (Pre, Post, 1-hr and 24-hr) following the breakfast meal that was 
consumed immediately after the measurements were collected at 1-hr and there was no 
effect of walking on this depression in plasma NEFA. Despite plasma NEFA being 
unaffected by 30×50% during day one it was significantly higher than CON at 24-hr. 
 
The greatest fluctuations in serum TAG occurred at 4-hr, after the breakfast meal, 
following CON, 30×65% and 60×50% but not following 30×50% (Figure 4.14). Mean 
serum TAG remained relatively uniform throughout the study, particularly following 
30×50%, where even following the breakfast meal serum TAG remained unchanged at 4-
hr compared to CON, which increased significantly compared to 30×50%, and 30×65% 
and 60×50% also tended to increase at 4-hr (both NS). However, the Bonferroni corrected 
analyses and low statistical power (0.072) may explain why the postprandial elevations in 
serum TAG following 30×65% and 60×50% did not attain statistical significance. The 
blood lipoprotein profile (TC, HDL-C, TC/HDL-C ratio & LDL-C) appeared to be 
unaffected by the walking trials compared to CON, where not only were there no 
significant differences between the treatments there were no clear changes throughout the 
24 hour intervention in any trial (Figures 4.24-4.27). Despite minor fluctuations, 
particularly TC/HDL-C ratio, the blood lipoprotein profile remained steady throughout the 
four trials. There appeared to be a trend for 30×65% to decrease TC and LDL-C, and 
increase HDL-C, highlighted in the greater fluctuations in TC/HDL-C ratio. Data from 
other studies indicates a dose-response for PAEE in reducing postprandial lipaemia 
because walking for 90 minutes at a moderate intensity (61 ± 1% OO2max) was more 
effective than walking for the same duration at a low intensity (31 ± 1% OO2max) 
(Tsetsonis & Hardman, 1996b). It has been demonstrated that increases in LPLa are 
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responsible for some of the reductions in postprandial lipaemia resulting from moderate 
intensity activities, such as walking, however LPLa does not explain all of the effects (Gill 
et al., 2003). However, an oral fat challenge was consumed in the above studies, whereas 
in the present study the majority of the blood samples were in the fasted state (except 4-hr). 
As with OGTTs, oral fat loads pose a greater challenge to the body in the rested state and 
allow a greater demonstration of the effects of prior exercise on metabolism than in the 
fasted state. 
 
Other walking studies have investigated the effect of walking intensity on the blood lipid 
and lipoprotein profile. During the 48-hr post-exercise period, 11 pre-menopausal and 10 
post-menopausal women performed 2 isocaloric walking trials expending 350 kcal at 50% 
OO2max and 70% OO2max (Pronk et al., 1995). The author reported that serum LDL-C 
decreased immediately following walking at 70% OO2max in both the menopausal and post-
menopausal women, indicating that there was a different response between the two 
walking intensities, despite both intensities appearing to slightly raise serum LDL-C, and 
from looking at the data there appeared to be little favourable improvement in TC, HDL-C 
(including HDL2-C & HDL3-C), LDL-C or TAG. More recently, a 10-day walking 
intervention was performed by a group of young (24 ± 3 years) and a group of older (56 ± 
3 years) participants (Ainslie et al., 2005). The main findings of the study were that TC 
and LDL-C decreased and HDL-C increased significantly greater in the older group 
compared to the young group. 
 
Physical activity may improve the dyslipidaemic profile associated with MetS by 
increasing the ability of muscle tissue to take up and oxidize NEFA and increasing the 
activity of LPL in muscle (Pollare et al., 1991). The effects of acute PA on blood lipids are 
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proportional to the PAEE, rather than meeting a specific EE threshold. However, despite 
those with the greatest TAG values having the potential for the greatest PA-induced 
reductions in blood TAG, unconditioned individuals may be unable to expend sufficient 
energy do so (Thompson et al., 2001). In healthy trained men, a PA session expending 
1,100 kcal may be sufficient to elevate HDL-C, however a lower EE threshold than this 
may be sufficient for sedentary individuals (Ferguson et al., 1998). Indeed, evidence 
suggests that a PAEE of 350-400 kcal may be sufficient to acutely increase blood HDL-C 
values in moderately fit individuals. Furthermore, changes in total cholesterol and LDL-C 
are more equivocal and potential favourable changes may be due to plasma volume 
expansion rather than changes in lipid metabolism (Thompson et al., 2001), which were 
corrected for this factor in the present study.  
 
Despite moderate or vigorous PA apparently being initially advocated by ACSM (1978), in 
the next recommendations (ACSM, 1990) there was an important distinction made 
between PA for health and exercise training for fitness, where the exercise prescriptions to 
enhance fitness were not absolutely necessary to improve health. Subsequently, the more 
heralded recommendations by CDC & ACSM (1995) and USGR (1996) were published, 
which along with the findings in the present study, are highly important to health-fitness 
professionals and the sedentary public because the perceived intensity and mode of 
exercise necessary to enhance health is often a barrier to exercise adoption for sedentary 
individuals who mistakenly believe that exercise must be vigorous to be of benefit 
(Buckworth & Dishman, 2002). However, sedentary individuals are more likely to choose 
and adhere to lower intensity leisure activities, such as walking programs than more 
vigorous exercise (Dishman & Buckworth, 1996).  
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In conclusion, the main findings of this sudy were that a single 30 minute walking session 
at 50% OO2max was sufficient to significantly reduce systolic blood pressure, mean arterial 
pressure and the rate-pressure product for at least four hours post-exercise, however there 
did not appear to be any significant effects on glucose homeostasis or the blood lipid and 
lipoprotein profile. Furthermore, an interesting and perhaps important finding is that 
increasing the walking intensity to 65% OO2max or the duration to 60 minutes failed to 
significantly augment the physiological responses to the 30 minute walk at 50% OO2max. 
These findings are significant because demonstrating that low volumes of PA are capable 
of enhancing certain aspects of health may encourage sedentary individuals to increase 
habitual leisure time activities and discourage the assumption that exercise must be 
vigorous to be of benefit to health. 
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5.0 The acute and chronic effects of walking on risk 
factors associated with metabolic syndrome 
 
Metabolic syndrome has been associated with future CVD during 11-year follow-up, with 
elevations in BP and low HDL-C independently associated with CVD development in the 
Atherosclerosis Risk in Communities (ARIC) study, however MetS was less predictive 
than Framingham Risk Score (FRS) (McNeill et al., 2005). Evidence suggests that 
although the presence of ATPIII-defined MetS is a significant predictor of CVD and type 
II diabetes, it is a stronger indicator of type II diabetes, but not as predictive of CHD as 
FRS (Wannamethee et al., 2005). However, when three or more components are present, 
MetS is a strong predictor of CVD and type II diabetes in Britian (Wannamethee, 2008). 
Despite the majority of this risk being already predicted by FRS it is possible that 
identification of those with MetS may provide earlier opportunities to intervene with 
individuals predisposed to diabetes and/or CVD, where measures of abdominal obesity, 
inflammatory markers, IFG, and prothrombotic activity are included in the ATPIII MetS 
definition, but not FRS (Wilson, 2004). Evidence suggests that CRP independently predicts 
CVD, which is more common in those with MetS who have elevated CRP, and therefore 
stratification based on CRP may add further prognostic value in CVD prediction in those 
with MetS (Malik et al., 2005). 
 
The WHO-defined prevalence of MetS is >44.8% and 33.9% in English males and females 
aged 40-65, respectively, demonstrating the highest worldwide prevalence using these 
criteria, whereas the mean worldwide prevalence of ATPIII-defined MetS, which was used 
to diagnose MetS in this thesis, is 27.9% for females and 22.8% for males (Cameron et al., 
2004). There are different lifestyle and genetic factors that encourage the development of 
MetS, however when a combination of several low-risk lifestyle factors (physically active, 
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non-smoking and moderate carbohydrate & fat consumption) are present in individuals 
with a BMI <30 kg·m2 those individuals are at a lower risk of developing MetS (Zhu et al., 
2004). In the UK alone, the direct costs of obesity are at least 500 million per year, with 
costs to the individual and industry ~£2 billion per year (Bourn, 2001) and CHD costs the 
UK health care system £1.73 billion (Liu et al., 2002), which can both be addressed 
through lifestyle modification, particularly PA. Data from the Health Survey for England, 
covering 95,342 individuals in 1991-4, 1997-9 and 2003-4, demonstrated that despite 
occupational PA being on the decline there was a significantly consistent upward trend in 
regular sporting participation and an overall increase in time spent performing PA and the 
percentage of adults meeting public heath recommendations for PA (Stamatakis et al., 
2007). Therefore, within this context the initial aim of the work included in this thesis was 
to recruit individuals with MetS to demonstrate the influence of accumulative walking on 
ameliorating the components of MetS, particularly abdominal obesity, elevated fasting 
blood glucose, dyslipidaemia and hypertension, and the associated elevated risk for a pro-
thrombotic and pro-inflammatory state.  
 
There are at least four definitions used to diagnose MetS, however the definition proposed 
by ATPIII (Cleeman, 2001) was used to diagnose MetS within this thesis because the 
criteria most closely match the health outcomes recorded during the pre- and post-walking 
assessments. This definition requires 3 or more of: WC >102 cm, plasma TAG – ≥1.69 
mmol·L-1, HDL-C <1.04 mmol·L-1, blood pressure ≥130/≥85 mmHg and fasting blood 
glucose ≥6.1 mmol·L-1. Despite many attempts trying to recruit individuals with MetS, due 
to potential participants being required to volunteer for the studies, these attempts were 
relatively unsuccessful. Shown below is the list of methods that were employed to attract 
volunteers to take part in the research: 
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 Adverts in GP surgeries throughout Kent 
 Adverts in Schools and Colleges throughout Kent 
 Notice letters to Kent businesses  
 Notice letters to Primary Care Trusts 
 Notice letters to and leaflets Taxi companies 
 Notice letters to and leaflets Bowling clubs 
 Advert in Kent County Cricket Club match-day programme 
 Circular emails to local councils 
 Link on University of Kent homepage 
 Own webpage on Canterbury Christ Church University homepage 
 Email to Sport Science, Tourism & Leisure students 
 Notice on staff and student PC desktop alerts at Canterbury Christ Church University 
 Adverts in supermarkets 
 Adverts in libraries 
 Handing out flyers at Canterbury train stations and Ashford International 
 Editorial in local newspapers 
 Interview on local radio stations in Kent – twice 
 Interview on South East television news 
 
Additionally, many of the volunteers that participated in the 24 week study were using 
anti-hypertensive and/or lipid-lowering medication. Due to the nature of the required 
participants (see Mets criteria above) and that these individuals were low active, many of 
the volunteers for the 24-week intervention study were likely to be prescribed hypertensive 
or lipid-lowering medications (Rantala et al., 1999; Williams & Franklin, 2007). However, 
despite medication use being a confounding factor to the impact of walking interventions 
on MetS risk factors, these participants were allowed onto the study in order to reduce the 
presence or risk of their developing MetS. Eventually, medicated participants’ results were 
not included in the final analyses of the study in order to present full results for each 
component associated with MetS, rather than using different participants’ data for different 
parameters based on whether they were medicated or not. Therefore, lack of volunteers and 
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ruling out participants using certain medications led to relatively low numbers of 
participants in each of the groups: CON (15), SBW (13) and ABW (13). A small selection 
of participants that took part in the 24 week intervention study also took part in the 24 hour 
study in order to avoid having to re-recruit for participants to take part in a study that 
potentially offered less personal reward than the 24 week study. All of the participants that 
were not prescribed medication were contacted to volunteer for the study and a small 
selection did volunteer. There was also an intention to investigate the influence of the 24-
week and 24-hour walking interventions on CRP, a marker of inflammation and strong 
predictor of future CVD for those with MetS (Malik et al., 2005). However, there were 
calibration problems with the CRP assay resulting in insufficient numbers of the samples 
being assayed to be included in the results of either study. 
 
The 24 week intervention study within this thesis demonstrates that walking can influence 
risk factors associated with MetS. In contrast to the common misconception that exercise 
must be vigorous and sport-related to be of benefit to health (Dishman & Buckworth, 
1996), both accumulative brisk walking during the day and a single walking session at no 
more than a moderate intensity (50% OO2max) are capable of reducing risk factor associated 
with MetS. Furthermore, the evidence in this thesis suggests that brisk walking in multiple 
smaller sessions during the day or a short walk (30 minutes) at a moderate intensity are at 
least as effective for improving risk factors associated with MetS than walking sessions of 
greater duration or intensity. Indeed, despite a trend for the walking intervention requiring 
150 min·wk-1 to be performed in 5 × 30 minute sessions per week (SBW) to decrease waist 
circumference and its associated insulin resistance, only when this volume of walking was 
accumulated in smaller sessions during the day (ABW) were these effects significant. 
Conversely, in a study investigating similar health outcomes to those presented in section 
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3.0 demonstrated that by instructing sedentary obese Japanese participants to add 1,000 
steps to daily walking activity at baseline for 1 year the increase in steps·d-1 significantly 
reduced visceral adiposity and decreases in insulin resistance assessed using HOMA 
(Miyatake et al., 2002). Furthermore, a prospective study investigating the efficacy of 
walking on future risk of developing in 70,102 female nurses aged 40-65 years found that 
walking produced similar magnitudes in T2D risk reduction as vigorous activity of 
equivalent energy expenditure and that increased walking pace was independently 
associated with decreased risk during 8-year follow up (Hu et al., 1999). Together these 
findings have significant health implications since all-cause mortality has been reported to 
be 39% lower in individuals who walk at least 2 h·wk-1 and those who walked 3-4 h·wk-1 
had the lowest risk at 8-year follow up (Gregg et al., 2003).   
 
Similarly to the study in section 3.0, the response of various health outcomes to 
accumulative walking has been variable, but generally positive. In one of the earliest 
RCTs, investigating 10 weeks of accumulative brisk walking at 70-80% HRmax in either 
one 30 minute walk (LB) or three 10 minute walks per day (SB), body mass and waist 
circumference decreased significantly only in the SB group. A further 18 week RCT of 
accumulative walking studied 49 males and females, involving either single daily brisk 
walking sessions of 20-40 minutes (LB) or accumulating the same volume of walking in 
10-15 minute daily sessions found that aerobic capacity significantly decreased and factor 
XIIa, a marker of coagulation, significantly increased in the control group, however there 
were no significant changes in lipid profiles (TC, LDL-C, HDL-C and apos A-I, A-II & B) 
in the walking groups compared with controls (Woolf-May et al., 1998). A further study 
by the same group added an additional group, in which participants were instructed to 
perform brisk walking sessions in 5-10 minute bouts totalling 20-40 min·d-1, which found 
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that although each of the walking groups produced improvements in aerobic fitness the 
long and intermediate groups also demonstrated favourable improvements in the blood 
lipid profile (Woolf-May et al., 1999). 
  
Despite not attaining statistical significance, there were favourable improvements in blood 
pressure following both patterns of brisk walking (SBW & ABW) compared to control, 
which is a similar finding to the majority of walking interventions (Murphy et al., 2007). 
The outcome for plasma fibrinogen, a marker of blood clotting risk, was similar, where 
despite favourable decreases in plasma fibrinogen compared to control in both walking 
patterns these were statistically non-significant. Conversely, one of the few previous 
studies to investigate the influence of walking on coagulation dmonstrated that walking at 
a higher intensity at 73.5 ± 7.2% HRmax for 18 weeks significantly decreased factor XIIa 
(FXIIa), the active form of FXII that is involved in coagulation however there were no 
decreases in blood lipid profile (Woolf-May et al., 2000). Similarly, in the study in section 
3.0 apart from TC/HDL-C ratio and serum LDL-C, there appeared to be no pattern for both 
SBW and ABW to improve the blood lipid and lipoprotein profile, which is a common 
finding in the majority of other published walking interventions (Kelley et al., 2004). 
Despite a 24 week walking intervention requiring 60 min·d-1 at 60% OO2peak on 5 d·wk-1 
significantly improving OO2peak 14% and percent body fat by -1.3%, this was still 
insufficient to favourably alter serum lipids. (Ready et al., 1996). Furthermore, an RCT, 
130 postmenopausal women completed single or double daily walking sessions, expending 
a total daily PA volume of 300 kcal·d-1 at 65% OO2max with both single and multiple 
sessions of walking providing similar increases in OO2max (2.5 mL·kg-1·min-1 for both 
walking groups) and decreases in BF% (1.7% in SB & 21.1% in LB) (Asikainen et al., 
2002). An extension of this study, looking at a wider array of risk factors found that 
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diastolic blood pressure was not significantly reduced when the walking groups were 
analysed separately and only when these were combined as a single group that a mean 
decrease of -3 mmHg was demonstrated compared to controls and despite 15 weeks of 
walking, neither the lipid profiles nor insulin concentrations changed (Asikainen et al., 
2003).  
 
The independent association between fitness and components of MetS may be relatively 
small and benefits associated with PA may be partly as a consequence of the acute effects 
of the last bout of exercise rather than from favourable adaptations to chronic PA 
(Thompson et al., 2001). However, no published study appears to have investigated the 
potential for PA to impact on MetS risk factors (blood pressure, dyslipidaemia, glucose 
control & haemostatic factors) in the immediate post-exercise period, that may be 
maintained through regular PA, despite evidence demonstrating short-term improvements 
in independent MetS risk factors, such as blood glucose control (Englert et al., 2006), 
blood pressure (Jones et al., 2007), lipid and lipoprotein profile (Ferguson et al., 1998), 
markers of pro-thrombotic (Ivey et al., 2003) and pro-inflammatory states (Murtagh et al., 
2005a) may be gained from a single PA session. Therefore, since there appears to be no 
published studies to have investigated MetS risk factors collectively in acute PA 
interventions in general, the findings are important. In contrast to the influence of 24 weeks 
of brisk walking on risk factors associated with MetS, a single session of brisk walking 
affects different risk factors. Systolic blood pressure in particular significantly responds to 
a 30 minute walking session at 50% OO2max for at least four hours, which was at least as 
effective as a 60 minute walking session at a similar intensity and more effective than a 30 
minute walking session of higher intensity (65% OO2max). Combined with the reduced 
increments in post-walk heart rate associated with walking at 50% OO2max, the lower 
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intensity walk significantly reduced rate-pressure product, an index of myocardial 
workload, for at least four hours compared to CON and generally resulted in lower 
perturbations in rate-pressure product than either 30×50% or 30×65%, with RPP following 
30×65% significantly higher than the other walking trials as well as CON.  
 
Patterns in response to the walking sessions could only be assessed within the design of the 
24-hour study, ie. measured BP, therefore mechanisms can only be postulated. The 
mechanisms by which PA may acutely modulate post-exercise hypotension include 
sympathoinhibition, where sympathetic nerve fibre activity-induced vasoconstriction of the 
musculature becomes inhibited, and increases in circulating vasodilator substances, such as 
nitric oxide, which attenuate the vasoconstrictor response to α-adrenergic receptor 
stimulation, and these responses are not fully offset by increases in cardiac output during 
post-exercise hypotension (Halliwill, 2001). In a study of the influence of PA intensity on 
blood pressure, during the 90 minute post-exercise period following cycling for 45 minutes 
at 30%, 50% and 75% OO2peak, only the 50% and 75% OO2peak sessions significantly 
decreased blood pressure in normotensives compared to the control session, and were 
associated with a decrease in systemic vascular resistance (Forjaz et al., 2004). However, a 
similarly designed study, but recording for a longer post-exercise period (9 hours) and 
using hypertensive participants, demonstrated that reductions in systolic blood pressure 
were similar between cycling for 15 minutes at 40% or 60% OO2max or for 30 minutes at 
40% or 60% OO2max (Guidry et al., 2006). Thus, reinforcing the benefits of performing 
short bouts of PA at a low intensity, and even though the exact PA dose needed to lower 
blood pressure remains to be identified it may be possible that a threshold intensity of only 
40% OO2max may be required to elicit a hypotensive effect and only three training sessions 
for this effect to become chronic (Thompson et al., 2001). Data appears to demonstrate that 
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PAEE is more significant than PA intensity for the mediation of post-exercise hypotension, 
where isoenergetic PA sessions at either 40% or 70% OO2peak produced ‘clinically similar’ 
reductions in blood pressure during the 20 minute post-exercise period (Jones et al., 2007). 
 
None of the short-term walking treatments produced significant favourable improvements 
in insulin sensitivity or blood lipoprotein profile compared to CON. However, both of the 
walking interventions that required the greatest PAEE produced significant increases in 
plasma NEFA immediately post-walk, but only 30×50% induced significant decreases in 
serum TAG at 4-hours after the mid morning breakfast. To investigate the effect of 
walking intensity on the blood lipoprotein profile during the 48-hr post-exercise period, 11 
pre-menopausal and 10 post-menopausal women performed 2 isocaloric walking trials 
expending 350 kcal at 50% OO2max and 70% OO2max (Pronk et al., 1995). The author 
reported that serum LDL-C decreased immediately following walking at 70% OO2max in 
both the menopausal and post-menopausal women, indicating that there was a different 
response between the two walking intensities, despite both intensities appearing to slightly 
raise serum LDL-C and from looking at the data there appears to be little favourable 
improvement in TC, HDL-C, LDL-C or TAG. 
 
Certain health outcomes responded positively to the walking interventions, such as 
adaptations in body composition and insulin resistance following the 24 week study, and 
short term blood pressure and cardiac responses to the acute walking sessions. However, 
other health outcomes, such as blood pressure and blood lipid and lipoprorein profile in the 
24-week walking intervention and blood lipid and lipoprotein profile in the 24-hour 
walking study appeared relatively unchanged. These are in line with current data, where 
even meta-analyses have been unable to demonstrate favourable changes following 
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walking interventions and SBP (Murphy et al., 2007), serum TAG, TC and HDL-C (Kelley 
et al., 2004) have not been found to respond significantly. Indeed, the findings in this 
thesis contribute to current knowledge because to the author’s understanding is this is the 
first published walking intervention to demonstrate improvements in glucose homeostasis 
associated with changes in abdominal adiposity, which is especially novel because the 
accumulation of walking was particularly effective. Furthermore, although favourable 
adaptations in blood pressure were not present following 24 weeks of walking, short-term 
favourable responses occurred in SBP and MAP following walking at 50% OO2max for at 
least 4 hours, which is significant for PA promotion because this appeared to be more 
effective than walking at 65% OO2max and this phenomenon has also not been 
demonstrated before. Additionally, rate-presure product, an index of myocardial workload, 
was influenced by both chronic and acute bouts of walking. Most notably, despite a trend 
for SBW to decrease RPP, this was only significantly decreased following ABW, and RPP 
was also most beneficially effected following the shorter duration and lower intensity 
30×50% walking session. These findings suggest that low-moderate activities of daily 
living, such as walking should be recommended to decrease the risk of cardiac events 
during activity and future development of heart conditions. Consequently, if this type of 
activity can decrease RPP in an apparently healthy population then it may be speculated 
that this type of activity should also be recommended to participants with current heart 
conditions, such as angina and post-myocardial infarction. Therefore, this area warrants 
further thorough research. 
 
The findings from both of the main studies in this thesis (sections 3.0 and 4.0) are 
significant for promoting health through activities of daily living. The studies clearly 
suggest that a lifestyle activity, such as walking, at only moderate intensities can promote 
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significant improvements in health outcomes both in the short and long term. This thesis 
therefore has important implications for guiding the current public health policies for 
promoting lifestyle activities. The Chief Medical Officer’s report (2004) is a ‘high level 
Department of Health document’ aimed towards public health and Primary Care Trusts to 
encourage the promotion of physical activity and active travel to achieve health gains. This 
thesis is crucial to help these aims because walking exemplifies the most accessible mode 
of active travel and also illustrates the potential health outcomes, particularly the 
immediate optimisation of blood pressure and long term decreases in abdominal adiposity 
and decreased insulin resistance. 
 
The findings in this thesis add particular weight to the fight to promote PA to those in need 
(the sedentary) in the face of others (the highly active) who believe that promoting 
vigorous PA will improve the health status of the wider population. A recent article has 
been written describing the need to promote vigorous intensity PA because of the 
increasing perception that moderate intensity PA is more beneficial to health than vigorous 
PA (O’Donovan & Shave, 2006). However, although the PA-health dose-response 
relationship clearly demonstrates that with increasing PA volume there are greater health 
benefits, this is logarithmic rather than linear (Paffenbarger et al., 1986). Furthermore, 
findings from the same group demonstrate that only LDL-cholesterol and apo-B 
concentrations were lower in lean exercisers than in lean sedentary men, indicating that 
energy balance is more of a key to health than PA intensity per se (O’Donovan et al., 
2005). The key to this debate is PA promotion, at any intensity, rather than promoting the 
most effective PA intensity because frequency and adherence to PA are much more 
important for achieving the required PA volume (American College of Sports Medicine & 
American Heart Association, 2007). This is precisely why, despite health responses to 
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moderate intensity PA may be lesser compared to those attained by adhering to vigorous 
PA, moderate intensity PA is promoted: because it can be attained by the masses rather 
than being a preserve for those who already demonstrate high ‘performance-related 
fitness’. The problem with these groups advocating vigorous intensity PA is that the 
perceived intensity and mode of exercise necessary to enhance health is often a barrier to 
exercise adoption for sedentary individuals who mistakenly believe that PA must be 
vigorous to be of benefit (Buckworth & Dishman, 2002). However, sedentary individuals 
are more likely to choose and adhere to lower intensity leisure activities, such as walking, 
than more vigorous PA (Dishman & Buckworth, 1996). Both the lower intensity walks and 
the accumulative walking groups in this thesis support the assertions that lifestyle activities 
can be beneficial to health. 
 
This work supports the governments aims to increase adults PA to at least 30 minutes per 
day on at least 5 days per week, which was initially developed in 2004 (Department of 
Health, 2004). Indeed, this thesis contributes to each aspect of the ‘be active, be healthy’ 
strategy for increasing PA, where walking forms part of each activity category: ‘everyday 
activities’, ‘active recreation’ and ‘sport’ (Department of Health, 2009). This thesis clearly 
demonstrates that walking should be at the forefront of PA promotion policies due to the 
weight of physiological evidence (see sections 3.0 & 4.0), and especially considering it 
should have no cost to the participant. This message appears to have been missed during 
the past 200 years since daily PA levels have been systematically reduced by 
advancements in technology, such as cars and occupational instruments, despite walking 
being modern homo sapiens’ main source of PA during ambulation and daily chores during 
the previous 100,000 years (Haskell & Torburn, 2006). Due to the rise in sedentary 
occupations, the ‘Work place health promotion strategy’ advises employers to create 
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policies to encourage their staff to use other modes of transport involving physical activity 
and this thesis could contribute to information on how to be more physically active and on 
the health benefits of such activity (National Institute for Health and Clinical Excellence 
(NICE), 2008). Therefore, this work supports their recommendations to ‘move around 
more at work’, such as walking to external meetings, using the stairs rather than lifts, 
providing information about walking routes and encouraging walks during work breaks. 
The work in this thesis complements evidence from a prospective study of 6,017 
normotensive Japanese men aged 35-60 by demonstrating that despite BP not being 
significantly lowered, RPP, WC and measures of insulin resistance were significantly 
decreased. That study found that walking to work and walking during leisure time for more 
than 20 min·d-1 was associated with a 0.71 relative risk of developing hypertension in 
compared to those who walked less than 10 min·d-1 (Hayashi et al., 1999).  
 
In 2006 a NICE report also stated that there were still gaps in current knowledge relating to 
the efficacy and cost effectiveness of PA interventions, therefore this thesis presents 
evidence that physical benefits can occur when accumulating walking according to 
national PA recommendations (5×30 min·wk-1) and that no costs accompany such 
activities. Therefore this information will be valuable to professionals working in the NHS, 
local authorities and the voluntary sector, such as directors of public health, public health 
advisers, commissioners of services, general practitioners (GPs), other primary healthcare 
professionals, those working in Healthy Living Centres, leisure service managers, walking 
and cycling officers, exercise and leisure professionals and community development 
workers and those developing and delivering walking schemes or pedometer loan schemes 
(NICE, 2006).  
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This research is also timely considering that the 2012 Olmpic Games in London legacy 
plans are currently being formulated (Weed et al., 2009; Department of Health, 2009). 
Indeed, given that a recent systematic review found that “there was no usable evidence 
returned in relation to the direct leveraging of public health… or of ‘active living’ or 
incidental physical activity from Olympic Games” (Weed et al., 2009); it may be 
suggested that publicising work from this thesis may promote the development of such 
evidence in the run up to and post-2012. Crucially, evidence suggests that only if 
individuals become physically active before the Games that London 2012 and be sustained 
rather than stimulate sedentary individuals to become more active once the Games have 
finished (Weed et al., 2009). Therefore, widespread publicity of effective health-enhancing 
PA initiatives prior to the Games combined with the event may be an effective health 
promotion tool in order to develop pre-contemplators into preparers for PA and ready for 
‘action’. 
 
With regards to sport the studies in this thesis lend weight to using golf as a health 
promotion tool because due to the distances covered whilst walking with a golf bag during 
a round there is potential for significant health benefits. During a 20-week trial 55 male 
golfers playing 2-3 full rounds of golf per week improved their time to fatigue on an 
exercise test by 36 seconds, WC decreased by 2.2 cm and abdominal skin folds also 
decreased by 2.2 cm, and HDL-C were increased (Parkkari et al., 2000). Furthermore, 
recent evidence demonstrates that walking is associated with reduced medication use for 
MetS components such as diabetes, hypertension and hypercholesterolaemia, where 
weekly walking distance, the longest distance walked and walking intensity were inversely 
related to anti-diabetic, anti-hypertensive and LDL-C lowering medication use in 32,683 
females and 8,112 males in the National Walkers’ Health Study (Williams, 2008). Those 
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whose walking speed exceeded 2.1 m·s-1 had 64% lower odds for anti-diabetic medication 
use, 50% lower odds for anti-hypertensive medication use and 47% lower odds for LDL-C 
lowering medication use compared with those whose walking speed was <1.2 m·s-1. This is 
of significance to those with MetS since many, as was a complication of the studies in this 
thesis, that many individuals suffering from MetS are also prescribed medication (Rantala 
et al., 1999). 
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5.1 Conclusion 
Metabolic syndrome is a strong predictor of future CVD, diabetes and increased all-cause 
mortality (Wannamethee et al., 2005; Lakka et al., 2002), however lifestyle modification 
appears to prevent and/or treat symptoms associated with MetS (Irwin et al., 2002; Rennie 
et al., 2003; Anderssen et al., 2007). Indeed, the research included in this thesis 
demonstrates that walking may attenuate some of the risk factors associated with MetS. 
These effects are even possible following a single walking session and are independent of 
the favourable adaptations that are possible following long term adherence to a walking 
programme.  
 
Data from the study in Section 4.0 has demonstrated that not only does a single 30 minute 
session of walking at 50% OO2max optimise systolic blood pressure, mean arterial pressure 
and myocardial workload more than walking for 30 minutes at 65% OO2max, for at least 
four hours. Furthermore, increasing the duration of the walking session to 60 minutes at 
50% OO2max had no additional effect on blood pressure and myocardial workload. 
However, there were no significant effects of walking on blood glucose homeostasis and 
blood lipoprotein profile from any of the walking trials. 
 
Conversely, in the study presented in Section 3, accumulating 30 minutes of brisk walking 
per day in 10-15 minute sessions on five days of the week for 24 weeks was equally as 
effective as performing the same volume of walking performed in single daily sessions in 
significantly decreasing waist circumference, which was also associated with significant 
reductions in insulin resistance and circulating insulin. However, there were no adaptations 
in blood pressure or blood lipid and lipoprotein profile associated with 24 weeks of brisk 
walking. 
  204
5.2 Limitations 
Limitations are apparent in both studies. In the 24 week training study, the majority of the 
participants accepted onto the study were relatively healthy, which precluded their being 
diagnosed with MetS. This meant that the population were only at risk of MetS rather than 
actually being diagnosed with MetS, which lessened their potential for positive gains from 
the walking intervention (Wilmore, 2001). Furthermore, other participants using anti-
hypertensive and lipid-lowering medications that volunteered for the study were excluded 
to ensure that these individuals did not confound the findings. The use of medication in the 
target population is non-surprising since sedentary individuals at risk of MetS are known to 
use such medications (Williams & Franklin, 2007) and are included in the diagnostic 
criteria in MetS (Alberti & Zimmet, 1998; Cleeman, 2001). Added to the relatively low 
number of participants that volunteered for the study, the ramifications of these events 
possibly resulted in the low statistical power that limited the significance of the walking 
intervention on blood pressure, plasma fibrinogen, TC/HDL-C ratio and serum LDL-C.  
 
The main limitation of the 24-hour study, investigating the short-term effects of walking on 
MetS risk factors, was the large ‘window’ between the measurements at 4-hours post-walk 
and 24-hours post-walk. This was particularly apparent for the measurements of systolic 
blood pressure, which appeared to carry on increasing from Pre to 4-hr in CON and 
remained lowered in 30×50% and 60×50%. This limitation in the study was unfortunate 
because the exact duration of the blood pressure-lowering effect of the two lower intensity 
walking trials could not be discerned and it could only be concluded that 30×50% was at 
least as effective as 60×50% for at least 4 hours. 
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5.3 Future research 
Although the studies included in this thesis answered some compelling questions regarding 
the efficacy of single and chronic walking sessions for improving risk factors associated 
with MetS, some uncertainty remained. In the 24-week study, future research could recruit 
more non-medicated participants to the study groups who fulfil the diagnostic criteria for 
MetS, in an effort to remove the confounding effects of the low statistical power 
experienced for certain measures. In terms of the 24-hour study, extending the blood 
pressure measurements by using 24-hr ambulatory blood pressure monitoring rather than 
ending at 4-hours post-walk may help to determine the exact end-point of the effects of the 
walking sessions. Additional measures may also be included, such as measures of 
fibrinolytic activity and cardiovascular control. Analysing the plasma samples for 
fibrinogen concentrations and its metabolic agents – tPA & PAI-1 – would shed light on 
the influence of acute PA, particularly different intensities and durations of walking, on the 
risk of blood clotting and the mediating thrombotic pathways. Furthermore, although 
cardiovascular function, i.e. blood pressure and resting heart rate, were measured in this 
study and the efficacy of 30×50% for modifying these variables was established, the exact 
mechanisms by which this was possible could not be elucidated, particularly why 30×50% 
was more effective in this respect than 30×65%. Therefore, future studies may wish to 
make use of other measurement techniques to assess the underlying physiological 
processes that mediate these effects, such as heart rate variability and baroreflex reactivity. 
Furthermore, due to the problems in analysing the serum samples for CRP, these could be 
analysed to gauge the effect of a single session and 24 weeks of walking on chronic low-
grade inflammation.  
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